2,4-ペンタンジオンのマウスを用いた
吸入によるがん原性試験報告書

試験番号：0676

TABLES

TABLES

TABLE A CONCENTRATIONS OF 2,4-PENTANEDIONE IN THE INHALATION CHAMBER OF THE 2-YEAR INHALATION STUDY

TABLE B 1 SURVIVAL ANIMAL NUMBERS: MALE

TABLE B 2 SURVIVAL ANIMAL NUMBERS: FEMALE

TABLE C 1 CLINICAL OBSERVATION: MALE

TABLE C 2 CLINICAL OBSERVATION: FEMALE

TABLE D 1 BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : MALE

TABLE D 2 BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : FEMALE

TABLE D 3 BODY WEIGHT CHANGES: MALE

TABLE D 4 BODY WEIGHT CHANGES: FEMALE

TABLE E 1 FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS: MALE

TABLE E 2 FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS: FEMALE

TABLE E 3 FOOD CONSUMPTION CHANGES: MALE

TABLE E 4 FOOD CONSUMPTION CHANGES: FEMALE

TABLE F 1 HEMATOLOGY: MALE

TABLE F 2 HEMATOLOGY: FEMALE

TABLE G 1 BIOCHEMISTRY: MALE

TABLE G 2 BIOCHEMISTRY: FEMALE

TABLES (CONTINUED)

TABLE H 1 URINALYSIS: MALE

TABLE H 2 URINALYSIS: FEMALE

TABLE I 1 GROSS FINDINGS: MALE: ALL ANIMALS

TABLE I 2 GROSS FINDINGS: MALE: DEAD AND MORIBUND ANIMALS

TABLE I 3 GROSS FINDINGS: MALE: SACRIFICED ANIMALS

TABLE I 4 GROSS FINDINGS: FEMALE: ALL ANIMALS

TABLE I 5 GROSS FINDINGS: FEMALE: DEAD AND MORIBUND ANIMALS

TABLE I 6 GROSS FINDINGS: FEMALE: SACRIFICED ANIMALS

TABLE J 1 ORGAN WEIGHT, ABSOLUTE: MALE

TABLE J 2 ORGAN WEIGHT, ABSOLUTE: FEMALE

TABLE K 1 ORGAN WEIGHT, RELATIVE: MALE

TABLE K 2 ORGAN WEIGHT, RELATIVE: FEMALE

TABLE L 1 HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS : MALE: ALL ANIMALS

TABLE L 2 HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS : MALE: DEAD AND MORIBUND ANIMALS

TABLE L 3 HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS : MALE: SACRIFICED ANIMALS

TABLE L 4 HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS : FEMALE: ALL ANIMALS

TABLE L 5 HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS : FEMALE: DEAD AND MORIBUND ANIMALS

TABLE L 6 HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS : FEMALE: SACRIFICED ANIMALS

TABLES (CONTINUED)

TABLE M 1 NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS-TIME RELATED: MALE

TABLE M2 NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS-TIME RELATED: FEMALE

TABLE N 1 HISTOPATHOLOGICAL FINDINGS: NEOPLASTIC LESIONS: MALE

TABLE N 2 HISTOPATHOLOGICAL FINDINGS: NEOPLASTIC LESIONS: FEMALE

TABLE O 1 NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS: MALE

TABLE O 2 NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS: FEMALE

TABLE P 1 HISTOPATHOLOGICAL FINDINGS: METASTASIS OF TUMOR: MALE

TABLE P 2 HISTOPATHOLOGICAL FINDINGS: METASTASIS OF TUMOR: FEMALE

TABLE Q 1 CAUSE OF DEATH: MALE

TABLE Q 2 CAUSE OF DEATH: FEMALE

TABLE A

CONCENTRATIONS OF 2,4-PENTANEDIONE IN THE INHALATION CHAMBER OF THE 2-YEAR INHALATION STUDY

CONCENTRATIONS OF 2,4-PENTANEDIONE IN THE INHALATION CHAMBER OF THE 2-YEAR INHALATION STUDY

Group Name	Concentration(ppm) Mean ± S.D.
Control	0.0 ± 0.0
100 ppm	100.9 ± 0.9
200 ppm	200.9 ± 1.4
400 ppm	401.0 ± 1.8

TABLE B1

SURVIVAL ANIMAL NUMBERS : MALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 0	1	2	3	4	5	6	7	8	9	10	11	12	13
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
100 ppm	50	50/50	50/50	50/50	50/50	50/50	49/50	49/50	49/50	48/50	48/50	48/50	48/50	48/50	48/50
		100.0	100.0	100.0	100.0	100.0	98.0	98.0	98.0	96.0	96.0	96.0	96.0	96.0	96.0
200 ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
400 ppm	50	50/50	50/50	50/50	50/50	50/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		100.0	100.0	100.0	100.0	100.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 14	15	16	17	18	19	20	21	22	23	24	25	26	27
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
100 ppm	50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50
		96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0
200 ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
400 ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 28	29	30	31	32	33	34	35	36	37	38	39	40	41
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
100 ppm	50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50
		96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0
200 ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
400 ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 42	43	44	45	46	47	48	49	50	51	52	53	54	55
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
100 ppm	50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	47/50	46/50	46/50	46/50	46/50
		96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	94.0	92.0	92.0	92.0	92.0
200 ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0
400 ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	48/50	48/50	48/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	96.0	96.0	96.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 56	57	58	59	60	61	62	63	64	65	66	67	68	69
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
100 ppm	50	45/50	45/50	45/50	45/50	45/50	45/50	44/50	44/50	44/50	44/50	44/50	44/50	44/50	44/50
		90.0	90.0	90.0	90.0	90.0	90.0	88.0	88.0	88.0	88.0	88.0	88.0	88.0	88.0
200 ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	48/50	48/50	48/50	48/50	48/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	96.0	96.0	96.0	96.0	96.0
400 ppm	50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50
		96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 70	71	72	73	74	75	76	77	78	79	80	81	82	83
Control	50	50/50	50/50	50/50	50/50	49/50	49/50	49/50	49/50	49/50	48/50	47/50	47/50	47/50	45/50
		100.0	100.0	100.0	100.0	98.0	98.0	98.0	98.0	98.0	96.0	94.0	94.0	94.0	90.0
100 ppm	50	44/50	44/50	44/50	44/50	44/50	44/50	44/50	42/50	42/50	42/50	41/50	40/50	40/50	40/50
		88.0	88.0	88.0	88.0	88.0	88.0	88.0	84.0	84.0	84.0	82.0	80.0	80.0	80.0
200 ppm	50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	46/50
		96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	92.0
400 ppm	50	48/50	48/50	48/50	48/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	46/50	46/50
		96.0	96.0	96.0	96.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	92.0	92.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 84	85	86	87	88	89	90	91	92	93	94	95	96	97
Control	50	45/50	45/50	45/50	45/50	45/50	44/50	40/50	39/50	39/50	39/50	38/50	38/50	37/50	37/50
		90.0	90.0	90.0	90.0	90.0	88.0	80.0	78.0	78.0	78.0	76.0	76.0	74.0	74.0
100 ppm	50	40/50	40/50	40/50	40/50	39/50	37/50	37/50	37/50	37/50	36/50	35/50	35/50	34/50	34/50
		80.0	80.0	80.0	80.0	78.0	74.0	74.0	74.0	74.0	72.0	70.0	70.0	68.0	68.0
200 ppm	50	46/50	45/50	44/50	44/50	43/50	43/50	42/50	41/49	41/49	39/49	38/49	38/49	38/49	38/49
		92.0	90.0	88.0	88.0	86.0	86.0	84.0	83.7	83.7	79.6	77.6	77.6	77.6	77.6
400 ppm	50	46/50	45/50	45/50	45/50	45/50	44/50	44/50	44/50	44/50	44/50	44/50	44/50	43/50	41/50
		92.0	90.0	90.0	90.0	90.0	88.0	88.0	88.0	88.0	88.0	88.0	88.0	86.0	82.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 98	99	100	101	102	103	104
Control	50	37/50	36/50	36/50	36/50	36/50	33/50	30/50
		74.0	72.0	72.0	72.0	72.0	66.0	60.0
100 ppm	50	33/50	33/50	33/50	33/50	31/50	31/50	31/50
		66.0	66.0	66.0	66.0	62.0	62.0	62.0
200 ppm	50	37/49	37/49	37/49	37/49	36/49	35/49	34/49
		75.5	75.5	75.5	75.5	73.5	71.4	69.4
400 ppm	50	41/50	41/50	40/50	40/50	40/50	40/50	39/50
		82.0	82.0	80.0	80.0	80.0	80.0	78.0

Number of survival/ Number of effective animals
Survival rate(%)

TABLE B2

SURVIVAL ANIMAL NUMBERS : FEMALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 0	1	2	3	4	5	6	7	8	9	10	11	12	13
Control	50	50/50	50/50	50/50	50/50	50/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		100.0	100.0	100.0	100.0	100.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0
100 ppm	50	50/50	50/50	50/50	50/50	49/49	49/49	49/49	49/49	49/49	49/49	49/49	49/49	49/49	49/49
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
200 ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
400 ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	49/50	49/50	49/50	49/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.0	98.0	98.0	98.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 14	15	16	17	18	19	20	21	22	23	24	25	26	27
Control	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0
100 ppm	50	49/49	49/49	49/49	49/49	49/49	49/49	49/49	49/49	49/49	48/49	48/49	48/49	48/49	48/49
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.0	98.0	98.0	98.0	98.0
200 ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
400 ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 28	29	30	31	32	33	34	35	36	37	38	39	40	41
Control	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0
100 ppm	50	48/49	48/49	48/49	48/49	48/49	48/49	48/49	48/49	48/49	48/49	48/49	48/49	48/49	48/49
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0
200 ppm	50	50/50	50/50	50/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		100.0	100.0	100.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0
400 ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. :.0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 42	43	44	45	46	47	48	49	50	51	52	53	54	55
Control	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	48/50	48/50	48/50	48/50	48/50	48/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	96.0	96.0	96.0	96.0	96.0	96.0
100 ppm	50	48/49	48/49	48/49	48/49	48/49	48/49	48/49	48/49	48/49	47/49	47/49	47/49	47/49	47/49
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	95.9	95.9	95.9	95.9	95.9
200 ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0
400 ppm	50	49/50	49/50	49/50	49/50	49/50	48/50	48/50	48/50	48/50	48/50	48/50	47/50	47/50	47/50
		98.0	98.0	98.0	98.0	98.0	96.0	96.0	96.0	96.0	96.0	96.0	94.0	94.0	94.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 56	57	58	59	60	61	62	63	64	65	66	67	68	69
Control	50	48/50	48/50	47/50	47/50	47/50	47/50	47/50	47/50	46/50	45/50	45/50	45/50	45/50	45/50
		96.0	96.0	94.0	94.0	94.0	94.0	94.0	94.0	92.0	90.0	90.0	90.0	90.0	90.0
100 ppm	50	47/49	47/49	47/49	47/49	47/49	47/49	47/49	47/49	47/49	47/49	47/49	47/49	47/49	46/49
		95.9	95.9	95.9	95.9	95.9	95.9	95.9	95.9	95.9	95.9	95.9	95.9	95.9	93.9
200 ppm	50	49/50	49/50	48/50	48/50	48/50	48/50	48/50	48/50	47/50	47/50	47/50	47/50	47/50	47/50
		98.0	98.0	96.0	96.0	96.0	96.0	96.0	96.0	94.0	94.0	94.0	94.0	94.0	94.0
400 ppm	50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	46/50
		94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	92.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 70	71	72	73	74	75	76	77	78	79	80	81	82	83
Control	50	45/50	45/50	45/50	45/50	45/50	45/50	45/50	45/50	45/50	44/50	44/50	44/50	44/50	44/50
		90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	88.0	88.0	88.0	88.0	88.0
100 ppm	50	46/49	45/49	44/49	44/49	44/49	44/49	44/49	44/49	44/49	44/49	44/49	43/49	43/49	43/49
		93.9	91.8	89.8	89.8	89.8	89.8	89.8	89.8	89.8	89.8	89.8	87.8	87.8	87.8
200 ppm	50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	46/50	46/50	46/50	43/50	43/50	43/50	43/50
		94.0	94.0	94.0	94.0	94.0	94.0	94.0	92.0	92.0	92.0	86.0	86.0	86.0	86.0
400 ppm	50	46/50	46/50	46/50	46/50	46/50	46/50	46/50	46/50	46/50	46/50	45/50	45/50	45/50	44/50
		92.0	92.0	92.0	92.0	92.0	92.0	92.0	92.0	92.0	92.0	90.0	90.0	90.0	88.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 84	85	86	87	88	89	90	91	92	93	94	95	96	97
Control	50	44/50	44/50	44/50	44/50	43/50	42/50	42/50	42/50	42/50	42/50	41/50	41/50	41/50	39/50
		88.0	88.0	88.0	88.0	86.0	84.0	84.0	84.0	84.0	84.0	82.0	82.0	82.0	78.0
100 ppm	50	42/49	42/49	42/49	40/49	40/49	39/49	38/49	38/49	38/49	38/49	36/49	36/49	36/49	35/49
		85.7	85.7	85.7	81.6	81.6	79.6	77.6	77.6	77.6	77.6	73.5	73.5	73.5	71.4
200 ppm	50	42/50	40/50	39/50	39/50	39/50	39/50	38/50	37/50	36/50	33/50	32/50	30/50	29/50	29/50
		84.0	80.0	78.0	78.0	78.0	78.0	76.0	74.0	72.0	66.0	64.0	60.0	58.0	58.0
400 ppm	50	44/50	43/50	43/50	43/50	43/50	43/50	42/50	42/50	41/50	41/50	39/50	39/50	38/50	37/50
		88.0	86.0	86.0	86.0	86.0	86.0	84.0	84.0	82.0	82.0	78.0	78.0	76.0	74.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 98	99	100	101	102	103	104
Control	50	37/50	37/50	35/50	34/50	32/50	32/50	31/50
		74.0	74.0	70.0	68.0	64.0	64.0	62.0
100 ppm	50	34/49	34/49	31/49	30/49	29/49	27/49	27/49
		69.4	69.4	63.3	61.2	59.2	55.1	55.1
200 ppm	50	29/50	27/50	26/50	26/50	26/50	26/50	26/50
		58.0	54.0	52.0	52.0	52.0	52.0	52.0
400 ppm	50	37/50	36/50	36/50	36/50	36/50	34/50	34/50
		74.0	72.0	72.0	72.0	72.0	68.0	68.0

Number of survival/ Number of effective animals
Survival rate(%)

TABLE C1

CLINICAL OBSERVATION : MALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 104

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	1	1	1	1	1	1	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXCITEMENT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	1	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	2	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXCITEMENT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXCITEMENT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	1	1	1	1	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	1	1	1	1	1	1	1	1	1	1	1	1	1
	200 ppm	0	0	0	1	1	1	1	1	1	1	1	1	1	1
	400 ppm	0	0	0	1	1	1	1	1	1	1	1	1	1	1
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	1	1	1	1	1	1	1	2	2	2	2	2	2
	200 ppm	0	0	0	0	0	0	1	1	1	1	1	1	1	1
	400 ppm	1	1	1	1	1	1	1	1	1	1	2	2	2	2
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	1	1	1	1	1	1	1	1	2	2	2	2	3
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXCITEMENT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	1	1	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	1	1	1	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	1	2	2	2	2	2	2	2	2	2	2	2	1
	200 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	400 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	2	2	2	2	2	3	3	3	3	3	3	3	3	3
	200 ppm	1	1	1	1	1	1	1	1	2	2	2	2	2	2
	400 ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	3	3	3	3	3	3	3	3	3	3	3	3	3	3
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXCITEMENT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	200 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	400 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
DEATH	Control	0	0	0	1	1	1	1	1	2	3	3	3	5	5
	100 ppm	3	3	3	3	3	3	5	5	5	6	6	6	6	6
	200 ppm	2	2	2	2	2	2	2	2	2	2	2	2	4	4
	400 ppm	2	2	2	3	3	3	3	3	3	3	3	4	4	4
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	3	3	3	3	3	3	3	3	3	3	4	4	4	4
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	1	1	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	1	0	0	0
EXCITEMENT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	1	1	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	1	0	0
PILOERECTION	Control	0	0	0	0	0	0	1	1	1	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	1	2	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	1	1	1	1	1	1	1	2	1	1	1	2	2
	200 ppm	1	1	1	1	1	1	1	1	1	1	2	2	2	2
	400 ppm	1	1	1	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	1	1	1	1	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
DEATH	Control	5	5	5	5	6	9	10	10	10	11	11	12	12	12
	100 ppm	6	6	6	7	9	9	9	9	10	11	11	11	11	12
	200 ppm	5	6	6	7	7	8	8	8	10	11	11	11	11	12
	400 ppm	5	5	5	5	6	6	6	6	6	6	6	7	8	8
MORIBUND SACRIFICE	Control	0	0	0	0	0	1	1	1	1	1	1	1	1	1
	100 ppm	4	4	4	4	4	4	4	4	4	4	4	5	5	5
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXCITEMENT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	1	1	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	1	1	1	1	1	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	0
	200 ppm	0	0	0	0	0	0	1	1	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	2	2	2	2	0	0	0	0	0	0	0	0	0
	100 ppm	2	2	2	2	2	2	2	2	1	1	1	1	1	1
	200 ppm	1	1	1	1	1	1	1	1	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	1	2	2	2	1	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	0
	200 ppm	1	0	0	0	0	0	0	0	1	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
DEATH	Control	13	13	13	13	16	19
	100 ppm	12	12	12	13	13	13
	200 ppm	12	12	12	13	14	15
	400 ppm	8	9	9	9	9	10
MORIBUND SACRIFICE	Control	1	1	1	1	1	1
	100 ppm	5	5	5	6	6	6
	200 ppm	0	0	0	0	0	0
	400 ppm	1	1	1	1	1	1
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
EXCITEMENT	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0
	100 ppm	1	1	1	2	2	2
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLOSED EYELID	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	1	1	1	1	1	1	1	1	1	0	0
	100 ppm	0	0	4	5	3	3	3	2	2	2	2	2	1	1
	200 ppm	0	0	1	1	1	1	1	1	1	1	1	1	1	1
	400 ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	1
M. EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLOSED EYELID	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	100 ppm	2	2	3	3	3	3	3	3	3	3	3	3	3	3
	200 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	400 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
M. EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLOSED EYELID	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	100 ppm	3	5	5	4	4	4	4	4	4	4	4	4	4	4
	200 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	400 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
M. EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLOSED EYELID	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	1	1	1	1	1	1	1	1	1	1	1	1	1
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	1	1	1	1	1	0	0	0	0	0	0	0	0	0
	100 ppm	4	5	5	5	5	5	5	5	5	5	5	5	5	4
	200 ppm	1	1	1	1	1	1	2	2	2	2	2	2	2	2
	400 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
M. EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	1	1	1	1	1	1	1	1	1	1	1	1	1
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLOSED EYELID	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	1	1	1	1	1	2
	200 ppm	1	1	1	1	1	1	2	2	1	1	1	1	1	1
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	100 ppm	4	4	4	4	3	2	3	3	3	3	3	3	3	3
	200 ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	400 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
M. EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	1	1	1	1	1	1	1
	100 ppm	0	0	0	0	0	0	1	1	1	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GUM	Control	0	0	0	0	0	1	1	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLOSED EYELID	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	1	1	1	1	1	1	1	1	1	1	1	1
	200 ppm	0	0	0	0	0	0	1	1	1	1	1	1	1	1
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	1	1	0	0
	100 ppm	2	2	2	2	2	2	1	2	2	1	1	1	1	2
	200 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	400 ppm	1	1	1	0	0	0	0	0	0	0	1	0	0	0
INTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	0	1	2	1	3
	100 ppm	3	3	3	3	4	4	4	5	6	5	4	4	4	4
	200 ppm	2	2	2	2	2	2	2	2	2	2	2	3	3	3
	400 ppm	1	1	1	0	0	0	0	0	0	0	1	0	0	0
M. EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	1	1	0	0	0	0	0
	200 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	1	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	1	1	1	1	1	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
EXOPHTHALMOS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	1	1	1	1	1	1	1	1	1	1	1	1	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLOSED EYELID	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	1	1	1	2
	100 ppm	2	2	2	2	2	2	2	3	3	3	3	2	2	1
	200 ppm	2	2	2	2	2	2	2	2	2	2	2	2	3	3
	400 ppm	0	0	1	1	1	1	1	1	1	1	1	1	2	2
INTERNAL MASS	Control	4	5	6	6	5	3	1	2	2	4	4	4	4	4
	100 ppm	4	4	4	3	3	3	3	2	1	3	4	3	4	3
	200 ppm	3	3	3	3	3	3	2	2	1	1	1	1	3	2
	400 ppm	0	0	0	1	2	2	3	3	3	3	4	3	2	2
M. EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	2	2	2	2	2	2	2	2	2	2	2	2	3	3
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	100 ppm	0	0	0	0	0	0	0	1	1	1	1	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
EXOPHTHALMOS	Control	1	1	1	1	1	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
GUM	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
CLOSED EYELID	Control	0	0	0	0	0	0
	100 ppm	1	1	1	1	1	1
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
EXTERNAL MASS	Control	2	2	2	3	3	1
	100 ppm	1	1	1	1	1	1
	200 ppm	3	3	3	3	3	3
	400 ppm	3	3	3	2	2	1
INTERNAL MASS	Control	5	5	4	4	4	5
	100 ppm	5	5	5	4	5	6
	200 ppm	2	2	3	2	2	1
	400 ppm	3	2	2	2	2	3
M. EYE	Control	1	1	1	1	1	0
	100 ppm	0	0	0	0	0	0
	200 ppm	3	3	3	3	3	3
	400 ppm	1	1	1	1	1	1
M. NECK	Control	1	1	1	1	1	1
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	1	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. TAIL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. TAIL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. TAIL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. TAIL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	1	1	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. TAIL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	1	1	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	1	1	1	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. TAIL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	1	1	1	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	1	1	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	1	1	1	1	1	1	1
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	1	1	1	1	1	1	1	1	1	1	2	2
M. TAIL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	1	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	1	1	1	1	1	0	0	1	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	1	1	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	1	1	2
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	1	1	1	1	1	1	1	1	1	0	0	0	1	1
	400 ppm	0	0	0	0	0	0	0	0	0	0	1	1	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	1	1	1	1	1	1	1
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	1	1	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0
	100 ppm	1	1	1	1	1	1
	200 ppm	0	0	0	0	0	0
	400 ppm	2	2	2	1	1	0
M. TAIL	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
CRUSTA	Control	1	1	1	1	1	0
	100 ppm	0	0	0	0	1	1
	200 ppm	0	0	1	1	1	1
	400 ppm	0	0	0	0	0	0
TORTICOLLIS	Control	1	1	1	1	1	1
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	50	50	50	49	49	49	49	49	49	49	49	49	50	50
	100 ppm	50	50	46	45	46	46	46	46	46	46	46	46	47	47
	200 ppm	49	49	48	48	48	48	48	48	48	48	48	48	48	48
	400 ppm	49	50	50	50	49	49	49	49	49	48	48	48	48	48

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	50	50	50	50	50	50	50	50	50	49	49	49	49	49
	100 ppm	46	46	45	45	45	45	45	45	45	45	45	45	45	45
	200 ppm	48	48	48	48	48	48	48	48	48	48	48	48	48	48
	400 ppm	48	48	48	48	48	48	48	48	48	48	48	48	48	48

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	49	49	49	49	49	49	49	49	49	49	49	49	49	49
	100 ppm	45	43	43	44	44	44	44	44	44	44	44	44	44	44
	200 ppm	48	48	48	48	48	48	48	48	48	48	48	48	48	48
	400 ppm	48	48	48	48	48	48	48	48	48	48	48	48	48	48

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	1	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	49	49	49	49	49	50	50	50	50	50	50	50	50	50
	100 ppm	44	43	43	43	43	43	42	42	41	41	41	41	41	41
	200 ppm	48	47	47	47	47	47	45	45	45	45	45	45	45	45
	400 ppm	48	48	48	48	48	48	48	48	48	48	47	47	47	47

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	50	50	50	50	50	50	50	50	50	50	49	49	49	49
	100 ppm	40	41	41	41	42	42	41	41	40	40	40	40	40	39
	200 ppm	45	45	45	45	45	45	44	44	44	44	44	44	44	44
	400 ppm	47	47	47	47	47	47	47	47	47	47	47	47	47	47

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	1	1	0	0	0	0	0
	200 ppm	1	0	0	0	0	0	0	0	0	1	1	1	0	0
	400 ppm	1	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	1	1	0	1	1	0	0
	100 ppm	0	0	0	0	0	1	0	0	1	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	1	1	1	1
NON REMARKABLE	Control	49	49	49	48	48	47	46	46	45	45	43	43	43	41
	100 ppm	39	39	38	38	38	38	37	36	34	35	35	35	35	34
	200 ppm	44	44	44	44	44	44	43	42	42	42	41	41	40	40
	400 ppm	47	47	47	47	47	47	47	47	47	47	46	45	45	45

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	1	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	1	0	0	0	0	0	0	0	0
	200 ppm	1	0	0	0	0	0	1	1	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	40	39	37	37	37	36	37	35	35	32	32	30	30	29
	100 ppm	34	34	34	33	32	32	32	31	31	29	28	29	28	28
	200 ppm	38	38	38	37	37	36	36	36	35	35	35	35	31	31
	400 ppm	45	45	44	43	41	41	40	40	40	40	39	39	36	36

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
PROLAPSE OF PENIS	Control	0	0	0	0	0	1
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	1	1
IRREGULAR BREATHING	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
NON REMARKABLE	Control	28	28	29	29	26	24
	100 ppm	26	26	26	25	23	22
	200 ppm	32	32	31	31	30	30
	400 ppm	35	35	35	36	36	35

TABLE C2

CLINICAL OBSERVATION : FEMALE

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
DEATH	Control	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROLLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ABNORMAL GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
STEP BACK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
DEATH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	100 ppm	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROLLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ABNORMAL GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
STEP BACK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
DEATH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	100 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	200 ppm	0	0	1	1	1	1	1	1	1	1	1	1	1	1
	400 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROLLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ABNORMAL GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
STEP BACK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
DEATH	Control	1	1	1	1	1	1	1	2	2	2	2	2	2	2
	100 ppm	1	1	1	1	1	1	1	1	2	2	2	2	2	2
	200 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	400 ppm	1	1	1	1	2	2	2	2	2	2	3	3	3	3
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROLLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ABNORMAL GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
STEP BACK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
DEATH	Control	2	3	3	3	3	3	3	4	5	5	5	5	5	5
	100 ppm	2	2	2	2	2	2	2	2	2	2	2	2	3	3
	200 ppm	1	2	2	2	2	2	2	3	3	3	3	3	3	3
	400 ppm	3	3	3	3	3	3	3	3	3	3	3	3	4	4
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROLLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	1	1	1	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ABNORMAL GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
STEP BACK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
DEATH	Control	5	5	5	5	5	5	5	5	6	6	6	6	6	6
	100 ppm	4	5	5	5	5	5	5	5	5	5	6	6	6	7
	200 ppm	3	3	3	3	3	3	4	4	4	6	6	6	6	7
	400 ppm	4	4	4	4	4	4	4	4	4	4	4	4	5	5
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	400 ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	1
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	1	1	1	1	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	1	1	1	1	1	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROLLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ABNORMAL GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	1	1	1	1	1	1	1	1
	200 ppm	0	0	0	0	0	0	0	1	1	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
STEP BACK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	1	1	1	1	1	1	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
DEATH	Control	6	6	6	7	8	8	8	8	8	9	9	9	10	12
	100 ppm	7	7	8	8	9	10	10	10	10	12	12	12	13	13
	200 ppm	9	10	10	10	10	11	11	12	15	15	17	17	17	17
	400 ppm	6	6	6	6	6	7	7	8	8	10	10	11	12	12
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	100 ppm	0	0	1	1	1	1	1	1	1	1	1	1	1	2
	200 ppm	1	1	1	1	1	1	2	2	2	3	3	4	4	4
	400 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	1	1	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROLLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ABNORMAL GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	1	1	1	1	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
STEP BACK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	1	1	1	1	1	1	1	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
DEATH	Control	12	13	14	16	16	16
	100 ppm	13	16	17	18	20	20
	200 ppm	19	19	19	19	19	19
	400 ppm	13	13	13	13	13	13
MORIBUND SACRIFICE	Control	1	2	2	2	2	3
	100 ppm	2	2	2	2	2	2
	200 ppm	4	5	5	5	5	5
	400 ppm	1	1	1	1	3	3
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0
	100 ppm	0	0	0	1	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0
	100 ppm	1	0	0	0	1	1
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
ROLLING	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
ABNORMAL GAIT	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
STEP BACK	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	1	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	3	3	3	3	3	3	3	3	2	2	1	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	1	1	1	1	1	1	1

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	1	0	0	0	0	0	0	1
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	1	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	1	1	1	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	1	1	1	1	1	0	0	0	0	1	1	1
	100 ppm	1	1	2	2	2	1	1	1	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	400 ppm	1	1	2	3	2	2	2	2	2	2	1	0	0	0

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	1	0	2
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	1	0	0	0	0	0	1	1	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	200 ppm	1	0	0	1	1	1	1	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	1	0	0	0	0	1	1	1	0	0	0	0	1	1
	100 ppm	0	0	0	0	0	0	1	1	1	1	1	2	1	1
	200 ppm	1	0	0	0	1	1	1	0	0	0	0	0	0	1
	400 ppm	0	0	0	0	0	0	0	0	0	0	1	1	1	1

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	1	1	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	1	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	100 ppm	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	1	1	2	2	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	1	1	1	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	0	0	0	0	0	1	1	1	2	2	2	2	2
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
INTERNAL MASS	Control	1	1	1	1	1	1	1	1	0	0	0	0	0	1
	100 ppm	0	0	1	1	1	0	0	0	0	0	0	0	0	0
	200 ppm	1	1	1	1	1	2	1	2	2	1	2	3	3	4
	400 ppm	0	0	0	0	0	0	0	0	0	2	2	2	1	1

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	1	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	1	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	1	1	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	1	1	2	2	2	2	3	3	3	3	1
	100 ppm	0	0	0	0	0	0	0	1	1	0	0	0	0	0
	200 ppm	1	0	0	1	1	2	3	2	2	3	2	1	1	1
	400 ppm	0	0	0	0	0	0	1	1	1	1	2	1	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	1	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	1	1	1	1	1	1	1	1	1	1	1	1	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	1	1	1	1	1	1	1	1	1	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	0	1	1	1	1	1	1	1	1	0	0
	100 ppm	2	2	0	0	0	0	0	0	0	0	0	0	0	1
	200 ppm	1	1	1	1	0	0	0	0	0	0	0	0	1	1
	400 ppm	1	1	1	1	1	1	2	2	3	3	3	3	3	3
INTERNAL MASS	Control	2	2	2	2	2	2	2	4	3	4	4	6	5	3
	100 ppm	0	0	0	0	0	0	0	2	2	1	1	1	1	2
	200 ppm	3	2	2	3	3	2	3	4	3	3	2	1	1	1
	400 ppm	1	1	2	2	3	2	3	2	2	2	2	1	2	0

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
WASTING	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
FROG BELLY	Control	2	0	0	0	1	1
	100 ppm	0	1	0	0	0	0
	200 ppm	1	1	1	1	1	2
	400 ppm	0	0	1	1	0	1
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	1
EXTERNAL MASS	Control	0	0	0	0	0	0
	100 ppm	1	0	0	1	1	1
	200 ppm	1	0	0	0	0	0
	400 ppm	3	3	3	2	2	2
INTERNAL MASS	Control	4	2	2	3	3	2
	100 ppm	2	2	1	1	0	1
	200 ppm	0	0	1	0	0	0
	400 ppm	0	0	2	0	0	0

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
M. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. INTERSCAPULUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
M. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. INTERSCAPULUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
M. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. INTERSCAPULUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
M. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. INTERSCAPULUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	1	1	1	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
M. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. INTERSCAPULUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	1	1	1	1	1	1	1	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
M. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	1	1	1	1	1	1	1	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. INTERSCAPULUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	0	0	0	0	0	0	0	0	0	0	0	0	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
M. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
M. NECK	Control	1	1	1	0	0	0	0	1	1	1	1	1	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	1	1	1	1	0	0
M. FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	1	0	0	0	0	0	0	0	0	0	0	0	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR. DORSUM	Control	0	0	0	0	1	1	1	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
M. INTERSCAPULUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	1	1	1	1	1	1	1	1
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	1	1	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
M. PERI EAR	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	1	1	1	1	1	1
M. NECK	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
M. FORELIMB	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0
	100 ppm	1	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	1	1	1	0	0	0
M. INTERSCAPULUM	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	1	1	1	1	1	1
M. HINDLIMB	Control	0	0	0	0	0	0
	100 ppm	0	0	0	1	1	1
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
M. ANUS	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	1	0	0	0	0	0
	400 ppm	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SUBNORMAL TEMP	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	50	50	50	50	49	49	49	49	49	49	49	49	49	49
	100 ppm	49	49	46	46	46	46	46	46	46	46	47	47	48	48
	200 ppm	50	50	50	50	50	50	50	50	50	50	50	50	50	50
	400 ppm	50	50	50	50	50	49	50	50	50	49	49	49	49	49

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SUBNORMAL TEMP	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	49	49	49	49	49	49	49	49	49	49	49	49	49	49
	100 ppm	48	48	48	48	48	48	48	47	47	47	47	47	47	47
	200 ppm	50	50	50	50	50	50	50	50	50	50	50	50	50	49
	400 ppm	49	49	49	49	49	49	49	49	49	49	49	49	49	49

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	1	1	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SUBNORMAL TEMP	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	49	49	49	49	49	49	49	49	49	49	49	49	49	49
	100 ppm	47	47	47	47	47	47	47	47	47	47	47	47	47	47
	200 ppm	49	49	49	49	49	49	49	49	49	49	49	49	49	49
	400 ppm	49	49	49	49	49	49	49	48	48	48	48	48	48	48

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	1	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SUBNORMAL TEMP	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	49	49	48	48	48	48	48	48	48	48	48	47	47	47
	100 ppm	47	47	46	46	46	46	46	46	47	47	47	47	47	47
	200 ppm	49	49	49	49	49	49	49	49	49	49	49	48	48	48
	400 ppm	48	48	47	46	46	46	46	46	46	46	46	47	47	47

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	1	1	1	1	1	1	1	2	2	2	2	2
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SUBNORMAL TEMP	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	47	47	47	47	47	46	46	45	45	45	45	45	44	44
	100 ppm	46	47	46	46	45	45	44	44	44	43	43	42	42	42
	200 ppm	48	48	48	47	47	47	47	47	47	47	47	47	47	46
	400 ppm	47	47	47	47	47	47	47	47	47	47	46	46	45	45

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	100 ppm	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	1	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	1	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SUBNORMAL TEMP	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	44	44	44	44	44	44	44	44	44	44	44	43	43	43
	100 ppm	42	42	42	42	42	42	41	41	41	40	39	39	39	38
	200 ppm	46	46	46	46	45	44	44	42	42	42	41	40	40	37
	400 ppm	46	46	46	46	46	46	46	46	46	43	43	43	42	42

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	2	2	2	2	2	1	1	1	1	1	1	1	1	1
	200 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	1	1	1	1	2	2	2	0	1
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0	2	1	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	1	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	1	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SUBNORMAL TEMP	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 ppm	0	0	0	0	1	0	0	0	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	41	41	41	41	39	39	39	37	38	36	36	34	34	33
	100 ppm	38	38	38	38	37	37	37	35	35	34	34	34	33	30
	200 ppm	35	35	35	34	35	33	31	30	29	27	26	26	26	26
	400 ppm	41	41	40	40	39	39	37	37	36	34	34	34	32	34

Clinical sign	Group Name	Administration Week-day 99-7	100-7	101-7	102-7	103-7	104-7
CRUSTA	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0
	100 ppm	1	1	1	0	0	0
	200 ppm	1	1	1	1	1	1
	400 ppm	0	0	0	0	0	0
IRREGULAR BREATHING	Control	1	1	1	0	0	0
	100 ppm	0	0	0	1	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
SUBNORMAL TEMP	Control	0	0	0	0	0	0
	100 ppm	0	0	0	0	0	0
	200 ppm	0	0	0	0	0	0
	400 ppm	0	0	0	0	0	0
NON REMARKABLE	Control	32	32	31	29	29	29
	100 ppm	29	28	28	27	26	25
	200 ppm	25	24	23	24	24	23
	400 ppm	33	33	31	33	32	31

TABLE D1

BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : MALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

MEAN BODY WEIGHTS AND SURVIVAL

Week on Study	Control Av. Wt.	Control No. of Surviv. <50>	100 ppm Av. Wt.	100 ppm % of cont. <50>	100 ppm No. of Surviv.	200 ppm Av. Wt.	200 ppm % of cont. <49>	200 ppm No. of Surviv.	400 ppm Av. Wt.	400 ppm % of cont. <50>	400 ppm No. of Surviv.
0	23.5 (50)	50/50	23.5 (50)	100	50/50	23.5 (49)	100	49/49	23.5 (50)	100	50/50
1	24.6 (50)	50/50	24.4 (50)	99	50/50	24.9 (49)	101	49/49	24.3 (50)	99	50/50
2	25.7 (50)	50/50	25.1 (50)	98	50/50	25.6 (49)	100	49/49	24.9 (50)	97	50/50
3	26.3 (50)	50/50	25.3 (50)	96	50/50	26.1 (49)	99	49/49	25.6 (50)	97	50/50
4	26.8 (50)	50/50	25.5 (50)	95	50/50	26.7 (49)	100	49/49	26.1 (50)	97	50/50
5	27.5 (50)	50/50	26.3 (49)	96	49/50	27.5 (49)	100	49/49	26.5 (49)	96	49/50
6	28.1 (50)	50/50	26.9 (49)	96	49/50	27.9 (49)	99	49/49	27.0 (49)	96	49/50
7	28.9 (50)	50/50	27.6 (49)	96	49/50	28.5 (49)	99	49/49	27.5 (49)	95	49/50
8	29.7 (50)	50/50	28.7 (48)	97	48/50	29.3 (49)	99	49/49	28.0 (49)	94	49/50
9	30.3 (50)	50/50	29.2 (48)	96	48/50	29.7 (49)	98	49/49	28.5 (49)	94	49/50
10	30.9 (50)	50/50	29.5 (48)	95	48/50	30.4 (49)	98	49/49	29.1 (49)	94	49/50
11	31.5 (50)	50/50	30.1 (48)	96	48/50	31.2 (49)	99	49/49	29.9 (49)	95	49/50
12	32.5 (50)	50/50	31.2 (48)	96	48/50	31.9 (49)	98	49/49	30.6 (49)	94	49/50
13	33.0 (50)	50/50	31.8 (48)	96	48/50	32.5 (49)	98	49/49	31.1 (49)	94	49/50
14	33.3 (50)	50/50	31.9 (48)	96	48/50	33.0 (49)	99	49/49	31.5 (49)	95	49/50
18	36.1 (50)	50/50	35.0 (48)	97	48/50	35.8 (49)	99	49/49	34.3 (49)	95	49/50
22	38.4 (50)	50/50	38.0 (48)	99	48/50	38.1 (49)	99	49/49	36.6 (49)	95	49/50
26	39.8 (50)	50/50	39.3 (48)	99	48/50	39.8 (49)	100	49/49	38.3 (49)	96	49/50
30	41.6 (50)	50/50	41.5 (48)	100	48/50	41.8 (49)	100	49/49	40.2 (49)	97	49/50
34	43.7 (50)	50/50	43.6 (48)	100	48/50	43.9 (49)	100	49/49	42.5 (49)	97	49/50
38	44.8 (50)	50/50	45.1 (48)	101	48/50	45.1 (49)	101	49/49	43.4 (49)	97	49/50
42	45.7 (50)	50/50	46.0 (48)	101	48/50	45.8 (49)	100	49/49	44.2 (49)	97	49/50
46	46.3 (50)	50/50	46.6 (48)	101	48/50	46.8 (49)	101	49/49	44.6 (49)	96	49/50
50	47.3 (50)	50/50	47.3 (48)	100	48/50	47.6 (48)	101	48/49	45.1 (49)	95	49/50
54	48.2 (50)	50/50	48.3 (46)	100	46/50	47.8 (48)	99	48/49	46.0 (48)	95	48/50
58	48.9 (50)	50/50	48.7 (45)	100	45/50	48.8 (48)	100	48/49	46.6 (48)	95	48/50
62	49.5 (50)	50/50	49.1 (44)	99	44/50	49.0 (48)	99	48/49	47.2 (48)	95	48/50
66	50.2 (50)	50/50	49.5 (44)	99	44/50	49.3 (47)	98	47/49	47.9 (48)	95	48/50
70	51.0 (50)	50/50	50.1 (44)	98	44/50	50.1 (47)	98	47/49	48.6 (48)	95	48/50
74	52.0 (49)	49/50	50.9 (44)	98	44/50	50.4 (47)	97	47/49	49.0 (47)	94	47/50
78	51.7 (49)	49/50	50.6 (42)	98	42/50	50.9 (47)	98	47/49	49.7 (47)	96	47/50
82	51.7 (47)	47/50	51.9 (40)	100	40/50	51.2 (47)	99	47/49	49.9 (46)	97	46/50
86	50.9 (45)	45/50	51.0 (40)	100	40/50	50.8 (43)	100	43/49	49.8 (45)	98	45/50
90	51.5 (40)	40/50	51.2 (37)	99	37/50	50.4 (41)	98	41/49	49.6 (44)	96	44/50
94	51.2 (38)	38/50	50.7 (35)	99	35/50	50.6 (38)	99	38/49	49.3 (44)	96	44/50
98	50.1 (37)	37/50	49.7 (33)	99	33/50	50.5 (37)	101	37/49	49.0 (41)	98	41/50
102	49.1 (36)	36/50	49.6 (31)	101	31/50	49.9 (36)	102	36/49	47.8 (40)	97	40/50
104	49.8 (30)	30/50	48.6 (31)	98	31/50	50.4 (34)	101	34/49	48.3 (39)	97	39/50

< >:No. of effective animals, ( ):No. of measured animals Av. Wt. : g

TABLE D2

BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : FEMALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

MEAN BODY WEIGHTS AND SURVIVAL

Week on Study	Control Av. Wt.	Control No. of Surviv. <50>	100 ppm Av. Wt.	100 ppm % of cont. <49>	100 ppm No. of Surviv.	200 ppm Av. Wt.	200 ppm % of cont. <50>	200 ppm No. of Surviv.	400 ppm Av. Wt.	400 ppm % of cont. <50>	400 ppm No. of Surviv.
0	19.5 (50)	50/50	19.5 (49)	100	49/49	19.5 (50)	100	50/50	19.5 (50)	100	50/50
1	20.0 (50)	50/50	19.7 (49)	99	49/49	19.9 (50)	100	50/50	19.8 (50)	99	50/50
2	20.8 (50)	50/50	20.3 (49)	98	49/49	20.5 (50)	99	50/50	20.3 (50)	98	50/50
3	21.1 (50)	50/50	20.7 (49)	98	49/49	20.9 (50)	99	50/50	20.9 (50)	99	50/50
4	21.6 (50)	50/50	21.3 (49)	99	49/49	21.5 (50)	100	50/50	21.5 (50)	100	50/50
5	22.0 (49)	49/50	21.6 (49)	98	49/49	22.3 (50)	101	50/50	21.9 (50)	100	50/50
6	22.4 (49)	49/50	22.3 (49)	100	49/49	22.7 (50)	101	50/50	22.4 (50)	100	50/50
7	23.0 (49)	49/50	22.8 (49)	99	49/49	22.9 (50)	100	50/50	23.0 (50)	100	50/50
8	23.5 (49)	49/50	23.2 (49)	99	49/49	23.8 (50)	101	50/50	23.3 (50)	99	50/50
9	23.4 (49)	49/50	23.1 (49)	99	49/49	23.9 (50)	102	50/50	23.7 (50)	101	50/50
10	23.7 (49)	49/50	23.5 (49)	99	49/49	24.2 (50)	102	50/50	24.0 (49)	101	49/50
11	24.0 (49)	49/50	23.9 (49)	100	49/49	24.4 (50)	102	50/50	24.4 (49)	102	49/50
12	24.9 (49)	49/50	24.5 (49)	98	49/49	25.0 (50)	100	50/50	24.7 (49)	99	49/50
13	24.7 (49)	49/50	24.5 (49)	99	49/49	25.0 (50)	101	50/50	24.7 (49)	100	49/50
14	24.6 (49)	49/50	24.9 (49)	101	49/49	25.3 (50)	103	50/50	25.1 (49)	102	49/50
18	26.2 (49)	49/50	26.5 (49)	101	49/49	27.0 (50)	103	50/50	26.6 (49)	102	49/50
22	27.1 (49)	49/50	27.4 (49)	101	49/49	27.7 (50)	102	50/50	27.2 (49)	100	49/50
26	27.5 (49)	49/50	28.0 (48)	102	48/49	28.5 (50)	104	50/50	28.0 (49)	102	49/50
30	28.5 (49)	49/50	29.1 (48)	102	48/49	30.0 (50)	105	50/50	29.4 (49)	103	49/50
34	29.9 (49)	49/50	30.5 (48)	102	48/49	31.8 (49)	106	49/50	30.4 (49)	102	49/50
38	30.2 (49)	49/50	30.9 (48)	102	48/49	32.0 (49)	106	49/50	30.5 (49)	101	49/50
42	30.9 (49)	49/50	31.2 (48)	101	48/49	32.6 (49)	106	49/50	31.3 (49)	101	49/50
46	31.1 (49)	49/50	31.9 (48)	103	48/49	33.3 (49)	107	49/50	32.1 (49)	103	49/50
50	31.6 (48)	48/50	32.6 (48)	103	48/49	33.8 (49)	107	49/50	32.1 (48)	102	48/50
54	32.4 (48)	48/50	33.6 (47)	104	47/49	34.5 (49)	106	49/50	31.9 (47)	98	47/50
58	32.5 (47)	47/50	34.1 (47)	105	47/49	34.9 (48)	107	48/50	32.6 (47)	100	47/50
62	32.6 (47)	47/50	33.9 (47)	104	47/49	35.4 (48)	109	48/50	32.7 (47)	100	47/50
66	33.1 (45)	45/50	35.2 (47)	106	47/49	36.0 (47)	109	47/50	33.1 (47)	100	47/50
70	33.8 (45)	45/50	35.6 (46)	105	46/49	36.9 (47)	109	47/50	33.9 (46)	100	46/50
74	34.5 (45)	45/50	36.1 (44)	105	44/49	37.1 (47)	108	47/50	34.3 (46)	99	46/50
78	34.9 (45)	45/50	36.6 (44)	105	44/49	37.0 (46)	106	46/50	34.6 (46)	99	46/50
82	34.9 (44)	44/50	37.0 (43)	106	43/49	37.7 (43)	108	43/50	35.1 (45)	101	45/50
86	34.4 (44)	44/50	36.6 (42)	106	42/49	37.5 (39)	109	39/50	34.6 (43)	101	43/50
90	34.8 (42)	42/50	37.1 (38)	107	38/49	37.6 (38)	108	38/50	35.2 (42)	101	42/50
94	35.0 (41)	41/50	37.3 (36)	107	36/49	37.1 (32)	106	32/50	35.6 (39)	102	39/50
98	33.9 (37)	37/50	37.6 (34)	111	34/49	37.5 (29)	111	29/50	34.3 (37)	101	37/50
102	33.8 (32)	32/50	37.6 (29)	111	29/49	36.7 (26)	109	26/50	34.4 (36)	102	36/50
104	33.7 (31)	31/50	37.3 (27)	111	27/49	37.0 (26)	110	26/50	33.9 (34)	101	34/50

< >:No. of effective animals, ( ):No. of measured animals Av. Wt. : g

TABLE D3

BODY WEIGHT CHANGES : MALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 0	1	2	3	4	5	6
Control	23.5± 0.9	24.6± 1.1	25.7± 1.2	26.3± 1.4	26.8± 1.5	27.5± 1.6	28.1± 1.9
100 ppm	23.5± 0.9	24.4± 1.1	25.1± 1.1*	25.3± 1.4**	25.5± 1.8**	26.3± 1.8**	26.9± 1.9**
200 ppm	23.5± 0.8	24.9± 1.0	25.6± 1.3	26.1± 1.4	26.7± 1.6	27.5± 1.6	27.9± 1.8
400 ppm	23.5± 0.9	24.3± 1.6	24.9± 1.1**	25.6± 1.1*	26.1± 1.3	26.5± 1.4*	27.0± 1.5**

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 7	8	9	10	11	12	13
Control	28.9± 1.9	29.7± 2.0	30.3± 2.2	30.9± 2.5	31.5± 2.6	32.5± 2.6	33.0± 2.8
100 ppm	27.6± 2.0**	28.7± 1.9*	29.2± 1.9*	29.5± 2.0**	30.1± 2.2**	31.2± 2.2*	31.8± 2.3
200 ppm	28.5± 1.8	29.3± 2.0	29.7± 2.2	30.4± 2.4	31.2± 2.4	31.9± 2.6	32.5± 2.6
400 ppm	27.5± 1.7**	28.0± 1.9**	28.5± 2.0**	29.1± 2.1**	29.9± 2.4**	30.6± 2.4**	31.1± 2.6**

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 14	18	22	26	30	34	38
Control	33.3± 3.0	36.1± 3.2	38.4± 3.8	39.8± 4.2	41.6± 4.4	43.7± 4.4	44.8± 4.6
100 ppm	31.9± 2.4*	35.0± 2.7	38.0± 3.2	39.3± 3.7	41.5± 3.9	43.6± 4.2	45.1± 4.2
200 ppm	33.0± 2.9	35.8± 3.1	38.1± 3.6	39.8± 4.1	41.8± 4.5	43.9± 4.5	45.1± 4.7
400 ppm	31.5± 2.6**	34.3± 3.1**	36.6± 3.5	38.3± 3.6	40.2± 3.8	42.5± 4.0	43.4± 4.2

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 42	46	50	54	58	62	66
Control	45.7± 4.6	46.3± 4.5	47.3± 4.8	48.2± 4.6	48.9± 4.7	49.5± 4.4	50.2± 4.5
100 ppm	46.0± 4.3	46.6± 4.2	47.3± 4.5	48.3± 4.1	48.7± 4.2	49.1± 4.0	49.5± 4.0
200 ppm	45.8± 4.7	46.8± 4.8	47.6± 5.0	47.8± 4.9	48.8± 4.9	49.0± 5.1	49.3± 5.4
400 ppm	44.2± 4.1	44.6± 4.1	45.1± 4.1*	46.0± 4.4*	46.6± 4.4*	47.2± 4.4	47.9± 4.3

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 70	74	78	82	86	90	94
Control	51.0± 4.4	52.0± 4.9	51.7± 6.0	51.7± 6.3	50.9± 6.0	51.5± 6.4	51.2± 6.2
100 ppm	50.1± 4.5	50.9± 4.8	50.6± 5.6	51.9± 5.7	51.0± 6.2	51.2± 6.3	50.7± 6.7
200 ppm	50.1± 5.5	50.4± 6.1	50.9± 6.2	51.2± 6.5	50.8± 6.4	50.4± 7.4	50.6± 6.9
400 ppm	48.6± 4.6	49.0± 4.9	49.7± 5.1	49.9± 6.3	49.8± 5.2	49.6± 5.2	49.3± 5.0

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 98	102	104
Control	50.1± 6.9	49.1± 8.1	49.8± 7.7
100 ppm	49.7± 7.8	49.6± 8.2	48.6± 8.7
200 ppm	50.5± 7.0	49.9± 7.4	50.4± 7.0
400 ppm	49.0± 5.3	47.8± 6.5	48.3± 5.5

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE D4

BODY WEIGHT CHANGES : FEMALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 0	1	2	3	4	5	6
Control	19.5± 0.8	20.0± 0.9	20.8± 1.0	21.1± 1.0	21.6± 0.9	22.0± 1.1	22.4± 1.1
100 ppm	19.5± 0.8	19.7± 0.9	20.3± 1.1	20.7± 0.9	21.3± 1.0	21.6± 1.1	22.3± 0.9
200 ppm	19.5± 0.8	19.9± 0.8	20.5± 1.0	20.9± 0.8	21.5± 1.0	22.3± 1.0	22.7± 1.0
400 ppm	19.5± 0.8	19.8± 0.8	20.3± 0.9	20.9± 0.8	21.5± 0.9	21.9± 1.0	22.4± 1.1

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 7	8	9	10	11	12	13
Control	23.0± 1.1	23.5± 1.3	23.4± 1.2	23.7± 1.1	24.0± 1.0	24.9± 1.4	24.7± 1.4
100 ppm	22.8± 1.2	23.2± 1.3	23.1± 1.2	23.5± 1.2	23.9± 1.3	24.5± 1.5	24.5± 1.5
200 ppm	22.9± 1.1	23.8± 1.3	23.9± 1.1	24.2± 1.3	24.4± 1.3	25.0± 1.3	25.0± 1.5
400 ppm	23.0± 1.0	23.3± 1.3	23.7± 1.4	24.0± 1.4	24.4± 1.5	24.7± 1.6	24.7± 1.6

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 14	18	22	26	30	34	38
Control	24.6± 1.4	26.2± 1.6	27.1± 1.7	27.5± 2.1	28.5± 2.4	29.9± 2.8	30.2± 2.6
100 ppm	24.9± 1.5	26.5± 1.6	27.4± 2.3	28.0± 2.4	29.1± 2.5	30.5± 2.8	30.9± 3.1
200 ppm	25.3± 1.6	27.0± 1.8	27.7± 2.0	28.5± 2.5	30.0± 3.5	31.8± 3.4**	32.0± 4.0
400 ppm	25.1± 1.5	26.6± 1.8	27.2± 1.8	28.0± 2.2	29.4± 3.1	30.4± 3.0	30.5± 3.0

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 42	46	50	54	58	62	66
Control	30.9± 2.9	31.1± 3.2	31.6± 3.3	32.4± 3.3	32.5± 3.6	32.6± 3.9	33.1± 4.2
100 ppm	31.2± 3.1	31.9± 3.3	32.6± 3.7	33.6± 3.6	34.1± 3.9	33.9± 4.0	35.2± 4.2*
200 ppm	32.6± 4.0*	33.3± 4.0**	33.8± 4.2*	34.5± 4.1*	34.9± 4.6**	35.4± 4.8**	36.0± 4.6**
400 ppm	31.3± 3.0	32.1± 3.6	32.1± 3.3	31.9± 3.6	32.6± 3.5	32.7± 3.6	33.1± 3.7

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 70	74	78	82	86	90	94
Control	33.8± 4.4	34.5± 4.5	34.9± 5.3	34.9± 4.2	34.4± 4.1	34.8± 4.6	35.0± 5.0
100 ppm	35.6± 4.9	36.1± 4.9	36.6± 4.8	37.0± 4.5	36.6± 4.6	37.1± 4.9*	37.3± 4.8
200 ppm	36.9± 5.0**	37.1± 5.0*	37.0± 5.4	37.7± 4.5*	37.5± 4.7**	37.6± 6.6*	37.1± 4.9
400 ppm	33.9± 3.8	34.3± 3.8	34.6± 3.8	35.1± 4.0	34.6± 4.0	35.2± 3.9	35.6± 5.3

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 98	102	104
Control	33.9± 4.3	33.8± 3.2	33.7± 3.9
100 ppm	37.6± 4.9**	37.6± 4.5**	37.3± 4.1*
200 ppm	37.5± 4.6**	36.7± 4.7*	37.0± 6.3*
400 ppm	34.3± 3.5	34.4± 5.9	33.9± 4.4

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE E1

FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS · MALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

MEAN FOOD CONSUMPTION(FC) AND SURVIVAL

Week on Study	Control Av. FC.	Control No. of Surviv. <50>	100 ppm Av. FC.	100 ppm % of cont. <50>	100 ppm No. of Surviv.	200 ppm Av. FC.	200 ppm % of cont. <49>	200 ppm No. of Surviv.	400 ppm Av. FC.	400 ppm % of cont. <50>	400 ppm No. of Surviv.
1	3.8 (50)	50/50	3.7 (50)	97	50/50	3.8 (49)	100	49/49	3.7 (50)	97	50/50
2	3.8 (50)	50/50	3.7 (50)	97	50/50	3.8 (49)	100	49/49	3.6 (50)	95	50/50
3	3.8 (50)	50/50	3.7 (50)	97	50/50	3.9 (49)	103	49/49	3.8 (50)	100	50/50
4	3.9 (50)	50/50	3.8 (50)	97	50/50	3.9 (49)	100	49/49	3.8 (50)	97	50/50
5	3.9 (50)	50/50	3.9 (49)	100	49/50	4.0 (49)	103	49/49	3.9 (49)	100	49/50
6	4.0 (50)	50/50	4.0 (49)	100	49/50	4.0 (49)	100	49/49	3.9 (49)	98	49/50
7	4.1 (50)	50/50	4.0 (49)	98	49/50	4.1 (49)	100	49/49	4.0 (49)	98	49/50
8	4.1 (50)	50/50	4.1 (48)	100	48/50	4.1 (49)	100	49/49	4.0 (49)	98	49/50
9	4.2 (50)	50/50	4.2 (48)	100	48/50	4.2 (49)	100	49/49	4.1 (49)	98	49/50
10	4.1 (50)	50/50	4.1 (48)	100	48/50	4.2 (49)	102	49/49	4.1 (49)	100	49/50
11	4.1 (50)	50/50	4.0 (48)	98	48/50	4.1 (49)	100	49/49	4.0 (49)	98	49/50
12	4.4 (50)	50/50	4.4 (48)	100	48/50	4.3 (49)	98	49/49	4.2 (49)	95	49/50
13	4.2 (50)	50/50	4.2 (48)	100	48/50	4.3 (49)	102	49/49	4.3 (49)	102	49/50
14	4.3 (50)	50/50	4.2 (48)	98	48/50	4.3 (49)	100	49/49	4.2 (49)	98	49/50
18	4.5 (50)	50/50	4.5 (48)	100	48/50	4.6 (49)	102	49/49	4.6 (49)	102	49/50
22	4.5 (50)	50/50	4.5 (48)	100	48/50	4.5 (49)	100	49/49	4.4 (49)	98	49/50
26	4.6 (50)	50/50	4.6 (48)	100	48/50	4.7 (49)	102	49/49	4.5 (49)	98	49/50
30	4.8 (50)	50/50	4.8 (48)	100	48/50	4.8 (49)	100	49/49	4.6 (49)	96	49/50
34	4.9 (50)	50/50	4.9 (48)	100	48/50	4.9 (49)	100	49/49	4.7 (49)	96	49/50
38	4.8 (50)	50/50	4.8 (48)	100	48/50	4.9 (49)	102	49/49	4.6 (49)	96	49/50
42	4.8 (50)	50/50	4.7 (48)	98	48/50	4.8 (47)	100	49/49	4.6 (49)	96	49/50
46	4.7 (50)	50/50	4.6 (48)	98	48/50	4.7 (49)	100	49/49	4.5 (49)	96	49/50
50	4.8 (50)	50/50	4.7 (48)	98	48/50	4.7 (48)	98	48/49	4.6 (49)	96	49/50
54	4.8 (50)	50/50	4.8 (46)	100	46/50	4.7 (48)	98	48/49	4.5 (48)	94	48/50
58	4.8 (50)	50/50	4.7 (45)	98	45/50	4.9 (48)	102	48/49	4.5 (48)	94	48/50
62	4.9 (50)	50/50	4.8 (44)	98	44/50	4.7 (48)	96	48/49	4.5 (48)	92	48/50
66	5.0 (50)	50/50	4.9 (44)	98	44/50	4.9 (47)	98	47/49	4.7 (48)	94	48/50
70	5.0 (50)	50/50	4.9 (44)	98	44/50	4.9 (47)	98	47/49	4.7 (48)	94	48/50
74	5.0 (49)	49/50	4.9 (44)	98	44/50	5.1 (46)	102	47/49	4.8 (47)	96	47/50
78	5.2 (49)	49/50	5.0 (42)	96	42/50	5.2 (46)	100	47/49	4.9 (47)	94	47/50
82	5.3 (47)	47/50	5.2 (40)	98	40/50	5.2 (47)	98	47/49	5.0 (46)	94	46/50
86	5.0 (45)	45/50	4.9 (40)	98	40/50	5.1 (43)	102	43/49	4.7 (45)	94	45/50
90	5.3 (40)	40/50	5.1 (37)	96	37/50	5.2 (41)	98	41/49	4.9 (44)	92	44/50
94	5.0 (38)	38/50	4.9 (35)	98	35/50	5.2 (38)	104	38/49	4.8 (44)	96	44/50
98	5.0 (37)	37/50	4.9 (33)	98	33/50	5.3 (37)	106	37/49	4.9 (41)	98	41/50
102	4.9 (36)	36/50	5.0 (31)	102	31/50	5.1 (36)	104	36/49	4.7 (40)	96	40/50
104	5.1 (30)	30/50	5.0 (31)	98	31/50	5.2 (34)	102	34/49	5.1 (39)	100	39/50

< >:No. of effective animals, ( ):No. of measured animals Av. FC. : g

TABLE E2

FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS : FEMALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

MEAN FOOD CONSUMPTION(FC) AND SURVIVAL

Week on Study	Control Av. FC.	Control No. of Surviv. <50>	100 ppm Av. FC.	100 ppm % of cont. <49>	100 ppm No. of Surviv.	200 ppm Av. FC.	200 ppm % of cont. <50>	200 ppm No. of Surviv.	400 ppm Av. FC.	400 ppm % of cont. <50>	400 ppm No. of Surviv.
1	3.2 (50)	50/50	3.1 (49)	97	49/49	3.1 (50)	97	50/50	3.2 (50)	100	50/50
2	3.2 (50)	50/50	3.2 (49)	100	49/49	3.2 (50)	100	50/50	3.2 (50)	100	50/50
3	3.4 (50)	50/50	3.4 (49)	100	49/49	3.4 (50)	100	50/50	3.4 (50)	100	50/50
4	3.5 (50)	50/50	3.5 (49)	100	49/49	3.6 (50)	103	50/50	3.5 (50)	100	50/50
5	3.6 (49)	49/50	3.6 (49)	100	49/49	3.8 (50)	106	50/50	3.6 (50)	100	50/50
6	3.7 (49)	49/50	3.8 (49)	103	49/49	3.8 (50)	103	50/50	3.7 (50)	100	50/50
7	3.9 (49)	49/50	3.8 (49)	97	49/49	3.9 (50)	100	50/50	3.9 (50)	100	50/50
8	3.9 (49)	49/50	3.8 (49)	97	49/49	3.9 (50)	100	50/50	3.8 (50)	97	50/50
9	3.9 (49)	49/50	3.9 (49)	100	49/49	3.9 (50)	100	50/50	4.0 (50)	103	50/50
10	3.9 (49)	49/50	3.8 (49)	97	49/49	3.9 (50)	100	50/50	4.0 (49)	103	49/50
11	3.8 (49)	49/50	3.7 (49)	97	49/49	3.8 (50)	100	50/50	3.6 (49)	95	49/50
12	4.1 (49)	49/50	4.0 (49)	98	49/49	4.0 (50)	98	50/50	4.0 (49)	98	49/50
13	4.0 (49)	49/50	3.9 (49)	98	49/49	4.0 (50)	100	50/50	4.0 (49)	100	49/50
14	3.9 (49)	49/50	3.9 (49)	100	49/49	4.1 (50)	105	50/50	4.1 (49)	105	49/50
18	4.1 (49)	49/50	4.2 (49)	102	49/49	4.3 (50)	105	50/50	4.3 (49)	105	49/50
22	4.1 (49)	49/50	4.0 (49)	98	49/49	4.2 (50)	102	50/50	4.2 (49)	102	49/50
26	4.3 (49)	49/50	4.2 (48)	98	48/49	4.3 (50)	100	50/50	4.3 (49)	100	49/50
30	4.4 (49)	49/50	4.4 (48)	100	48/49	4.5 (50)	102	50/50	4.4 (49)	100	49/50
34	4.7 (49)	49/50	4.7 (48)	100	48/49	4.7 (49)	100	49/50	4.6 (49)	98	49/50
38	4.5 (49)	49/50	4.4 (48)	98	48/49	4.6 (49)	102	49/50	4.3 (49)	96	49/50
42	4.3 (49)	49/50	4.2 (48)	98	48/49	4.5 (49)	105	49/50	4.2 (49)	98	49/50
46	4.2 (49)	49/50	4.2 (48)	100	48/49	4.3 (49)	102	49/50	4.2 (49)	100	49/50
50	4.4 (48)	48/50	4.2 (48)	95	48/49	4.5 (49)	102	49/50	4.3 (48)	98	48/50
54	4.5 (48)	48/50	4.4 (47)	98	47/49	4.5 (49)	100	49/50	4.1 (47)	91	47/50
58	4.2 (47)	47/50	4.4 (47)	105	47/49	4.5 (48)	107	48/50	4.2 (47)	100	47/50
62	4.1 (47)	47/50	4.0 (47)	98	47/49	4.2 (48)	102	48/50	4.0 (47)	98	47/50
66	4.4 (45)	45/50	4.5 (47)	102	47/49	4.5 (47)	102	47/50	4.2 (47)	95	47/50
70	4.5 (45)	45/50	4.4 (46)	98	46/49	4.6 (47)	102	47/50	4.4 (46)	98	46/50
74	4.5 (45)	45/50	4.5 (44)	100	44/49	4.6 (47)	102	47/50	4.4 (46)	98	46/50
78	4.6 (45)	45/50	4.6 (44)	100	44/49	4.5 (46)	98	46/50	4.5 (46)	98	46/50
82	4.6 (44)	44/50	4.7 (43)	102	43/49	4.6 (43)	100	43/50	4.6 (45)	100	45/50
86	4.4 (44)	44/50	4.5 (42)	102	42/49	4.6 (39)	105	39/50	4.5 (43)	102	43/50
90	4.6 (42)	42/50	4.8 (38)	104	38/49	4.7 (38)	102	38/50	4.7 (42)	102	42/50
94	4.5 (41)	41/50	4.7 (36)	104	36/49	4.6 (32)	102	32/50	4.5 (39)	100	39/50
98	4.5 (37)	37/50	4.8 (34)	107	34/49	5.0 (29)	111	29/50	4.6 (37)	102	37/50
102	4.4 (32)	32/50	4.6 (29)	105	29/49	4.8 (26)	109	26/50	4.4 (36)	100	36/50
104	4.5 (31)	31/50	4.6 (27)	102	27/49	4.8 (26)	107	26/50	4.7 (34)	104	34/50

< >:No. of effective animals, ( ):No. of measured animals Av. FC. : g

TABLE E3

FOOD CONSUMPTION CHANGES : MALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 1	2	3	4	5	6	7
Control	3.8± 0.2	3.8± 0.2	3.8± 0.3	3.9± 0.3	3.9± 0.3	4.0± 0.2	4.1± 0.3
100 ppm	3.7± 0.3	3.7± 0.3*	3.7± 0.4	3.8± 0.5	3.9± 0.3	4.0± 0.4	4.0± 0.4
200 ppm	3.8± 0.2	3.8± 0.3	3.9± 0.3	3.9± 0.4	4.0± 0.3	4.0± 0.3	4.1± 0.3
400 ppm	3.7± 0.4	3.6± 0.3**	3.8± 0.3	3.8± 0.3**	3.9± 0.3	3.9± 0.3	4.0± 0.3

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 8	9	10	11	12	13	14
Control	4.1± 0.3	4.2± 0.2	4.1± 0.3	4.1± 0.3	4.4± 0.3	4.2± 0.2	4.3± 0.2
100 ppm	4.1± 0.3	4.2± 0.3	4.1± 0.3	4.0± 0.3	4.4± 0.3	4.2± 0.3	4.2± 0.3
200 ppm	4.1± 0.3	4.2± 0.3	4.2± 0.4	4.1± 0.3	4.3± 0.3	4.3± 0.3	4.3± 0.3
400 ppm	4.0± 0.3	4.1± 0.3	4.1± 0.3	4.0± 0.3*	4.2± 0.3	4.3± 0.3	4.2± 0.3

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 18	22	26	30	34	38	42
Control	4.5± 0.3	4.5± 0.3	4.6± 0.3	4.8± 0.3	4.9± 0.3	4.8± 0.3	4.8± 0.3
100 ppm	4.5± 0.3	4.5± 0.3	4.6± 0.4	4.8± 0.3	4.9± 0.3	4.8± 0.3	4.7± 0.3
200 ppm	4.6± 0.2	4.5± 0.3	4.7± 0.3	4.8± 0.3	4.9± 0.3	4.9± 0.4	4.8± 0.3
400 ppm	4.6± 0.2	4.4± 0.3	4.5± 0.2	4.6± 0.3**	4.7± 0.3	4.6± 0.3**	4.6± 0.3**

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 46	50	54	58	62	66	70
Control	4.7± 0.3	4.8± 0.3	4.8± 0.3	4.8± 0.3	4.9± 0.2	5.0± 0.3	5.0± 0.3
100 ppm	4.6± 0.3	4.7± 0.3	4.8± 0.3	4.7± 0.3	4.8± 0.3	4.9± 0.3	4.9± 0.3
200 ppm	4.7± 0.3	4.7± 0.3	4.7± 0.7	4.9± 0.3	4.7± 0.5**	4.9± 0.4	4.9± 0.3
400 ppm	4.5± 0.3**	4.6± 0.3**	4.5± 0.3**	4.5± 0.3**	4.5± 0.3**	4.7± 0.3**	4.7± 0.3**

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 74	78	82	86	90	94	98
Control	5.0± 0.4	5.2± 0.4	5.3± 0.4	5.0± 0.5	5.3± 0.4	5.0± 0.5	5.0± 0.6
100 ppm	4.9± 0.5	5.0± 0.5	5.2± 0.3	4.9± 0.6	5.1± 0.6	4.9± 0.6	4.9± 0.7
200 ppm	5.1± 0.5	5.2± 0.5	5.2± 0.6	5.1± 0.5	5.2± 0.9	5.2± 0.8	5.3± 0.7
400 ppm	4.8± 0.3**	4.9± 0.4**	5.0± 0.6**	4.7± 0.4*	4.9± 0.5**	4.8± 0.4*	4.9± 0.5

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 102	104
Control	4.9± 0.9	5.1± 0.8
100 ppm	5.0± 0.6	5.0± 0.6
200 ppm	5.1± 0.7	5.2± 0.6
400 ppm	4.7± 0.6*	5.1± 0.7

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE E4

FOOD CONSUMPTION CHANGES : FEMALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 1	2	3	4	5	6	7
Control	3.2± 0.2	3.2± 0.3	3.4± 0.2	3.5± 0.3	3.6± 0.3	3.7± 0.2	3.9± 0.3
100 ppm	3.1± 0.3	3.2± 0.2	3.4± 0.2	3.5± 0.2	3.6± 0.3	3.8± 0.2	3.8± 0.3
200 ppm	3.1± 0.3	3.2± 0.2	3.4± 0.2	3.6± 0.3	3.8± 0.3*	3.8± 0.3	3.9± 0.3
400 ppm	3.2± 0.2	3.2± 0.2	3.4± 0.2	3.5± 0.2	3.6± 0.2	3.7± 0.3	3.9± 0.3

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 8	9	10	11	12	13	14
Control	3.9± 0.3	3.9± 0.2	3.9± 0.2	3.8± 0.3	4.1± 0.3	4.0± 0.3	3.9± 0.3
100 ppm	3.8± 0.3	3.9± 0.2	3.8± 0.3	3.7± 0.3	4.0± 0.3	3.9± 0.2	3.9± 0.3
200 ppm	3.9± 0.3	3.9± 0.3	3.9± 0.3	3.8± 0.3	4.0± 0.2	4.0± 0.3	4.1± 0.3*
400 ppm	3.8± 0.3	4.0± 0.2	4.0± 0.3	3.6± 0.3**	4.0± 0.3	4.0± 0.3	4.1± 0.3**

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 18	22	26	30	34	38	42
Control	4.1± 0.3	4.1± 0.3	4.3± 0.4	4.4± 0.4	4.7± 0.4	4.5± 0.4	4.3± 0.4
100 ppm	4.2± 0.3	4.0± 0.5	4.2± 0.3	4.4± 0.4	4.7± 0.4	4.4± 0.3	4.2± 0.5
200 ppm	4.3± 0.3	4.2± 0.4	4.3± 0.4	4.5± 0.4	4.7± 0.4	4.6± 0.4	4.5± 0.4
400 ppm	4.3± 0.4*	4.2± 0.3	4.3± 0.3	4.4± 0.4	4.6± 0.5	4.3± 0.4	4.2± 0.4

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 46	50	54	58	62	66	70
Control	4.2± 0.5	4.4± 0.4	4.5± 0.4	4.2± 0.4	4.1± 0.5	4.4± 0.4	4.5± 0.4
100 ppm	4.2± 0.3	4.2± 0.4**	4.4± 0.5	4.4± 0.5	4.0± 0.5	4.5± 0.4	4.4± 0.7
200 ppm	4.3± 0.4	4.5± 0.5	4.5± 0.5	4.5± 0.4*	4.2± 0.5	4.5± 0.5	4.6± 0.5
400 ppm	4.2± 0.4	4.3± 0.4	4.1± 0.4**	4.2± 0.3	4.0± 0.4	4.2± 0.5	4.4± 0.4

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 74	78	82	86	90	94	98
Control	4.5± 0.5	4.6± 0.6	4.6± 0.5	4.4± 0.5	4.6± 0.5	4.5± 0.6	4.5± 0.5
100 ppm	4.5± 0.6	4.6± 0.6	4.7± 0.6	4.5± 0.6	4.8± 0.6	4.7± 0.5	4.8± 0.8*
200 ppm	4.6± 0.6	4.5± 0.6	4.6± 0.5	4.6± 0.5	4.7± 0.7	4.6± 1.0	5.0± 0.8**
400 ppm	4.4± 0.5	4.5± 0.4	4.6± 0.5	4.5± 0.6	4.7± 0.7	4.5± 0.5	4.6± 0.7

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 102	104
Control	4.4± 0.6	4.5± 0.6
100 ppm	4.6± 0.6	4.6± 0.5
200 ppm	4.8± 0.6*	4.8± 0.5
400 ppm	4.4± 0.6	4.7± 0.5

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE F1

HEMATOLOGY : MALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	RED BLOOD CELL $10^6/\mu\ell$	HEMOGLOBIN g/dℓ	HEMATOCRIT %	MCV fℓ	MCH pg	MCHC g/dℓ	PLATELET $10^3/\mu\ell$
Control	30	9.57± 0.79	14.2± 1.4	41.5± 3.6	43.4± 1.3	14.8± 0.6	34.0± 0.8	1648± 384
100 ppm	30	9.35± 1.34	13.7± 1.8	40.5± 4.9	43.5± 2.4	14.7± 0.9	33.8± 0.9	1724± 260
200 ppm	33	9.43± 1.10	14.2± 1.2	41.8± 3.2	44.8± 4.4	15.2± 1.0	33.9± 1.2	1615± 446
400 ppm	39	9.25± 1.29	14.0± 1.9	40.8± 5.2	44.3± 1.8	15.1± 0.5	34.2± 0.9	1595± 344

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	RETICULOCYTE %
Control	30	2.1± 0.5
100 ppm	30	2.9± 2.1
200 ppm	33	2.8± 2.9
400 ppm	39	2.7± 2.2

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	WBC $10^3/\mu\ell$		Differential WBC (%) NEUTRO		LYMPHO		MONO		EOSINO		BASO		OTHER	
Control	30	4.65±	4.45	31±	17	62±	17	3±	1	3±	2	0±	0	1±	1
100 ppm	30	3.74±	2.12	31±	13	62±	15	4±	6	2±	1	0±	0	1±	1
200 ppm	33	3.37±	1.67	28±	11	64±	12	4±	3	3±	2	0±	0	1±	1
400 ppm	39	3.22±	1.44	28±	10	64±	11	3±	2	3±	2	0±	0	1±	2

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE F2

HEMATOLOGY : FEMALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	RED BLOOD CELL $10^6/\mu\ell$	HEMOGLOBIN g/dℓ	HEMATOCRIT %	MCV fℓ	MCH pg	MCHC g/dℓ	PLATELET $10^3/\mu\ell$
Control	30	9.23± 1.77	14.0± 2.7	40.9± 6.3	44.9± 3.6	15.2± 0.7	33.9± 1.9	1149± 367
100 ppm	27	9.24± 1.73	13.9± 2.6	40.5± 7.1	43.9± 2.1	15.0± 0.7	34.2± 1.1	980± 376
200 ppm	25	9.25± 1.38	14.0± 1.9	40.9± 4.9	44.5± 2.2	15.2± 0.7	34.1± 1.5	989± 364
400 ppm	34	9.31± 1.17	14.1± 1.8	40.8± 4.6	44.0± 2.1	15.1± 0.5	34.4± 1.1	1119± 317

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	RETICULOCYTE %	
Control	30	4.0±	5.1
100 ppm	27	3.0±	2.4
200 ppm	25	4.1±	4.6
400 ppm	34	3.0±	3.3

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	WBC $10^3/\mu\ell$		Differential WBC (%) NEUTRO		LYMPHO		MONO		EOSINO		BASO		OTHER	
Control	30	6.99±	13.55	25±	15	67±	16	3±	2	3±	2	0±	0	2±	3
100 ppm	27	2.67±	1.05	27±	11	66±	10	3±	1	3±	2	0±	0	1±	1
200 ppm	25	3.36±	1.55	31±	14	62±	16	3±	1	3±	2	0±	0	1±	1
400 ppm	34	3.32±	2.84	29±	14	64±	15	3±	2	3±	2	0±	0	2±	4

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE G1

BIOCHEMISTRY : MALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	TOTAL PROTEIN g/dl		ALBUMIN g/dl		A/G RATIO		T-BILIRUBIN mg/dl		GLUCOSE mg/dl		T-CHOLESTEROL mg/dl		TRIGLYCERIDE mg/dl	
Control	30	5.1±	0.5	2.5±	0.3	0.9±	0.1	0.12±	0.02	164±	39	106±	26	47±	24
100 ppm	31	5.4±	0.9	2.6±	0.5	1.0±	0.1	0.13±	0.03	166±	46	132±	107	48±	23
200 ppm	34	5.3±	0.6	2.6±	0.3	1.0±	0.1*	0.13±	0.04	190±	25**	107±	36	45±	22
400 ppm	39	5.1±	0.4	2.6±	0.2	1.1±	0.1**	0.12±	0.03	188±	35**	101±	25	44±	22

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	PHOSPHOLIPID mg/dl	AST IU/l	ALT IU/l	LDH IU/l	ALP IU/l	G-GTP IU/l	CK IU/l
Control	30	189± 42	94± 97	39± 37	294± 335	239± 251	1± 1	81± 103
100 ppm	31	221± 137	148± 239	119± 246	504± 959	316± 341	1± 2	79± 65
200 ppm	34	198± 59	76± 62	47± 53	229± 95	258± 256	1± 1	57± 22
400 ppm	39	182± 37	77± 124*	36± 69*	283± 447	230± 218	1± 1	52± 30*

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	UREA NITROGEN mg/dl	SODIUM mEq/l	POTASSIUM mEq/l	CHLORIDE mEq/l	CALCIUM mg/dl	INORGANIC PHOSPHORUS mg/dl
Control	30	25.3± 9.9	153± 4	4.2± 0.3	122± 3	8.8± 0.4	6.8± 0.9
100 ppm	31	25.4± 11.9	154± 2	4.1± 0.5	121± 4	9.0± 0.7	6.7± 1.2
200 ppm	34	22.6± 6.0	153± 3	4.3± 0.4	122± 3	8.8± 0.4	6.7± 0.9
400 ppm	39	24.4± 16.6*	153± 2	4.3± 0.5	122± 2	8.7± 0.3	6.5± 2.3*

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE G2

BIOCHEMISTRY : FEMALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	TOTAL PROTEIN g/dl	ALBUMIN g/dl	A/G RATIO	T-BILIRUBIN mg/dl	GLUCOSE mg/dl	T-CHOLESTEROL mg/dl	TRIGLYCERIDE mg/dl
Control	30	5.1± 0.4	2.5± 0.3	1.0± 0.2	0.12± 0.02	121± 27	79± 25	32± 17
100 ppm	27	5.2± 0.5	2.7± 0.3	1.1± 0.2	0.13± 0.07	128± 29	81± 45	27± 19
200 ppm	25	5.6± 1.7	2.5± 0.2	1.0± 0.2	0.15± 0.17	126± 26	78± 34	37± 30
400 ppm	34	5.1± 0.4	2.6± 0.2	1.1± 0.2	0.12± 0.03	134± 32	75± 26	28± 19

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	PHOSPHOLIPID mg/dl	AST IU/l	ALT IU/l	LDH IU/l	ALP IU/l	G-GTP IU/l	CK IU/l
Control	30	135± 33	109± 79	51± 62	220± 181	305± 102	1± 1	117± 155
100 ppm	27	149± 74	108± 91	46± 47	422± 961	328± 130	2± 4	132± 300
200 ppm	25	135± 43	110± 81	58± 83	344± 562	286± 146	1± 1	109± 108
400 ppm	34	135± 45	109± 78	43± 30	329± 491	315± 157	1± 1	127± 291

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (105W)

Group Name	NO. of Animals	UREA NITROGEN mg/dl	SODIUM mEq/l	POTASSIUM mEq/l	CHLORIDE mEq/l	CALCIUM mg/dl	INORGANIC PHOSPHORUS mg/dl
Control	30	25.6± 53.4	152± 3	4.1± 0.9	121± 3	8.9± 0.4	6.4± 3.7
100 ppm	27	16.4± 6.4	152± 2	3.9± 0.5	121± 2	9.0± 0.5	6.4± 1.2
200 ppm	25	20.0± 20.7	152± 2	4.0± 0.4	121± 2	9.0± 0.6	6.6± 2.1
400 ppm	34	17.5± 11.8	151± 2	4.1± 0.4	121± 2	8.7± 0.4	6.2± 1.0

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE H1

URINALYSIS : MALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

URINALYSIS

Group Name	NO. of Animals	pH 5.0	6.0	6.5	7.0	7.5	8.0	8.5	CHI	Protein −	±	+	2+	3+	4+	CHI	Glucose −	±	+	2+	3+	4+	CHI	Ketone body −	±	+	2+	3+	4+	CHI	Occult blood −	±	+	2+	3+	CHI
Control	36	0	2	5	6	11	8	4		0	0	26	7	3	0		36	0	0	0	0	0		4	29	3	0	0	0		32	0	0	0	4	
100 ppm	32	0	1	4	6	5	13	3		0	3	18	10	1	0		32	0	0	0	0	0		9	22	1	0	0	0		29	2	0	1	0	
200 ppm	37	0	2	7	1	7	19	1		0	5	29	3	0	0	*	37	0	0	0	0	0		12	23	2	0	0	0		35	1	0	0	1	
400 ppm	40	0	0	3	3	11	16	7		0	1	26	12	1	0		40	0	0	0	0	0		1	35	4	0	0	0		36	0	1	0	3	

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01

Test of CHI SQUARE

STUDY NO. : 0676 URINALYSIS
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

Group Name	NO. of Animals	Urobilinogen ±	+	2+	3+	4+	CHI
Control	36	36	0	0	0	0	
100 ppm	32	32	0	0	0	0	
200 ppm	37	37	0	0	0	0	
400 ppm	40	40	0	0	0	0	

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of CHI SQUARE

TABLE H2

URINALYSIS : FEMALE

STUDY NO. : 0676 URINALYSIS
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : FEMALE REPORT TYPE : A1

Group Name	NO. of Animals	pH 5.0	6.0	6.5	7.0	7.5	8.0	8.5	CHI	Protein −	±	+	2+	3+	4+	CHI	Glucose −	±	+	2+	3+	4+	CHI	Ketone body −	±	+	2+	3+	4+	CHI	Occult blood −	±	+	2+	3+	CHI
Control	34	0	2	3	2	8	12	7		0	25	5	3	1	0		34	0	0	0	0	0		23	3	8	0	0	0		32	0	0	1	1	
100 ppm	30	0	1	1	6	9	6	7		0	20	7	3	0	0		30	0	0	0	0	0		17	7	5	1	0	0		29	0	1	0	0	
200 ppm	26	0	1	3	4	6	8	4		0	14	10	1	1	0		26	0	0	0	0	0		19	3	4	0	0	0		25	0	0	1	0	
400 ppm	36	0	0	3	7	11	11	4		0	11	12	11	2	0	**	36	0	0	0	0	0		11	6	8	9	2	0	**	31	0	0	2	3	

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of CHI SQUARE

URINALYSIS

Group Name	NO. of Animals	Urobilinogen ±	+	2+	3+	4+	CHI
Control	34	34	0	0	0	0	
100 ppm	30	30	0	0	0	0	
200 ppm	26	26	0	0	0	0	
400 ppm	36	36	0	0	0	0	

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of CHI SQUARE

TABLE I 1

GROSS FINDINGS : MALE

ALL ANIMALS

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE

GROSS FINDINGS (SUMMARY)
ALL ANIMALS (0-105W)

Organ	Findings	Group Name / NO. of Animals	Control 50 (%)	100 ppm 50 (%)	200 ppm 49 (%)	400 ppm 50 (%)
skin/app	nodule		0 (0)	0 (0)	1 (2)	0 (0)
	erosion		1 (2)	1 (2)	1 (2)	1 (2)
	scab		2 (4)	1 (2)	1 (2)	0 (0)
subcutis	edema		1 (2)	0 (0)	1 (2)	0 (0)
	nodule		0 (0)	0 (0)	0 (0)	1 (2)
	mass		3 (6)	4 (8)	1 (2)	1 (2)
lung	red		1 (2)	0 (0)	0 (0)	0 (0)
	white zone		0 (0)	0 (0)	1 (2)	0 (0)
	red zone		0 (0)	1 (2)	0 (0)	1 (2)
	nodule		5 (10)	8 (16)	4 (8)	7 (14)
	adhesion		0 (0)	0 (0)	1 (2)	0 (0)
lymph node	enlarged		7 (14)	3 (6)	5 (10)	11 (22)
spleen	enlarged		6 (12)	3 (6)	2 (4)	6 (12)
	white zone		1 (2)	1 (2)	0 (0)	0 (0)
	black zone		1 (2)	2 (4)	0 (0)	1 (2)
	nodule		0 (0)	1 (2)	0 (0)	2 (4)
	deformed		0 (0)	0 (0)	0 (0)	1 (2)
tongue	nodule		0 (0)	1 (2)	0 (0)	0 (0)
esophagus	nodule		1 (2)	0 (0)	0 (0)	0 (0)
forestomach	nodule		1 (2)	1 (2)	1 (2)	0 (0)
gl stomach	nodule		0 (0)	0 (0)	1 (2)	0 (0)
	thick		1 (2)	0 (0)	0 (0)	0 (0)

Organ	Findings	Group Name / NO. of Animals	Control 50 (%)	100 ppm 50 (%)	200 ppm 49 (%)	400 ppm 50 (%)
small intes	nodule		1 (2)	1 (2)	0 (0)	1 (2)
liver	enlarged		1 (2)	0 (0)	0 (0)	2 (4)
	yellow		0 (0)	1 (2)	0 (0)	0 (0)
	white zone		4 (8)	5 (10)	0 (0)	4 (8)
	red zone		2 (4)	1 (2)	5 (10)	1 (2)
	nodule		13 (26)	16 (32)	18 (37)	12 (24)
	deformed		0 (0)	0 (0)	1 (2)	0 (0)
pancreas	nodule		0 (0)	0 (0)	0 (0)	1 (2)
kidney	enlarged		0 (0)	0 (0)	0 (0)	1 (2)
	white zone		2 (4)	0 (0)	1 (2)	0 (0)
	nodule		2 (4)	0 (0)	0 (0)	1 (2)
	cyst		2 (4)	0 (0)	0 (0)	0 (0)
	hydronephrosis		3 (6)	10 (20)	3 (6)	1 (2)
urin bladd	urine:marked retention		7 (14)	4 (8)	2 (4)	0 (0)
	Urine:white		1 (2)	0 (0)	1 (2)	0 (0)
pituitary	red zone		0 (0)	0 (0)	1 (2)	0 (0)
	nodule		0 (0)	1 (2)	0 (0)	0 (0)
epididymis	nodule		0 (0)	1 (2)	0 (0)	0 (0)
semin ves	red		1 (2)	0 (0)	0 (0)	0 (0)
prep/cli gl	nodule		1 (2)	0 (0)	1 (2)	0 (0)
brain	red zone		0 (0)	0 (0)	0 (0)	1 (2)
	brown zone		0 (0)	0 (0)	1 (2)	0 (0)

Organ	Findings	Group Name / NO. of Animals	Control 50 (%)	100 ppm 50 (%)	200 ppm 49 (%)	400 ppm 50 (%)
eye	small		0 (0)	1 (2)	0 (0)	0 (0)
Harder gl	enlarged		1 (2)	0 (0)	1 (2)	1 (2)
	nodule		1 (2)	1 (2)	2 (4)	1 (2)
bone	nodule		1 (2)	0 (0)	0 (0)	0 (0)
mediastinum	mass		0 (0)	1 (2)	1 (2)	1 (2)
peritoneum	nodule		0 (0)	2 (4)	0 (0)	1 (2)
	cyst		0 (0)	1 (2)	0 (0)	0 (0)
retroperit	mass		0 (0)	0 (0)	1 (2)	0 (0)
abdominal c	hemorrhage		1 (2)	0 (0)	0 (0)	0 (0)
	ascites		5 (10)	4 (8)	4 (8)	1 (2)
thoracic ca	hemorrhage		1 (2)	0 (0)	1 (2)	0 (0)
	pleural fluid		3 (6)	3 (6)	2 (4)	4 (8)
other	tail:nodule		0 (0)	1 (2)	0 (0)	0 (0)
whole body	anemic		0 (0)	1 (2)	0 (0)	0 (0)

TABLE I 2

GROSS FINDINGS : MALE

DEAD AND MORIBUND ANIMALS

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE

GROSS FINDINGS (SUMMARY)
DEAD AND MORIBUND ANIMALS (0-105W)

Organ	Findings	Group Name / NO. of Animals	Control 20 (%)	100 ppm 19 (%)	200 ppm 15 (%)	400 ppm 11 (%)
skin/app	erosion		1 (5)	1 (5)	1 (7)	1 (9)
	scab		2 (10)	0 (0)	0 (0)	0 (0)
subcutis	edema		1 (5)	0 (0)	1 (7)	0 (0)
	nodule		0 (0)	0 (0)	0 (0)	1 (9)
	mass		1 (5)	3 (16)	1 (7)	1 (9)
lung	red		1 (5)	0 (0)	0 (0)	0 (0)
	red zone		0 (0)	1 (5)	0 (0)	0 (0)
	nodule		1 (5)	2 (11)	0 (0)	3 (27)
	adhesion		0 (0)	0 (0)	1 (7)	0 (0)
lymph node	enlarged		4 (20)	0 (0)	2 (13)	3 (27)
spleen	enlarged		5 (25)	1 (5)	0 (0)	1 (9)
	white zone		1 (5)	0 (0)	0 (0)	0 (0)
	black zone		0 (0)	1 (5)	0 (0)	0 (0)
	nodule		0 (0)	0 (0)	0 (0)	1 (9)
	deformed		0 (0)	0 (0)	0 (0)	1 (9)
esophagus	nodule		1 (5)	0 (0)	0 (0)	0 (0)
forestomach	nodule		1 (5)	0 (0)	1 (7)	0 (0)
gl stomach	nodule		0 (0)	0 (0)	1 (7)	0 (0)
small intes	nodule		1 (5)	0 (0)	0 (0)	1 (9)
liver	enlarged		1 (5)	0 (0)	0 (0)	1 (9)
	white zone		2 (10)	2 (11)	0 (0)	2 (18)
	red zone		1 (5)	0 (0)	2 (13)	0 (0)

Organ	Findings	Group Name / NO. of Animals	Control 20	(%)	100 ppm 19	(%)	200 ppm 15	(%)	400 ppm 11	(%)
liver	nodule		7	(35)	3	(16)	4	(27)	4	(36)
	deformed		0	(0)	0	(0)	1	(7)	0	(0)
pancreas	nodule		0	(0)	0	(0)	0	(0)	1	(9)
kidney	white zone		2	(10)	0	(0)	1	(7)	0	(0)
	nodule		1	(5)	0	(0)	0	(0)	0	(0)
	cyst		1	(5)	0	(0)	0	(0)	0	(0)
	hydronephrosis		1	(5)	8	(42)	2	(13)	1	(9)
urin bladd	urine:marked retention		6	(30)	4	(21)	2	(13)	0	(0)
	Urine:white		1	(5)	0	(0)	1	(7)	0	(0)
pituitary	nodule		0	(0)	1	(5)	0	(0)	0	(0)
epididymis	nodule		0	(0)	1	(5)	0	(0)	0	(0)
semin ves	red		1	(5)	0	(0)	0	(0)	0	(0)
prep/cli gl	nodule		1	(5)	0	(0)	0	(0)	0	(0)
brain	red zone		0	(0)	0	(0)	0	(0)	1	(9)
	brown zone		0	(0)	0	(0)	1	(7)	0	(0)
Harder gl	enlarged		1	(5)	0	(0)	0	(0)	0	(0)
	nodule		1	(5)	1	(5)	0	(0)	0	(0)
bone	nodule		1	(5)	0	(0)	0	(0)	0	(0)
mediastinum	mass		0	(0)	1	(5)	1	(7)	1	(9)
peritoneum	nodule		0	(0)	1	(5)	0	(0)	1	(9)
retroperit	mass		0	(0)	0	(0)	1	(7)	0	(0)
abdominal c	hemorrhage		1	(5)	0	(0)	0	(0)	0	(0)

Organ	Findings	Group Name / NO. of Animals	Control 20	(%)	100 ppm 19	(%)	200 ppm 15	(%)	400 ppm 11	(%)
abdominal c	ascites		4	(20)	3	(16)	3	(20)	1	(9)
thoracic ca	hemorrhage		1	(5)	0	(0)	1	(7)	0	(0)
	pleural fluid		2	(10)	1	(5)	2	(13)	4	(36)
other	tail:nodule		0	(0)	1	(5)	0	(0)	0	(0)
whole body	anemic		0	(0)	1	(5)	0	(0)	0	(0)

TABLE I 3

GROSS FINDINGS : MALE

SACRIFICED ANIMALS

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE

GROSS FINDINGS (SUMMARY)
SACRIFICED ANIMALS (105W)

Organ	Findings	Group Name / NO. of Animals	Control 30	(%)	100 ppm 31	(%)	200 ppm 34	(%)	400 ppm 39	(%)
skin/app	nodule		0	(0)	0	(0)	1	(3)	0	(0)
	scab		0	(0)	1	(3)	1	(3)	0	(0)
subcutis	mass		2	(7)	1	(3)	0	(0)	0	(0)
lung	white zone		0	(0)	0	(0)	1	(3)	0	(0)
	red zone		0	(0)	0	(0)	0	(0)	1	(3)
	nodule		4	(13)	6	(19)	4	(12)	4	(10)
lymph node	enlarged		3	(10)	3	(10)	3	(9)	8	(21)
spleen	enlarged		1	(3)	2	(6)	2	(6)	5	(13)
	white zone		0	(0)	1	(3)	0	(0)	0	(0)
	black zone		1	(3)	1	(3)	0	(0)	1	(3)
	nodule		0	(0)	1	(3)	0	(0)	1	(3)
tongue	nodule		0	(0)	1	(3)	0	(0)	0	(0)
forestomach	nodule		0	(0)	1	(3)	0	(0)	0	(0)
gl stomach	thick		1	(3)	0	(0)	0	(0)	0	(0)
small intes	nodule		0	(0)	1	(3)	0	(0)	0	(0)
liver	enlarged		0	(0)	0	(0)	0	(0)	1	(3)
	yellow		0	(0)	1	(3)	0	(0)	0	(0)
	white zone		2	(7)	3	(10)	0	(0)	2	(5)
	red zone		1	(3)	1	(3)	3	(9)	1	(3)
	nodule		6	(20)	13	(42)	14	(41)	8	(21)
kidney	enlarged		0	(0)	0	(0)	0	(0)	1	(3)
	nodule		1	(3)	0	(0)	0	(0)	1	(3)

Organ	Findings	Group Name / NO. of Animals	Control 30	(%)	100 ppm 31	(%)	200 ppm 34	(%)	400 ppm 39	(%)
kidney	cyst		1	(3)	0	(0)	0	(0)	0	(0)
	hydronephrosis		2	(7)	2	(6)	1	(3)	0	(0)
urin bladd	urine:marked retention		1	(3)	0	(0)	0	(0)	0	(0)
pituitary	red zone		0	(0)	0	(0)	1	(3)	0	(0)
prep/cli gl	nodule		0	(0)	0	(0)	1	(3)	0	(0)
eye	small		0	(0)	1	(3)	0	(0)	0	(0)
Harder gl	enlarged		0	(0)	0	(0)	1	(3)	1	(3)
	nodule		0	(0)	0	(0)	2	(6)	1	(3)
peritoneum	nodule		0	(0)	1	(3)	0	(0)	0	(0)
	cyst		0	(0)	1	(3)	0	(0)	0	(0)
abdominal c	ascites		1	(3)	1	(3)	1	(3)	0	(0)
thoracic ca	pleural fluid		1	(3)	2	(6)	0	(0)	0	(0)

TABLE I 4

GROSS FINDINGS : FEMALE

ALL ANIMALS

Organ	Findings	Group Name / NO. of Animals	Control 50	(%)	100 ppm 49	(%)	200 ppm 50	(%)	400 ppm 50	(%)
skin/app	nodule		0	(0)	1	(2)	0	(0)	1	(2)
	scab		1	(2)	0	(0)	1	(2)	0	(0)
subcutis	edema		4	(8)	3	(6)	6	(12)	5	(10)
	mass		2	(4)	5	(10)	2	(4)	1	(2)
lung	nodule		2	(4)	1	(2)	1	(2)	0	(0)
lymph node	enlarged		12	(24)	9	(18)	14	(28)	8	(16)
spleen	enlarged		8	(16)	7	(14)	9	(18)	4	(8)
	white zone		1	(2)	0	(0)	0	(0)	0	(0)
	nodule		1	(2)	1	(2)	0	(0)	0	(0)
	deformed		0	(0)	0	(0)	1	(2)	1	(2)
tongue	nodule		2	(4)	0	(0)	0	(0)	0	(0)
forestomach	nodule		3	(6)	0	(0)	1	(2)	1	(2)
gl stomach	ulcer		1	(2)	0	(0)	0	(0)	0	(0)
small intes	nodule		0	(0)	2	(4)	1	(2)	1	(2)
liver	enlarged		5	(10)	2	(4)	8	(16)	5	(10)
	white zone		7	(14)	4	(8)	6	(12)	6	(12)
	red zone		2	(4)	4	(8)	2	(4)	0	(0)
	nodule		3	(6)	7	(14)	11	(22)	10	(20)
	cyst		0	(0)	0	(0)	1	(2)	0	(0)
pancreas	nodule		0	(0)	1	(2)	0	(0)	0	(0)
kidney	hydronephrosis		3	(6)	3	(6)	3	(6)	2	(4)
urin bladd	urine:marked retention		0	(0)	0	(0)	1	(2)	0	(0)

Organ	Findings	Group Name / NO. of Animals	Control 50 (%)	100 ppm 49 (%)	200 ppm 50 (%)	400 ppm 50 (%)
pituitary	enlarged		0 (0)	3 (6)	4 (8)	4 (8)
	red zone		0 (0)	1 (2)	2 (4)	1 (2)
	nodule		2 (4)	2 (4)	6 (12)	5 (10)
ovary	enlarged		6 (12)	2 (4)	6 (12)	5 (10)
	cyst		9 (18)	7 (14)	10 (20)	10 (20)
uterus	nodule		10 (20)	7 (14)	15 (30)	8 (16)
brain	red zone		1 (2)	1 (2)	0 (0)	1 (2)
spinal cord	nodule		0 (0)	0 (0)	1 (2)	0 (0)
periph nerv	nodule		0 (0)	1 (2)	0 (0)	0 (0)
eye	turbid		0 (0)	0 (0)	0 (0)	1 (2)
Harder gl	enlarged		1 (2)	0 (0)	0 (0)	0 (0)
	nodule		0 (0)	0 (0)	1 (2)	1 (2)
muscle	red zone		0 (0)	1 (2)	0 (0)	0 (0)
	nodule		0 (0)	1 (2)	0 (0)	0 (0)
bone	nodule		1 (2)	0 (0)	0 (0)	1 (2)
mediastinum	nodule		0 (0)	0 (0)	1 (2)	0 (0)
	mass		0 (0)	2 (4)	2 (4)	2 (4)
peritoneum	nodule		0 (0)	2 (4)	1 (2)	0 (0)
	thick		2 (4)	1 (2)	1 (2)	2 (4)
abdominal c	hemorrhage		2 (4)	0 (0)	1 (2)	0 (0)
	ascites		7 (14)	9 (18)	10 (20)	10 (20)
mesenterium	nodule		0 (0)	0 (0)	1 (2)	0 (0)

Organ	Findings	Group Name / NO. of Animals	Control 50 (%)	100 ppm 49 (%)	200 ppm 50 (%)	400 ppm 50 (%)
thoracic ca	hemorrhage		1 (2)	0 (0)	0 (0)	0 (0)
	pleural fluid		13 (26)	9 (18)	12 (24)	7 (14)
other	lower jaw:nodule		1 (2)	0 (0)	0 (0)	0 (0)

TABLE I 5

GROSS FINDINGS : FEMALE

DEAD AND MORIBUND ANIMALS

Organ	Findings	Group Name / NO. of Animals	Control 19	(%)	100 ppm 22	(%)	200 ppm 24	(%)	400 ppm 16	(%)
skin/app	nodule		0	(0)	1	(5)	0	(0)	0	(0)
	scab		1	(5)	0	(0)	1	(4)	0	(0)
subcutis	edema		4	(21)	3	(14)	6	(25)	5	(31)
	mass		2	(11)	4	(18)	1	(4)	0	(0)
lung	nodule		1	(5)	1	(5)	0	(0)	0	(0)
lymph node	enlarged		6	(32)	8	(36)	7	(29)	3	(19)
spleen	enlarged		4	(21)	4	(18)	5	(21)	2	(13)
	nodule		1	(5)	0	(0)	0	(0)	0	(0)
	deformed		0	(0)	0	(0)	1	(4)	0	(0)
tongue	nodule		1	(5)	0	(0)	0	(0)	0	(0)
forestomach	nodule		1	(5)	0	(0)	0	(0)	0	(0)
small intes	nodule		0	(0)	1	(5)	0	(0)	1	(6)
liver	enlarged		4	(21)	1	(5)	7	(29)	5	(31)
	white zone		5	(26)	3	(14)	5	(21)	5	(31)
	nodule		2	(11)	2	(9)	4	(17)	1	(6)
pancreas	nodule		0	(0)	1	(5)	0	(0)	0	(0)
kidney	hydronephrosis		1	(5)	2	(9)	2	(8)	1	(6)
urin bladd	urine:marked retention		0	(0)	0	(0)	1	(4)	0	(0)
pituitary	enlarged		0	(0)	1	(5)	3	(13)	2	(13)
	red zone		0	(0)	1	(5)	2	(8)	1	(6)
	nodule		0	(0)	0	(0)	0	(0)	3	(19)
ovary	enlarged		4	(21)	1	(5)	5	(21)	3	(19)

Organ	Findings	Group Name / NO. of Animals	Control 19 (%)	100 ppm 22 (%)	200 ppm 24 (%)	400 ppm 16 (%)
ovary	cyst		2 (11)	2 (9)	4 (17)	1 (6)
uterus	nodule		9 (47)	3 (14)	13 (54)	5 (31)
brain	red zone		1 (5)	1 (5)	0 (0)	1 (6)
spinal cord	nodule		0 (0)	0 (0)	1 (4)	0 (0)
periph nerv	nodule		0 (0)	1 (5)	0 (0)	0 (0)
Harder gl	enlarged		1 (5)	0 (0)	0 (0)	0 (0)
	nodule		0 (0)	0 (0)	1 (4)	1 (6)
bone	nodule		0 (0)	0 (0)	0 (0)	1 (6)
mediastinum	nodule		0 (0)	0 (0)	1 (4)	0 (0)
	mass		0 (0)	1 (5)	2 (8)	2 (13)
peritoneum	nodule		0 (0)	2 (9)	1 (4)	0 (0)
	thick		2 (11)	1 (5)	1 (4)	2 (13)
abdominal c	hemorrhage		2 (11)	0 (0)	1 (4)	0 (0)
	ascites		6 (32)	6 (27)	9 (38)	8 (50)
thoracic ca	hemorrhage		1 (5)	0 (0)	0 (0)	0 (0)
	pleural fluid		10 (53)	7 (32)	11 (46)	5 (31)
other	lower jaw:nodule		1 (5)	0 (0)	0 (0)	0 (0)

TABLE I 6

GROSS FINDINGS : FEMALE

SACRIFICED ANIMALS

Organ	Findings	Group Name / NO. of Animals	Control 31 (%)	100 ppm 27 (%)	200 ppm 26 (%)	400 ppm 34 (%)
skin/app	nodule		0 (0)	0 (0)	0 (0)	1 (3)
subcutis	mass		0 (0)	1 (4)	1 (4)	1 (3)
lung	nodule		1 (3)	0 (0)	1 (4)	0 (0)
lymph node	enlarged		6 (19)	1 (4)	7 (27)	5 (15)
spleen	enlarged		4 (13)	3 (11)	4 (15)	2 (6)
	white zone		1 (3)	0 (0)	0 (0)	0 (0)
	nodule		0 (0)	1 (4)	0 (0)	0 (0)
	deformed		0 (0)	0 (0)	0 (0)	1 (3)
tongue	nodule		1 (3)	0 (0)	0 (0)	0 (0)
forestomach	nodule		2 (6)	0 (0)	1 (4)	1 (3)
gl stomach	ulcer		1 (3)	0 (0)	0 (0)	0 (0)
small intes	nodule		0 (0)	1 (4)	1 (4)	0 (0)
liver	enlarged		1 (3)	1 (4)	1 (4)	0 (0)
	white zone		2 (6)	1 (4)	1 (4)	1 (3)
	red zone		2 (6)	4 (15)	2 (8)	0 (0)
	nodule		1 (3)	5 (19)	7 (27)	9 (26)
	cyst		0 (0)	0 (0)	1 (4)	0 (0)
kidney	hydronephrosis		2 (6)	1 (4)	1 (4)	1 (3)
pituitary	enlarged		0 (0)	2 (7)	1 (4)	2 (6)
	nodule		2 (6)	2 (7)	6 (23)	2 (6)
ovary	enlarged		2 (6)	1 (4)	1 (4)	2 (6)
	cyst		7 (23)	5 (19)	6 (23)	9 (26)

Organ	Findings	Group Name / NO. of Animals	Control 31	(%)	100 ppm 27	(%)	200 ppm 26	(%)	400 ppm 34	(%)
uterus	nodule		1	(3)	4	(15)	2	(8)	3	(9)
eye	turbid		0	(0)	0	(0)	0	(0)	1	(3)
muscle	red zone		0	(0)	1	(4)	0	(0)	0	(0)
	nodule		0	(0)	1	(4)	0	(0)	0	(0)
bone	nodule		1	(3)	0	(0)	0	(0)	0	(0)
mediastinum	mass		0	(0)	1	(4)	0	(0)	0	(0)
abdominal c	ascites		1	(3)	3	(11)	1	(4)	2	(6)
mesenterium	nodule		0	(0)	0	(0)	1	(4)	0	(0)
thoracic ca	pleural fluid		3	(10)	2	(7)	1	(4)	2	(6)

TABLE J1

ORGAN WEIGHT, ABSOLUTE : MALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	Body Weight	ADRENALS	TESTES	HEART	LUNGS	KIDNEYS
Control	30	45.8± 7.6	0.011± 0.002	0.208± 0.038	0.229± 0.022	0.221± 0.112	0.712± 0.262
100 ppm	31	44.9± 8.6	0.011± 0.003	0.210± 0.040	0.225± 0.031	0.217± 0.103	0.685± 0.246
200 ppm	34	46.5± 6.5	0.011± 0.002	0.204± 0.035	0.231± 0.023	0.214± 0.064	0.683± 0.050
400 ppm	39	44.4± 5.5	0.011± 0.002	0.210± 0.045	0.217± 0.026	0.213± 0.071	0.704± 0.332

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	SPLEEN		LIVER		BRAIN	
Control	30	0.163±	0.340	1.623±	0.281	0.462±	0.019
100 ppm	31	0.192±	0.449	2.080±	1.054	0.460±	0.016
200 ppm	34	0.102±	0.123	1.791±	0.567	0.458±	0.019
400 ppm	39	0.276±	0.781	1.679±	0.471	0.456±	0.016

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE J2

ORGAN WEIGHT, ABSOLUTE : FEMALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : FEMALE
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	Body Weight	ADRENALS	OVARIES	HEART	LUNGS	KIDNEYS
Control	30	29.1± 3.4	0.015± 0.003	0.201± 0.557	0.174± 0.026	0.213± 0.098	0.487± 0.219
100 ppm	27	33.2± 3.8**	0.015± 0.004	0.061± 0.043	0.182± 0.034	0.186± 0.015	0.458± 0.071
200 ppm	25	31.9± 4.6*	0.014± 0.002	0.079± 0.067	0.179± 0.023	0.196± 0.027	0.503± 0.241
400 ppm	34	30.1± 4.5	0.013± 0.003	0.063± 0.050	0.175± 0.024	0.194± 0.018	0.459± 0.138

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : FEMALE
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	SPLEEN		LIVER		BRAIN	
Control	30	0.246±	0.276	1.438±	0.248	0.483±	0.018
100 ppm	27	0.202±	0.218	1.731±	0.979	0.490±	0.016
200 ppm	25	0.232±	0.244	1.715±	1.070	0.474±	0.016
400 ppm	34	0.173±	0.148	1.417±	0.269	0.483±	0.018

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE K1

ORGAN WEIGHT, RELATIVE : MALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	TESTES	HEART	LUNGS	KIDNEYS
Control	30	45.8± 7.6	0.024± 0.007	0.469± 0.132	0.511± 0.090	0.513± 0.376	1.624± 0.856
100 ppm	31	44.9± 8.6	0.025± 0.010	0.485± 0.136	0.515± 0.112	0.519± 0.344	1.601± 0.814
200 ppm	34	46.5± 6.5	0.023± 0.007	0.448± 0.108	0.501± 0.056	0.476± 0.218	1.498± 0.264
400 ppm	39	44.4± 5.5	0.024± 0.006	0.476± 0.110	0.491± 0.059	0.484± 0.158	1.634± 1.034

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	30	0.392± 0.922	3.605± 0.717	1.039± 0.195
100 ppm	31	0.494± 1.241	5.125± 3.803	1.064± 0.231
200 ppm	34	0.234± 0.325	3.923± 1.549	1.004± 0.160
400 ppm	39	0.727± 2.271	3.862± 1.513	1.040± 0.127

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE K2

ORGAN WEIGHT, RELATIVE : FEMALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : FEMALE
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	OVARIES	HEART	LUNGS	KIDNEYS
Control	30	29.1± 3.4	0.051± 0.013	0.655± 1.732	0.607± 0.123	0.744± 0.364	1.710± 0.932
100 ppm	27	33.2± 3.8**	0.044± 0.013	0.184± 0.132	0.549± 0.094	0.566± 0.065**	1.382± 0.179*
200 ppm	25	31.9± 4.6*	0.044± 0.008	0.258± 0.246	0.573± 0.108	0.631± 0.144	1.645± 1.052
400 ppm	34	30.1± 4.5	0.045± 0.013	0.208± 0.160	0.594± 0.119	0.658± 0.102	1.549± 0.443

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : FEMALE
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	30	0.892± 1.154	4.981± 0.945	1.682± 0.194
100 ppm	27	0.599± 0.594	5.181± 2.653	1.494± 0.180**
200 ppm	25	0.777± 0.883	5.499± 3.664	1.516± 0.210*
400 ppm	34	0.572± 0.454	4.760± 0.864	1.642± 0.267

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE L1

HISTOPATHOLOGICAL FINDINGS :

NON-NEOPLASTIC LESIONS : MALE

ALL ANIMALS

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50				100 ppm 50				200 ppm 49				400 ppm 50			
			1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Integumentary system/appandage)																		
skin/app			<50>				<50>				<49>				<50>			
	ulcer		0 (0)	2 (4)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
	squamous cell hyperplasia		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
subcutis			<50>				<50>				<49>				<50>			
	inflammation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Respiratory system)																		
nasal cavit			<50>				<50>				<49>				<50>			
	exudate		0 (0)	0 (0)	0 (0)	0 (0)	4 (8)	2 (4)	0 (0)	0 * (0)	11 (22)	35 (71)	0 (0)	0 ** (0)	20 (40)	28 (56)	1 (2)	0 ** (0)
	mineralization		6 (12)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	inflammation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	50				50				49				50			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Respiratory system}																		
nasal cavit			<50>				<50>				<49>				<50>			
	eosinophilic change:olfactory epithelium		24	2	0	0	27	0	0	0	13	1	0	0	21	0	0	0
			(48)	(4)	(0)	(0)	(54)	(0)	(0)	(0)	(27)	(2)	(0)	(0)	(42)	(0)	(0)	(0)
	eosinophilic change:respiratory epithelium		17	0	0	0	17	0	0	0	40	2	0	0 **	38	1	0	0 **
			(34)	(0)	(0)	(0)	(34)	(0)	(0)	(0)	(82)	(4)	(0)	(0)	(76)	(2)	(0)	(0)
	inflammation:respiratory epithelium		1	0	0	0	0	0	0	0	3	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(6)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	respiratory metaplasia:olfactory epithelium		24	0	0	0	24	0	0	0	38	0	0	0 **	44	0	0	0 **
			(48)	(0)	(0)	(0)	(48)	(0)	(0)	(0)	(78)	(0)	(0)	(0)	(88)	(0)	(0)	(0)
	respiratory metaplasia:gland		36	0	0	0	39	1	0	0	36	3	0	0	39	6	0	0 **
			(72)	(0)	(0)	(0)	(78)	(2)	(0)	(0)	(73)	(6)	(0)	(0)	(78)	(12)	(0)	(0)
	squamous cell metaplasia:respiratory epithelium		1	0	0	0	1	0	0	0	12	0	0	0 **	18	2	0	0 **
			(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(24)	(0)	(0)	(0)	(36)	(4)	(0)	(0)
	ulcer:respiratory epithelium		0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(2)	(0)
	transitional cell hyperplasia		0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	50				50				49				50			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Respiratory system}																		
nasal cavit			<50>				<50>				<49>				<50>			
	xanthogranuloma		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	atrophy:olfactory epithelium		0	0	0	0	2	2	0	0	18	29	0	0 **	23	26	0	0 **
			(0)	(0)	(0)	(0)	(4)	(4)	(0)	(0)	(37)	(59)	(0)	(0)	(46)	(52)	(0)	(0)
	necrosis:respiratory epithelium		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
nasopharynx			<50>				<50>				<49>				<50>			
	eosinophilic change		1	0	0	0	1	0	0	0	5	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(10)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
lung			<50>				<50>				<49>				<50>			
	congestion		0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(2)	(0)	(0)
	hemorrhage		0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	inflammatory infiltration		1	0	0	0	1	0	1	0	3	1	0	0	0	1	0	0
			(2)	(0)	(0)	(0)	(2)	(0)	(2)	(0)	(6)	(2)	(0)	(0)	(0)	(2)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	50				50				49				50			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
(Respiratory system)																		
lung			<50>				<50>				<49>				<50>			
	lymphocytic infiltration		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	granulation		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	squamous cell metaplasia		0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)
	accumulation of foamy cells		1	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	bronchiolar-alveolar cell hyperplasia		0	0	0	0	1	0	0	0	3	1	0	0	1	1	0	0
			(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(6)	(2)	(0)	(0)	(2)	(2)	(0)	(0)
(Hematopoietic system)																		
bone marrow			<50>				<50>				<49>				<50>			
	angiectasis		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	increased hematopoiesis		0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	50				50				49				50			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Hematopoietic system}																		
spleen			<50>				<50>				<49>				<50>			
	deposit of melanin		0	0	0	0	2	0	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	extramedullary hematopoiesis		6	2	2	0	12	8	0	0 *	11	3	0	0	2	3	0	0
			(12)	(4)	(4)	(0)	(24)	(16)	(0)	(0)	(22)	(6)	(0)	(0)	(4)	(6)	(0)	(0)
	lymph-follicular hyperplasia		0	0	2	0	0	0	0	0	0	0	0	0	0	1	0	0
			(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)
{Circulatory system}																		
heart			<50>				<50>				<49>				<50>			
	mineralization		0	1	0	0	2	0	0	0	2	1	0	0	0	0	0	0
			(0)	(2)	(0)	(0)	(4)	(0)	(0)	(0)	(4)	(2)	(0)	(0)	(0)	(0)	(0)	(0)
	myocardial fibrosis		1	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Digestive system}																		
tooth			<50>				<50>				<49>				<50>			
	dysplasia		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	50				50				49				50			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
(Digestive system)																		
tongue			<50>				<50>				<49>				<50>			
	arteritis		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
salivary gl			<50>				<50>				<49>				<50>			
	lymphocytic infiltration		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	xanthogranuloma		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(2)	(0)	(0)
stomach			<50>				<50>				<49>				<50>			
	ulcer:forestomach		1	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	hyperplasia:forestomach		0	0	0	0	0	0	0	0	1	0	0	0	2	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)
	erosion:glandular stomach		8	0	0	0	7	1	0	0	5	0	0	0	7	2	0	0
			(16)	(0)	(0)	(0)	(14)	(2)	(0)	(0)	(10)	(0)	(0)	(0)	(14)	(4)	(0)	(0)
	ulcer:glandular stomach		0	0	0	0	1	0	0	0	2	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(2)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	50				50				49				50			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
(Digestive system)																		
stomach			<50>				<50>				<49>				<50>			
	hyperplasia:glandular stomach		4	0	0	0	12	0	0	0	5	1	0	0	8	0	0	0
			(8)	(0)	(0)	(0)	(24)	(0)	(0)	(0)	(10)	(2)	(0)	(0)	(16)	(0)	(0)	(0)
liver			<50>				<50>				<49>				<50>			
	angiectasis		0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	necrosis:focal		1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	collapse		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	inflammatory infiltration		0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	granulation		0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)
	inflammatory cell nest		1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(2)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	extramedullary hematopoiesis		1	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0
			(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50				100 ppm 50				200 ppm 49				400 ppm 50			
			1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Digestive system}																		
liver			<50>				<50>				<49>				<50>			
	clear cell focus		1	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)
	acidophilic cell focus		2	0	0	0	4	1	0	0	4	1	0	0	5	0	0	0
			(4)	(0)	(0)	(0)	(8)	(2)	(0)	(0)	(8)	(2)	(0)	(0)	(10)	(0)	(0)	(0)
	basophilic cell focus		0	0	0	0	2	0	0	0	1	0	0	0	2	0	1	0
			(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(4)	(0)	(2)	(0)
	hyperplasia:Ito-cell		0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
gall bladd			<50>				<50>				<49>				<50>			
	cyst		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
pancreas			<50>				<50>				<49>				<50>			
	islet cell hyperplasia		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	xanthogranuloma		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50				100 ppm 50				200 ppm 49				400 ppm 50			
			1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
(Urinary system)																		
kidney			<50>				<50>				<49>				<50>			
	hemorrhage		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	thrombus		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	cyst		2 (4)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	hyaline droplet		2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	basophilic change		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	lymphocytic infiltration		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	inflammatory polyp		0 (0)	2 (4)	1 (2)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	hydronephrosis		1 (2)	1 (2)	1 (2)	0 (0)	0 (0)	3 (6)	6 (12)	0 (0)	0 (0)	1 (2)	2 (4)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50				100 ppm 50				200 ppm 49				400 ppm 50			
			1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Urinary system}																		
kidney			<50>				<50>				<49>				<50>			
	dilated pelvis		1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
urin bladd			<50>				<50>				<49>				<50>			
	dilatation		0	0	8	0	0	0	5	0	0	0	2	0	0	0	0	0 **
			(0)	(0)	(16)	(0)	(0)	(0)	(10)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)
	nodular hyperplasia:transitional epithelium		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
{Endocrine system}																		
pituitary			<50>				<49>				<49>				<50>			
	angiectasis		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	cyst		1	0	0	0	1	0	0	0	1	0	0	0	2	0	0	0
			(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)
	hyperplasia		0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(2)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50				100 ppm 50				200 ppm 49				400 ppm 50			
			1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Endocrine system}																		
pituitary			<50>				<49>				<49>				<50>			
	Rathke pouch		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)
parathyroid			<50>				<50>				<49>				<50>			
	cyst		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
adrenal			<50>				<50>				<49>				<50>			
	spindle-cell hyperplasia		11 (22)	0 (0)	0 (0)	0 (0)	8 (16)	0 (0)	0 (0)	0 (0)	8 (16)	0 (0)	0 (0)	0 (0)	12 (24)	0 (0)	0 (0)	0 (0)
	hyperplasia:cortical cell		9 (18)	0 (0)	0 (0)	0 (0)	11 (22)	1 (2)	0 (0)	0 (0)	8 (16)	1 (2)	0 (0)	0 (0)	5 (10)	2 (4)	0 (0)	0 (0)
{Reproductive system}																		
testis			<50>				<50>				<49>				<50>			
	mineralization		3 (6)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
	interstitial cell hyperplasia		0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50				100 ppm 50				200 ppm 49				400 ppm 50			
			1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Reproductive system}																		
testis			<50>				<50>				<49>				<50>			
	spermatogenic granuloma		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
epididymis			<50>				<50>				<49>				<50>			
	spermatogenic granuloma		0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)
semin ves			<50>				<50>				<49>				<50>			
	hemorrhage		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
prostate			<50>				<50>				<49>				<50>			
	inflammatory infiltration		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
prep/cli gl			<50>				<50>				<49>				<50>			
	cyst		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
{Nervous system}																		
brain			<50>				<50>				<49>				<50>			
	hemorrhage		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50				100 ppm 50				200 ppm 49				400 ppm 50			
			1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Nervous system}																		
brain			<50>				<50>				<49>				<50>			
	mineralization		18	0	0	0	17	0	0	0	21	0	0	0	18	0	0	0
			(36)	(0)	(0)	(0)	(34)	(0)	(0)	(0)	(43)	(0)	(0)	(0)	(36)	(0)	(0)	(0)
{Special sense organs/appendage}																		
eye			<50>				<50>				<49>				<50>			
	keratitis		0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0
			(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	phthisis bulbi		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
Harder gl			<50>				<50>				<49>				<50>			
	hyperplasia		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Musculoskeletal system}																		
muscle			<50>				<50>				<49>				<50>			
	mineralization		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	50				50				49				50			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Musculoskeletal system}																		
bone			<50>				<50>				<49>				<50>			
	ostitis fibrosa		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Body cavities}																		
peritoneum			<50>				<50>				<49>				<50>			
	cyst		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

TABLE L2

HISTOPATHOLOGICAL FINDINGS :

NON-NEOPLASTIC LESIONS : MALE

DEAD AND MORIBUND ANIMALS

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	20				19				15				11			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Integumentary system/appandage}																		
skin/app			<20>				<19>				<15>				<11>			
	ulcer		0	2	0	0	0	1	0	0	1	1	0	0	0	1	0	0
			(0)	(10)	(0)	(0)	(0)	(5)	(0)	(0)	(7)	(7)	(0)	(0)	(0)	(9)	(0)	(0)
subcutis			<20>				<19>				<15>				<11>			
	inflammation		0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(11)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Respiratory system}																		
nasal cavit			<20>				<19>				<15>				<11>			
	exudate		0	0	0	0	0	2	0	0	3	11	0	0 **	1	8	1	0 **
			(0)	(0)	(0)	(0)	(0)	(11)	(0)	(0)	(20)	(73)	(0)	(0)	(9)	(73)	(9)	(0)
	mineralization		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	eosinophilic change:olfactory epithelium		11	0	0	0	9	0	0	0	6	0	0	0	0	0	0	0 **
			(55)	(0)	(0)	(0)	(47)	(0)	(0)	(0)	(40)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	eosinophilic change:respiratory epithelium		6	0	0	0	5	0	0	0	11	0	0	0 *	4	0	0	0
			(30)	(0)	(0)	(0)	(26)	(0)	(0)	(0)	(73)	(0)	(0)	(0)	(36)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	20				19				15				11			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
(Respiratory system)																		
nasal cavit			<20>				<19>				<15>				<11>			
	respiratory metaplasia:olfactory epithelium		7	0	0	0	4	0	0	0	8	0	0	0	6	0	0	0
			(35)	(0)	(0)	(0)	(21)	(0)	(0)	(0)	(53)	(0)	(0)	(0)	(55)	(0)	(0)	(0)
	respiratory metaplasia:gland		12	0	0	0	14	0	0	0	9	1	0	0	6	0	0	0
			(60)	(0)	(0)	(0)	(74)	(0)	(0)	(0)	(60)	(7)	(0)	(0)	(55)	(0)	(0)	(0)
	squamous cell metaplasia:respiratory epithelium		0	0	0	0	0	0	0	0	4	0	0	0	4	2	0	0 **
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(27)	(0)	(0)	(0)	(36)	(18)	(0)	(0)
	ulcer:respiratory epithelium		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(9)	(0)
	atrophy:olfactory epithelium		0	0	0	0	0	2	0	0	3	11	0	0 **	3	7	0	0 **
			(0)	(0)	(0)	(0)	(0)	(11)	(0)	(0)	(20)	(73)	(0)	(0)	(27)	(64)	(0)	(0)
	necrosis:respiratory epithelium		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
nasopharynx			<20>				<19>				<15>				<11>			
	eosinophilic change		0	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(13)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
lung			<20>				<19>				<15>				<11>			
	congestion		0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(7)	(0)	(0)	(0)	(0)	(9)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	20				19				15				11			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Respiratory system}																		
lung			<20>				<19>				<15>				<11>			
	hemorrhage		0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(0)	(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	inflammatory infiltration		1	0	0	0	1	0	1	0	2	1	0	0	0	0	0	0
			(5)	(0)	(0)	(0)	(5)	(0)	(5)	(0)	(13)	(7)	(0)	(0)	(0)	(0)	(0)	(0)
	accumulation of foamy cells		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(7)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Hematopoietic system}																		
bone marrow			<20>				<19>				<15>				<11>			
	increased hematopoiesis		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
spleen			<20>				<19>				<15>				<11>			
	deposit of melanin		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	extramedullary hematopoiesis		4	2	2	0	3	8	0	0	2	3	0	0	1	2	0	0
			(20)	(10)	(10)	(0)	(16)	(42)	(0)	(0)	(13)	(20)	(0)	(0)	(9)	(18)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	20				19				15				11			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Circulatory system}																		
heart			<20>				<19>				<15>				<11>			
	mineralization		0	1	0	0	2	0	0	0	1	1	0	0	0	0	0	0
			(0)	(5)	(0)	(0)	(11)	(0)	(0)	(0)	(7)	(7)	(0)	(0)	(0)	(0)	(0)	(0)
	myocardial fibrosis		1	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0
			(5)	(0)	(0)	(0)	(0)	(5)	(0)	(0)	(7)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Digestive system}																		
stomach			<20>				<19>				<15>				<11>			
	ulcer:forestomach		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	hyperplasia:forestomach		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(7)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	erosion:glandular stomach		2	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0
			(10)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(9)	(0)	(0)	(0)
	ulcer:glandular stomach		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(9)	(0)	(0)	(0)
	hyperplasia:glandular stomach		1	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0
			(5)	(0)	(0)	(0)	(11)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	20				19				15				11			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Digestive system}																		
liver			<20>				<19>				<15>				<11>			
	angiectasis		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(7)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	necrosis:focal		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	inflammatory infiltration		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	extramedullary hematopoiesis		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	acidophilic cell focus		0	0	0	0	2	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(11)	(0)	(0)	(0)	(7)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Urinary system}																		
kidney			<20>				<19>				<15>				<11>			
	hemorrhage		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	thrombus		0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(7)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	20				19				15				11			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Urinary system}																		
kidney			<20>				<19>				<15>				<11>			
	cyst		2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(10)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	hyaline droplet		2	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0
			(10)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(7)	(0)	(0)	(0)	(9)	(0)	(0)	(0)
	lymphocytic infiltration		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	inflammatory polyp		0	0	1	0	0	2	1	0	0	1	1	0	0	0	0	0
			(0)	(0)	(5)	(0)	(0)	(11)	(5)	(0)	(0)	(7)	(7)	(0)	(0)	(0)	(0)	(0)
	hydronephrosis		0	1	0	0	0	2	6	0 *	0	0	2	0	0	1	0	0
			(0)	(5)	(0)	(0)	(0)	(11)	(32)	(0)	(0)	(0)	(13)	(0)	(0)	(9)	(0)	(0)
	dilated pelvis		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
urin bladd			<20>				<19>				<15>				<11>			
	dilatation		0	0	7	0	0	0	5	0	0	0	2	0	0	0	0	0
			(0)	(0)	(35)	(0)	(0)	(0)	(26)	(0)	(0)	(0)	(13)	(0)	(0)	(0)	(0)	(0)
{Endocrine system}																		
pituitary			<20>				<18>				<15>				<11>			
	Rathke pouch		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(9)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	20				19				15				11			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Endocrine system}																		
parathyroid			<20>				<19>				<15>				<11>			
	cyst		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(7)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
adrenal			<20>				<19>				<15>				<11>			
	spindle-cell hyperplasia		2	0	0	0	0	0	0	0	2	0	0	0	1	0	0	0
			(10)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(13)	(0)	(0)	(0)	(9)	(0)	(0)	(0)
	hyperplasia:cortical cell		1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(9)	(0)	(0)	(0)
{Reproductive system}																		
testis			<20>				<19>				<15>				<11>			
	mineralization		0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(7)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
epididymis			<20>				<19>				<15>				<11>			
	spermatogenic granuloma		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(9)	(0)	(0)	(0)
semin ves			<20>				<19>				<15>				<11>			
	hemorrhage		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	20				19				15				11			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Reproductive system}																		
prostate			<20>				<19>				<15>				<11>			
	inflammatory infiltration		0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(7)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
prep/cli gl			<20>				<19>				<15>				<11>			
	cyst		1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(9)	(0)	(0)	(0)
{Nervous system}																		
brain			<20>				<19>				<15>				<11>			
	hemorrhage		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(7)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	mineralization		6	0	0	0	3	0	0	0	5	0	0	0	4	0	0	0
			(30)	(0)	(0)	(0)	(16)	(0)	(0)	(0)	(33)	(0)	(0)	(0)	(36)	(0)	(0)	(0)
{Special sense organs/appendage}																		
eye			<20>				<19>				<15>				<11>			
	keratitis		0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0
			(0)	(5)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	20				19				15				11			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Musculoskeletal system}																		
muscle			<20>				<19>				<15>				<11>			
	mineralization		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

TABLE L3

HISTOPATHOLOGICAL FINDINGS :

NON-NEOPLASTIC LESIONS : MALE

SACRIFICED ANIMALS

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	30				31				34				39			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Integumentary system/appandage}																		
skin/app			<30>				<31>				<34>				<39>			
	ulcer		0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	squamous cell hyperplasia		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Respiratory system}																		
nasal cavit			<30>				<31>				<34>				<39>			
	exudate		0	0	0	0	4	0	0	0	8	24	0	0 **	19	20	0	0 **
			(0)	(0)	(0)	(0)	(13)	(0)	(0)	(0)	(24)	(71)	(0)	(0)	(49)	(51)	(0)	(0)
	mineralization		6	0	0	0	1	0	0	0	3	0	0	0	1	0	0	0 *
			(20)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(9)	(0)	(0)	(0)	(3)	(0)	(0)	(0)
	inflammation		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	eosinophilic change:olfactory epithelium		13	2	0	0	18	0	0	0	7	1	0	0	21	0	0	0
			(43)	(7)	(0)	(0)	(58)	(0)	(0)	(0)	(21)	(3)	(0)	(0)	(54)	(0)	(0)	(0)
	eosinophilic change:respiratory epithelium		11	0	0	0	12	0	0	0	29	2	0	0 **	34	1	0	0 **
			(37)	(0)	(0)	(0)	(39)	(0)	(0)	(0)	(85)	(6)	(0)	(0)	(87)	(3)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	30				31				34				39			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Respiratory system}																		
nasal cavit			<30>				<31>				<34>				<39>			
	inflammation:respiratory epithelium		1	0	0	0	0	0	0	0	3	0	0	0	0	0	0	0
			(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(9)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	respiratory metaplasia:olfactory epithelium		17	0	0	0	20	0	0	0	30	0	0	0 *	38	0	0	0 **
			(57)	(0)	(0)	(0)	(65)	(0)	(0)	(0)	(88)	(0)	(0)	(0)	(97)	(0)	(0)	(0)
	respiratory metaplasia:gland		24	0	0	0	25	1	0	0	27	2	0	0	33	6	0	0 **
			(80)	(0)	(0)	(0)	(81)	(3)	(0)	(0)	(79)	(6)	(0)	(0)	(85)	(15)	(0)	(0)
	squamous cell metaplasia:respiratory epithelium		1	0	0	0	1	0	0	0	8	0	0	0	14	0	0	0 **
			(3)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(24)	(0)	(0)	(0)	(36)	(0)	(0)	(0)
	ulcer:respiratory epithelium		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	transitional cell hyperplasia		0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(3)	(0)	(0)	(0)
	xanthogranuloma		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	atrophy:olfactory epithelium		0	0	0	0	2	0	0	0	15	18	0	0 **	20	19	0	0 **
			(0)	(0)	(0)	(0)	(6)	(0)	(0)	(0)	(44)	(53)	(0)	(0)	(51)	(49)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	30				31				34				39			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Respiratory system}																		
nasopharynx			<30>				<31>				<34>				<39>			
	eosinophilic change		1	0	0	0	0	0	0	0	3	0	0	0	0	0	0	0
			(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(9)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
lung			<30>				<31>				<34>				<39>			
	inflammatory infiltration		0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(3)	(0)	(0)
	lymphocytic infiltration		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	granulation		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	squamous cell metaplasia		0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)
	accumulation of foamy cells		1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)
	bronchiolar-alveolar cell hyperplasia		0	0	0	0	1	0	0	0	3	1	0	0	1	1	0	0
			(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(9)	(3)	(0)	(0)	(3)	(3)	(0)	(0)
{Hematopoietic system}																		
bone marrow			<30>				<31>				<34>				<39>			
	angiectasis		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	30				31				34				39			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Hematopoietic system}																		
bone marrow			<30>				<31>				<34>				<39>			
	increased hematopoiesis		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)
spleen			<30>				<31>				<34>				<39>			
	deposit of melanin		0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)
	extramedullary hematopoiesis		2	0	0	0	9	0	0	0	9	0	0	0	1	1	0	0
			(7)	(0)	(0)	(0)	(29)	(0)	(0)	(0)	(26)	(0)	(0)	(0)	(3)	(3)	(0)	(0)
	lymph-follicular hyperplasia		0	0	2	0	0	0	0	0	0	0	0	0	0	1	0	0
			(0)	(0)	(7)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)
{Circulatory system}																		
heart			<30>				<31>				<34>				<39>			
	mineralization		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Digestive system}																		
tooth			<30>				<31>				<34>				<39>			
	dysplasia		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 30				100 ppm 31				200 ppm 34				400 ppm 39			
			1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Digestive system}																		
tongue			<30>				<31>				<34>				<39>			
	arteritis		1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
salivary gl			<30>				<31>				<34>				<39>			
	lymphocytic infiltration		1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	xanthogranuloma		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (3)	1 (3)	0 (0)	0 (0)
stomach			<30>				<31>				<34>				<39>			
	ulcer:forestomach		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)	0 (0)	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	hyperplasia:forestomach		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (5)	0 (0)	0 (0)	0 (0)
	erosion:glandular stomach		6 (20)	0 (0)	0 (0)	0 (0)	6 (19)	1 (3)	0 (0)	0 (0)	5 (15)	0 (0)	0 (0)	0 (0)	6 (15)	2 (5)	0 (0)	0 (0)
	ulcer:glandular stomach		0 (0)	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)	0 (0)	0 (0)	2 (6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	30				31				34				39			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Digestive system}																		
stomach			<30>				<31>				<34>				<39>			
	hyperplasia:glandular stomach		3	0	0	0	10	0	0	0	5	1	0	0	8	0	0	0
			(10)	(0)	(0)	(0)	(32)	(0)	(0)	(0)	(15)	(3)	(0)	(0)	(21)	(0)	(0)	(0)
liver			<30>				<31>				<34>				<39>			
	angiectasis		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	necrosis:focal		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	collapse		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	inflammatory infiltration		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	granulation		0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)
	inflammatory cell nest		1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(3)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	extramedullary hematopoiesis		1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	30				31				34				39			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Digestive system}																		
liver			<30>				<31>				<34>				<39>			
	clear cell focus		1	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0
			(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(6)	(0)	(0)	(0)	(0)	(0)	(0)
	acidophilic cell focus		2	0	0	0	2	1	0	0	3	1	0	0	5	0	0	0
			(7)	(0)	(0)	(0)	(6)	(3)	(0)	(0)	(9)	(3)	(0)	(0)	(13)	(0)	(0)	(0)
	basophilic cell focus		0	0	0	0	2	0	0	0	1	0	0	0	2	0	1	0
			(0)	(0)	(0)	(0)	(6)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(5)	(0)	(3)	(0)
	hyperplasia:Ito-cell		0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
gall bladd			<30>				<31>				<34>				<39>			
	cyst		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
pancreas			<30>				<31>				<34>				<39>			
	islet cell hyperplasia		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	xanthogranuloma		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	30				31				34				39			
		Grade	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Urinary system}																		
kidney			<30>				<31>				<34>				<39>			
	cyst		0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	basophilic change		1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	inflammatory polyp		0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(0)	(7)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	hydronephrosis		1	0	1	0	0	1	0	0	0	1	0	0	0	0	0	0
			(3)	(0)	(3)	(0)	(0)	(3)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)
	dilated pelvis		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
urin bladd			<30>				<31>				<34>				<39>			
	dilatation		0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	nodular hyperplasia:transitional epithelium		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)
{Endocrine system}																		
pituitary			<30>				<31>				<34>				<39>			
	angiectasis		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	30				31				34				39			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Endocrine system}																		
pituitary			<30>				<31>				<34>				<39>			
	cyst		1	0	0	0	1	0	0	0	1	0	0	0	2	0	0	0
			(3)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(5)	(0)	(0)	(0)
	hyperplasia		0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(3)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	Rathke pouch		0	0	0	0	1	1	0	0	0	0	0	0	2	0	0	0
			(0)	(0)	(0)	(0)	(3)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)
parathyroid			<30>				<31>				<34>				<39>			
	cyst		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
adrenal			<30>				<31>				<34>				<39>			
	spindle-cell hyperplasia		9	0	0	0	8	0	0	0	6	0	0	0	11	0	0	0
			(30)	(0)	(0)	(0)	(26)	(0)	(0)	(0)	(18)	(0)	(0)	(0)	(28)	(0)	(0)	(0)
	hyperplasia:cortical cell		8	0	0	0	11	1	0	0	8	1	0	0	4	2	0	0
			(27)	(0)	(0)	(0)	(35)	(3)	(0)	(0)	(24)	(3)	(0)	(0)	(10)	(5)	(0)	(0)
{Reproductive system}																		
testis			<30>				<31>				<34>				<39>			
	mineralization		3	0	0	0	1	0	0	0	0	0	0	0	2	0	0	0
			(10)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	30				31				34				39			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Reproductive system}																		
testis			<30>				<31>				<34>				<39>			
	interstitial cell hyperplasia		0	1	0	0	0	1	0	0	0	0	0	0	1	0	0	0
			(0)	(3)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)
	spermatogenic granuloma		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
epididymis			<30>				<31>				<34>				<39>			
	spermatogenic granuloma		0	0	0	0	2	0	0	0	1	0	0	0	0	1	0	0
			(0)	(0)	(0)	(0)	(6)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(3)	(0)	(0)
prep/cli gl			<30>				<31>				<34>				<39>			
	cyst		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Nervous system}																		
brain			<30>				<31>				<34>				<39>			
	mineralization		12	0	0	0	14	0	0	0	16	0	0	0	14	0	0	0
			(40)	(0)	(0)	(0)	(45)	(0)	(0)	(0)	(47)	(0)	(0)	(0)	(36)	(0)	(0)	(0)
{Special sense organs/appendage}																		
eye			<30>				<31>				<34>				<39>			
	phthisis bulbi		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; *. : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	30				31				34				39			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Special sense organs/appendage}																		
Harder gl			<30>				<31>				<34>				<39>			
	hyperplasia		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Musculoskeletal system}																		
bone			<30>				<31>				<34>				<39>			
	ostitis fibrosa		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Body cavities}																		
peritoneum			<30>				<31>				<34>				<39>			
	cyst		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

TABLE L4

HISTOPATHOLOGICAL FINDINGS :

NON-NEOPLASTIC LESIONS : FEMALE

ALL ANIMALS

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	50				49				50				50			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Respiratory system}																		
nasal cavit			<50>				<49>				<50>				<50>			
	exudate		1	0	0	0	6	7	2	0 **	7	15	25	0 **	15	23	10	0 **
			(2)	(0)	(0)	(0)	(12)	(14)	(4)	(0)	(14)	(30)	(50)	(0)	(30)	(46)	(20)	(0)
	mineralization		0	0	0	0	4	0	0	0	2	0	0	0	2	0	0	0
			(0)	(0)	(0)	(0)	(8)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(4)	(0)	(0)	(0)
	inflammation		0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)
	eosinophilic change:olfactory epithelium		27	0	0	0	20	0	0	0	22	1	0	0	45	1	0	0 **
			(54)	(0)	(0)	(0)	(41)	(0)	(0)	(0)	(44)	(2)	(0)	(0)	(90)	(2)	(0)	(0)
	eosinophilic change:respiratory epithelium		41	4	0	0	19	1	0	0 **	34	1	0	0 *	41	3	1	0
			(82)	(8)	(0)	(0)	(39)	(2)	(0)	(0)	(68)	(2)	(0)	(0)	(82)	(6)	(2)	(0)
	inflammation:respiratory epithelium		0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(2)	(0)	(0)
	respiratory metaplasia:olfactory epithelium		15	0	0	0	23	0	0	0	27	1	0	0 *	36	10	0	0 **
			(30)	(0)	(0)	(0)	(47)	(0)	(0)	(0)	(54)	(2)	(0)	(0)	(72)	(20)	(0)	(0)
	respiratory metaplasia:gland		34	0	0	0	30	0	0	0	40	0	0	0	47	0	0	0 **
			(68)	(0)	(0)	(0)	(61)	(0)	(0)	(0)	(80)	(0)	(0)	(0)	(94)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	50				49				50				50			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Respiratory system}																		
nasal cavit			<50>				<49>				<50>				<50>			
	squamous cell metaplasia:respiratory epithelium		2	0	0	0	3	0	0	0	19	1	0	0 **	22	8	1	0 **
			(4)	(0)	(0)	(0)	(6)	(0)	(0)	(0)	(38)	(2)	(0)	(0)	(44)	(16)	(2)	(0)
	ulcer:respiratory epithelium		1	0	0	0	0	0	1	0	0	0	0	0	1	0	3	0
			(2)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(6)	(0)
	atrophy:olfactory epithelium		0	0	0	0	6	5	1	0 **	10	16	22	0 **	7	33	7	0 **
			(0)	(0)	(0)	(0)	(12)	(10)	(2)	(0)	(20)	(32)	(44)	(0)	(14)	(66)	(14)	(0)
	necrosis:olfactory epithelium		0	0	0	0	0	0	0	0	5	0	0	0	2	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(10)	(0)	(0)	(0)	(4)	(2)	(0)	(0)
	necrosis:respiratory epithelium		0	0	0	0	0	0	0	0	7	1	0	0 *	5	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(14)	(2)	(0)	(0)	(10)	(0)	(0)	(0)
nasopharynx			<50>				<49>				<50>				<50>			
	eosinophilic change		4	0	0	0	2	0	0	0	4	0	0	0	1	1	0	0
			(8)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(8)	(0)	(0)	(0)	(2)	(2)	(0)	(0)
larynx			<50>				<49>				<50>				<50>			
	inflammatory infiltration		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	50				49				50				50			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Respiratory system}																		
trachea			<50>				<49>				<50>				<50>			
	eosinophilic change		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
lung			<50>				<49>				<50>				<50>			
	inflammatory infiltration		2	0	0	0	4	0	0	0	1	0	0	0	0	0	0	0
			(4)	(0)	(0)	(0)	(8)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	lymphocytic infiltration		2	0	0	0	1	0	0	0	0	0	0	0	4	0	0	0
			(4)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(8)	(0)	(0)	(0)
	accumulation of foamy cells		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	bronchiolar-alveolar cell hyperplasia		0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0
			(0)	(0)	(0)	(0)	(2)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)
{Hematopoietic system}																		
bone marrow			<50>				<49>				<50>				<50>			
	increased hematopoiesis		0	0	0	0	1	0	0	0	1	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50				100 ppm 49				200 ppm 50				400 ppm 50			
			1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Hematopoietic system}																		
bone marrow			<50>				<49>				<50>				<50>			
	granulopoiesis:increased		1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
spleen			<50>				<49>				<49>				<50>			
	deposit of melanin		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	extramedullary hematopoiesis		3 (6)	8 (16)	0 (0)	0 (0)	6 (12)	2 (4)	0 (0)	0 (0)	4 (8)	3 (6)	0 (0)	0 (0)	6 (12)	1 (2)	0 (0)	0 * (0)
	lymph-follicular hyperplasia		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
{Circulatory system}																		
heart			<50>				<49>				<50>				<50>			
	mineralization		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	myocardial fibrosis		2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	50				49				50				50			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Circulatory system}																		
heart			<50>				<49>				<50>				<50>			
	arthritis		0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)
{Digestive system}																		
salivary gl			<50>				<49>				<50>				<50>			
	lymphocytic infiltration		1	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0
			(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
stomach			<50>				<49>				<50>				<50>			
	hyperplasia:forestomach		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	erosion:glandular stomach		5	1	0	0	6	0	0	0	4	3	0	0	3	1	0	0
			(10)	(2)	(0)	(0)	(12)	(0)	(0)	(0)	(8)	(6)	(0)	(0)	(6)	(2)	(0)	(0)
	ulcer:glandular stomach		0	0	1	0	0	1	0	0	0	0	0	0	0	1	1	0
			(0)	(0)	(2)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(2)	(0)
	hyperplasia:glandular stomach		3	0	0	0	2	0	0	0	4	0	0	0	5	0	0	0
			(6)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(8)	(0)	(0)	(0)	(10)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50				100 ppm 49				200 ppm 50				400 ppm 50			
			1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Digestive system}																		
liver			<50>				<49>				<50>				<50>			
	angiectasis		1 (2)	1 (2)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	thrombus		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
	necrosis:focal		1 (2)	1 (2)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)
	cyst		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	inflammatory infiltration		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	lymphocytic infiltration		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	inflammatory cell nest		1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	extramedullary hematopoiesis		4 (8)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	50				49				50				50			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Digestive system}																		
liver			<50>				<49>				<50>				<50>			
	clear cell focus		0	0	0	0	2	0	0	0	0	0	0	0	0	1	0	0
			(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)
	acidophilic cell focus		1	0	1	0	3	0	0	0	1	2	0	0	1	2	1	0
			(2)	(0)	(2)	(0)	(6)	(0)	(0)	(0)	(2)	(4)	(0)	(0)	(2)	(4)	(2)	(0)
	bile duct hyperplasia		3	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(6)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Urinary system}																		
kidney			<50>				<49>				<50>				<50>			
	cyst		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	hyaline droplet		13	1	0	0	6	0	0	0	12	0	0	0	8	0	0	0
			(26)	(2)	(0)	(0)	(12)	(0)	(0)	(0)	(24)	(0)	(0)	(0)	(16)	(0)	(0)	(0)
	lymphocytic infiltration		1	0	0	0	2	0	0	0	1	0	0	0	2	0	0	0
			(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)
	inflammatory polyp		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1 (%)	Control 50 2 (%)	Control 50 3 (%)	Control 50 4 (%)	100 ppm 49 1 (%)	100 ppm 49 2 (%)	100 ppm 49 3 (%)	100 ppm 49 4 (%)	200 ppm 50 1 (%)	200 ppm 50 2 (%)	200 ppm 50 3 (%)	200 ppm 50 4 (%)	400 ppm 50 1 (%)	400 ppm 50 2 (%)	400 ppm 50 3 (%)	400 ppm 50 4 (%)
{Urinary system}																		
kidney			<50>				<49>				<50>				<50>			
	hydronephrosis		1 (2)	2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)
	glomerulosclerosis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
urin bladd			<50>				<49>				<50>				<50>			
	dilatation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	lymphocytic infiltration		1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
{Endocrine system}																		
pituitary			<50>				<48>				<50>				<50>			
	angiectasis		2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)
	hyperplasia		7 (14)	5 (10)	0 (0)	0 (0)	6 (13)	1 (2)	0 (0)	0 (0)	2 (4)	2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0) **

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50				100 ppm 49				200 ppm 50				400 ppm 50			
			1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Endocrine system}																		
pituitary		<50>					<48>				<50>				<50>			
	Rathke pouch		6 (12)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
thyroid		<50>					<49>				<50>				<50>			
	cyst		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	granulation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	ultimobranchial body remanet		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
adrenal		<50>					<49>				<50>				<50>			
	spindle-cell hyperplasia		16 (32)	27 (54)	6 (12)	0 (0)	16 (33)	21 (43)	9 (18)	0 (0)	16 (32)	31 (62)	3 (6)	0 (0)	19 (38)	22 (44)	5 (10)	0 (0)
	hyperplasia:cortical cell		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	focal fatty change:cortex		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1 (%)	Control 50 2 (%)	Control 50 3 (%)	Control 50 4 (%)	100 ppm 49 1 (%)	100 ppm 49 2 (%)	100 ppm 49 3 (%)	100 ppm 49 4 (%)	200 ppm 50 1 (%)	200 ppm 50 2 (%)	200 ppm 50 3 (%)	200 ppm 50 4 (%)	400 ppm 50 1 (%)	400 ppm 50 2 (%)	400 ppm 50 3 (%)	400 ppm 50 4 (%)
{Reproductive system}																		
ovary			<50>				<49>				<50>				<50>			
	thrombus		0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(2)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)
	cyst		9	1	0	0	8	0	0	0	7	2	0	0	15	1	0	0
			(18)	(2)	(0)	(0)	(16)	(0)	(0)	(0)	(14)	(4)	(0)	(0)	(30)	(2)	(0)	(0)
	hyperplasia		0	1	0	0	1	1	0	0	0	0	0	0	0	1	0	0
			(0)	(2)	(0)	(0)	(2)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)
uterus			<50>				<49>				<50>				<50>			
	cystic endometrial hyperplasia		34	0	0	0	31	0	0	0	27	0	0	0	34	0	0	0
			(68)	(0)	(0)	(0)	(63)	(0)	(0)	(0)	(54)	(0)	(0)	(0)	(68)	(0)	(0)	(0)
{Nervous system}																		
brain			<50>				<49>				<50>				<50>			
	necrosis:focal		0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	mineralization		8	0	0	0	10	0	0	0	9	0	0	0	11	0	0	0
			(16)	(0)	(0)	(0)	(20)	(0)	(0)	(0)	(18)	(0)	(0)	(0)	(22)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1 (%)	Control 50 2 (%)	Control 50 3 (%)	Control 50 4 (%)	100 ppm 49 1 (%)	100 ppm 49 2 (%)	100 ppm 49 3 (%)	100 ppm 49 4 (%)	200 ppm 50 1 (%)	200 ppm 50 2 (%)	200 ppm 50 3 (%)	200 ppm 50 4 (%)	400 ppm 50 1 (%)	400 ppm 50 2 (%)	400 ppm 50 3 (%)	400 ppm 50 4 (%)
{Special sense organs/appendage}																		
eye			<50>				<49>				<50>				<50>			
	keratitis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)
	mineralization:cornea		2 (4)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	7 (14)	0 (0)	0 (0)	0 (0)
Harder gl			<50>				<49>				<50>				<50>			
	hyperplasia		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
{Musculoskeletal system}																		
muscle			<50>				<49>				<50>				<50>			
	mineralization		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
bone			<50>				<49>				<50>				<50>			
	ostitis fibrosa		0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

TABLE L5

HISTOPATHOLOGICAL FINDINGS :

NON-NEOPLASTIC LESIONS : FEMALE

DEAD AND MORIBUND ANIMALS

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 19				100 ppm 22				200 ppm 24				400 ppm 16			
			1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
(Respiratory system)																		
nasal cavit			<19>				<22>				<24>				<16>			
	exudate		0 (0)	0 (0)	0 (0)	0 (0)	3 (14)	3 (14)	1 (5)	0 (0)	0 (0)	5 (21)	17 (71)	0 ** (0)	3 (19)	4 (25)	8 (50)	0 ** (0)
	mineralization		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (6)	0 (0)	0 (0)	0 (0)
	inflammation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	eosinophilic change:olfactory epithelium		11 (58)	0 (0)	0 (0)	0 (0)	7 (32)	0 (0)	0 (0)	0 (0)	10 (42)	0 (0)	0 (0)	0 (0)	11 (69)	1 (6)	0 (0)	0 (0)
	eosinophilic change:respiratory epithelium		13 (68)	1 (5)	0 (0)	0 (0)	8 (36)	0 (0)	0 (0)	0 * (0)	16 (67)	0 (0)	0 (0)	0 (0)	11 (69)	0 (0)	1 (6)	0 (0)
	inflammation:respiratory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (6)	0 (0)	0 (0)
	respiratory metaplasia:olfactory epithelium		7 (37)	0 (0)	0 (0)	0 (0)	9 (41)	0 (0)	0 (0)	0 (0)	12 (50)	1 (4)	0 (0)	0 (0)	8 (50)	4 (25)	0 (0)	0 * (0)
	respiratory metaplasia:gland		11 (58)	0 (0)	0 (0)	0 (0)	14 (64)	0 (0)	0 (0)	0 (0)	16 (67)	0 (0)	0 (0)	0 (0)	13 (81)	0 (0)	0 (0)	0 (0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 19				100 ppm 22				200 ppm 24				400 ppm 16			
			1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
(Respiratory system)																		
nasal cavit			<19>				<22>				<24>				<16>			
	squamous cell metaplasia:respiratory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	2 (9)	0 (0)	0 (0)	0 (0)	10 (42)	1 (4)	0 (0)	0 ** (0)	8 (50)	5 (31)	1 (6)	0 ** (0)
	ulcer:respiratory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (6)	0 (0)
	atrophy:olfactory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	2 (9)	2 (9)	1 (5)	0 (0)	2 (8)	6 (25)	15 (63)	0 ** (0)	0 (0)	7 (44)	6 (38)	0 ** (0)
	necrosis:olfactory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (17)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	necrosis:respiratory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	5 (21)	1 (4)	0 (0)	0 (0)	3 (19)	0 (0)	0 (0)	0 (0)
nasopharynx			<19>				<22>				<24>				<16>			
	eosinophilic change		0 (0)	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	2 (8)	0 (0)	0 (0)	0 (0)	0 (0)	1 (6)	0 (0)	0 (0)
lung			<19>				<22>				<24>				<16>			
	inflammatory infiltration		1 (5)	0 (0)	0 (0)	0 (0)	4 (18)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	19				22				24				16			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Respiratory system}																		
lung			<19>				<22>				<24>				<16>			
	bronchiolar-alveolar cell hyperplasia		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Hematopoietic system}																		
bone marrow			<19>				<22>				<24>				<16>			
	increased hematopoiesis		0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	granulopoiesis:increased		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
spleen			<19>				<22>				<23>				<16>			
	extramedullary hematopoiesis		2	6	0	0	2	2	0	0	1	3	0	0	2	0	0	0 *
			(11)	(32)	(0)	(0)	(9)	(9)	(0)	(0)	(4)	(13)	(0)	(0)	(13)	(0)	(0)	(0)
{Circulatory system}																		
heart			<19>				<22>				<24>				<16>			
	mineralization		0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 19				100 ppm 22				200 ppm 24				400 ppm 16			
			1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Circulatory system}																		
heart			<19>				<22>				<24>				<16>			
	myocardial fibrosis		0 (0)	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	1 (6)	0 (0)	0 (0)	0 (0)
	arthritis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Digestive system}																		
stomach			<19>				<22>				<24>				<16>			
	erosion:glandular stomach		1 (5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	ulcer:glandular stomach		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (6)	0 (0)
liver			<19>				<22>				<24>				<16>			
	necrosis:focal		0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (13)	0 (0)	0 (0)	0 (0)
	extramedullary hematopoiesis		1 (5)	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 19				100 ppm 22				200 ppm 24				400 ppm 16			
			1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Digestive system}																		
liver			<19>				<22>				<24>				<16>			
	acidophilic cell focus		0 (0)	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Urinary system}																		
kidney			<19>				<22>				<24>				<16>			
	hyaline droplet		11 (58)	1 (5)	0 (0)	0 (0)	5 (23)	0 (0)	0 (0)	0 * (0)	12 (50)	0 (0)	0 (0)	0 (0)	7 (44)	0 (0)	0 (0)	0 (0)
	inflammatory polyp		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	hydronephrosis		1 (5)	0 (0)	0 (0)	0 (0)	0 (0)	1 (5)	1 (5)	0 (0)	0 (0)	2 (8)	0 (0)	0 (0)	0 (0)	1 (6)	0 (0)	0 (0)
	glomerulosclerosis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
urin bladd			<19>				<22>				<24>				<16>			
	dilatation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 19				100 ppm 22				200 ppm 24				400 ppm 16			
			1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Endocrine system}																		
pituitary			<19>				<21>				<24>				<16>			
	angiectasis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	hyperplasia		2 (11)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	Rathke pouch		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (13)	0 (0)	0 (0)	0 (0)
thyroid			<19>				<22>				<24>				<16>			
	cyst		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (6)	0 (0)	0 (0)	0 (0)
	granulation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
adrenal			<19>				<22>				<24>				<16>			
	spindle-cell hyperplasia		12 (63)	5 (26)	1 (5)	0 (0)	9 (41)	9 (41)	1 (5)	0 (0)	12 (50)	10 (42)	2 (8)	0 (0)	13 (81)	0 (0)	0 (0)	0 (0)
	hyperplasia:cortical cell		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 19				100 ppm 22				200 ppm 24				400 ppm 16			
			1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Endocrine system}																		
adrenal		<a>	<19>				<22>				<24>				<16>			
	focal fatty change:cortex		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
		(c)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(6)	(0)
{Reproductive system}																		
ovary		<a>	<19>				<22>				<24>				<16>			
	thrombus		0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0
		(c)	(0)	(0)	(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)
	cyst		0	0	0	0	1	0	0	0	1	1	0	0	1	0	0	0
		(c)	(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(4)	(4)	(0)	(0)	(6)	(0)	(0)	(0)
	hyperplasia		0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0
		(c)	(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(6)	(0)	(0)
uterus		<a>	<19>				<22>				<24>				<16>			
	cystic endometrial hyperplasia		5	0	0	0	8	0	0	0	4	0	0	0	4	0	0	0
		(c)	(26)	(0)	(0)	(0)	(36)	(0)	(0)	(0)	(17)	(0)	(0)	(0)	(25)	(0)	(0)	(0)
{Nervous system}																		
brain		<a>	<19>				<22>				<24>				<16>			
	necrosis:focal		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
		(c)	(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	19				22				24				16			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Nervous system}																		
brain			<19>				<22>				<24>				<16>			
	mineralization		0	0	0	0	4	0	0	0	4	0	0	0	2	0	0	0
			(0)	(0)	(0)	(0)	(18)	(0)	(0)	(0)	(17)	(0)	(0)	(0)	(13)	(0)	(0)	(0)
{Special sense organs/appendage}																		
eye			<19>				<22>				<24>				<16>			
	keratitis		0	0	0	0	0	1	0	0	0	0	0	0	2	0	0	0
			(0)	(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(0)	(0)	(0)	(13)	(0)	(0)	(0)
	mineralization:cornea		0	0	0	0	2	0	0	0	1	0	0	0	2	0	0	0
			(0)	(0)	(0)	(0)	(9)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(13)	(0)	(0)	(0)
{Musculoskeletal system}																		
muscle			<19>				<22>				<24>				<16>			
	mineralization		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
bone			<19>				<22>				<24>				<16>			
	ostitis fibrosa		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

TABLE L6

HISTOPATHOLOGICAL FINDINGS :

NON-NEOPLASTIC LESIONS : FEMALE

SACRIFICED ANIMALS

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	31				27				26				34			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
(Respiratory system)																		
nasal cavit			<31>				<27>				<26>				<34>			
	exudate		1	0	0	0	3	4	1	0 *	7	10	8	0 **	12	19	2	0 **
			(3)	(0)	(0)	(0)	(11)	(15)	(4)	(0)	(27)	(38)	(31)	(0)	(35)	(56)	(6)	(0)
	mineralization		0	0	0	0	4	0	0	0	2	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(15)	(0)	(0)	(0)	(8)	(0)	(0)	(0)	(3)	(0)	(0)	(0)
	eosinophilic change:olfactory epithelium		16	0	0	0	13	0	0	0	12	1	0	0	34	0	0	0 **
			(52)	(0)	(0)	(0)	(48)	(0)	(0)	(0)	(46)	(4)	(0)	(0)	(100)	(0)	(0)	(0)
	eosinophilic change:respiratory epithelium		28	3	0	0	11	1	0	0 **.	18	1	0	0 **	30	3	0	0
			(90)	(10)	(0)	(0)	(41)	(4)	(0)	(0)	(69)	(4)	(0)	(0)	(88)	(9)	(0)	(0)
	inflammation:respiratory epithelium		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)
	respiratory metaplasia:olfactory epithelium		8	0	0	0	14	0	0	0	15	0	0	0 *	28	6	0	0 **
			(26)	(0)	(0)	(0)	(52)	(0)	(0)	(0)	(58)	(0)	(0)	(0)	(82)	(18)	(0)	(0)
	respiratory metaplasia:gland		23	0	0	0	16	0	0	0	24	0	0	0	34	0	0	0 **
			(74)	(0)	(0)	(0)	(59)	(0)	(0)	(0)	(92)	(0)	(0)	(0)	(100)	(0)	(0)	(0)
	squamous cell metaplasia:respiratory epithelium		2	0	0	0	1	0	0	0	9	0	0	0 *	14	3	0	0 **
			(6)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(35)	(0)	(0)	(0)	(41)	(9)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 'Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 31				100 ppm 27				200 ppm 26				400 ppm 34			
			1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Respiratory system}																		
nasal cavit			<31>				<27>				<26>				<34>			
	ulcer:respiratory epithelium		1	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0
			(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(6)	(0)
	atrophy:olfactory epithelium		0	0	0	0	4	3	0	0 *	8	10	7	0 **	7	26	1	0 **
			(0)	(0)	(0)	(0)	(15)	(11)	(0)	(0)	(31)	(38)	(27)	(0)	(21)	(76)	(3)	(0)
	necrosis:olfactory epithelium		0	0	0	0	0	0	0	0	1	0	0	0	2	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(6)	(3)	(0)	(0)
	necrosis:respiratory epithelium		0	0	0	0	0	0	0	0	2	0	0	0	2	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(8)	(0)	(0)	(0)	(6)	(0)	(0)	(0)
nasopharynx			<31>				<27>				<26>				<34>			
	eosinophilic change		4	0	0	0	1	0	0	0	2	0	0	0	1	0	0	0
			(13)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(8)	(0)	(0)	(0)	(3)	(0)	(0)	(0)
larynx			<31>				<27>				<26>				<34>			
	inflammatory infiltration		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
trachea			<31>				<27>				<26>				<34>			
	eosinophilic change		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 31				100 ppm 27				200 ppm 26				400 ppm 34			
			1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Respiratory system}																		
lung			<31>				<27>				<26>				<34>			
	inflammatory infiltration		1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	lymphocytic infiltration		2 (6)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (12)	0 (0)	0 (0)	0 (0)
	accumulation of foamy cells		1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	bronchiolar-alveolar cell hyperplasia		0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)	0 (0)
{Hematopoietic system}																		
bone marrow			<31>				<27>				<26>				<34>			
	increased hematopoiesis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)	0 (0)	0 (0)
	granulopoiesis:increased		1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
spleen			<31>				<27>				<26>				<34>			
	deposit of melanin		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)	0 (0)	0 (0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 31				100 ppm 27				200 ppm 26				400 ppm 34			
			1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Hematopoietic system}																		
spleen			<31>				<27>				<26>				<34>			
	extramedullary hematopoiesis		1 (3)	2 (6)	0 (0)	0 (0)	4 (15)	0 (0)	0 (0)	0 (0)	3 (12)	0 (0)	0 (0)	0 (0)	4 (12)	1 (3)	0 (0)	0 (0)
	lymph-follicular hyperplasia		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (6)	0 (0)	0 (0)	0 (0)
{Circulatory system}																		
heart			<31>				<27>				<26>				<34>			
	myocardial fibrosis		2 (6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (8)	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)	0 (0)	0 (0)
{Digestive system}																		
salivary gl			<31>				<27>				<26>				<34>			
	lymphocytic infiltration		1 (3)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)	0 (0)	0 (0)
stomach			<31>				<27>				<26>				<34>			
	hyperplasia:forestomach		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)	0 (0)	0 (0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	31				27				26				34			
		Grade	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Digestive system}																		
stomach			<31>				<27>				<26>				<34>			
	erosion:glandular stomach		4 (13)	1 (3)	0 (0)	0 (0)	6 (22)	0 (0)	0 (0)	0 (0)	4 (15)	2 (8)	0 (0)	0 (0)	3 (9)	1 (3)	0 (0)	0 (0)
	ulcer:glandular stomach		0 (0)	0 (0)	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)	0 (0)
	hyperplasia:glandular stomach		3 (10)	0 (0)	0 (0)	0 (0)	2 (7)	0 (0)	0 (0)	0 (0)	4 (15)	0 (0)	0 (0)	0 (0)	5 (15)	0 (0)	0 (0)	0 (0)
liver			<31>				<27>				<26>				<34>			
	angiectasis		1 (3)	1 (3)	0 (0)	0 (0)	2 (7)	0 (0)	0 (0)	0 (0)	4 (15)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	thrombus		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)	0 (0)
	necrosis:focal		1 (3)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)	0 (0)	0 (0)
	cyst		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	inflammatory infiltration		0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	31				27				26				34			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Digestive system}																		
liver			<31>				<27>				<26>				<34>			
	lymphocytic infiltration		0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)
	inflammatory cell nest		1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(3)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	extramedullary hematopoiesis		3	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0
			(10)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)
	clear cell focus		0	0	0	0	2	0	0	0	0	0	0	0	0	1	0	0
			(0)	(0)	(0)	(0)	(7)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)
	acidophilic cell focus		1	0	1	0	2	0	0	0	0	2	0	0	1	2	1	0
			(3)	(0)	(3)	(0)	(7)	(0)	(0)	(0)	(0)	(8)	(0)	(0)	(3)	(6)	(3)	(0)
	bile duct hyperplasia		3	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(10)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Urinary system}																		
kidney			<31>				<27>				<26>				<34>			
	cyst		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 31				100 ppm 27				200 ppm 26				400 ppm 34			
			1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Urinary system}																		
kidney			<31>				<27>				<26>				<34>			
	hyaline droplet		2	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0
			(6)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)
	lymphocytic infiltration		1	0	0	0	2	0	0	0	1	0	0	0	2	0	0	0
			(3)	(0)	(0)	(0)	(7)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(6)	(0)	(0)	(0)
	hydronephrosis		0	2	0	0	0	1	0	0	0	0	1	0	0	1	0	0
			(0)	(6)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(3)	(0)	(0)
urin bladd			<31>				<27>				<26>				<34>			
	lymphocytic infiltration		1	0	0	0	2	0	0	0	1	0	0	0	1	0	0	0
			(3)	(0)	(0)	(0)	(7)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(3)	(0)	(0)	(0)
{Endocrine system}																		
pituitary			<31>				<27>				<26>				<34>			
	angiectasis		2	0	0	0	0	0	0	0	1	1	0	0	4	0	0	0
			(6)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(4)	(0)	(0)	(12)	(0)	(0)	(0)
	hyperplasia		5	5	0	0	6	1	0	0	1	2	0	0	0	2	0	0 *
			(16)	(16)	(0)	(0)	(22)	(4)	(0)	(0)	(4)	(8)	(0)	(0)	(0)	(6)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	31				27				26				34			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Endocrine system}																		
pituitary			<31>				<27>				<26>				<34>			
	Rathke pouch		6	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0 *
			(19)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
thyroid			<31>				<27>				<26>				<34>			
	ultimobranchial body remanet		0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
adrenal			<31>				<27>				<26>				<34>			
	spindle-cell hyperplasia		4	22	5	0	7	12	8	0	4	21	1	0	6	22	5	0
			(13)	(71)	(16)	(0)	(26)	(44)	(30)	(0)	(15)	(81)	(4)	(0)	(18)	(65)	(15)	(0)
	focal fatty change:cortex		0	0	0	0	0	1	0	0	0	3	0	0	0	0	1	0
			(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(12)	(0)	(0)	(0)	(0)	(3)	(0)
{Reproductive system}																		
ovary			<31>				<27>				<26>				<34>			
	thrombus		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	cyst		9	1	0	0	7	0	0	0	6	1	0	0	14	1	0	0
			(29)	(3)	(0)	(0)	(26)	(0)	(0)	(0)	(23)	(4)	(0)	(0)	(41)	(3)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	31				27				26				34			
		Grade	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Reproductive system}																		
ovary			<31>				<27>				<26>				<34>			
	hyperplasia		0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0
			(0)	(3)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
uterus			<31>				<27>				<26>				<34>			
	cystic endometrial hyperplasia		29	0	0	0	23	0	0	0	23	0	0	0	30	0	0	0
			(94)	(0)	(0)	(0)	(85)	(0)	(0)	(0)	(88)	(0)	(0)	(0)	(88)	(0)	(0)	(0)
{Nervous system}																		
brain			<31>				<27>				<26>				<34>			
	necrosis:focal		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	mineralization		8	0	0	0	6	0	0	0	5	0	0	0	9	0	0	0
			(26)	(0)	(0)	(0)	(22)	(0)	(0)	(0)	(19)	(0)	(0)	(0)	(26)	(0)	(0)	(0)
{Special sense organs/appendage}																		
eye			<31>				<27>				<26>				<34>			
	keratitis		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				100 ppm				200 ppm				400 ppm			
		No. of Animals on Study	31				27				26				34			
		Grade	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Special sense organs/appendage}																		
eye			<31>				<27>				<26>				<34>			
	mineralization:cornea		2	0	0	0	1	0	0	0	2	0	0	0	5	0	0	0
			(6)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(8)	(0)	(0)	(0)	(15)	(0)	(0)	(0)
Harder gl			<31>				<27>				<26>				<34>			
	hyperplasia		1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
			(3)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(3)	(0)	(0)
{Musculoskeletal system}																		
bone			<31>				<27>				<26>				<34>			
	ostitis fibrosa		0	0	0	0	1	0	0	0	0	0	0	0	3	0	0	0
			(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(9)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

TABLE M1

NUMBER OF ANIMALS WITH TUMORS

AND NUMBER OF TUMORS-TIME RELATED : MALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

Time-related Weeks	Items	Group Name	Control	100 ppm	200 ppm	400 ppm
0 - 52	NO. OF EXAMINED ANIMALS		0	4	1	1
	NO. OF ANIMALS WITH TUMORS		0	0	1	0
	NO. OF ANIMALS WITH SINGLE TUMORS		0	0	1	0
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	0
	NO. OF BENIGN TUMORS		0	0	1	0
	NO. OF MALIGNANT TUMORS		0	0	0	0
	NO. OF TOTAL TUMORS		0	0	1	0
53 - 78	NO. OF EXAMINED ANIMALS		1	4	1	2
	NO. OF ANIMALS WITH TUMORS		1	2	1	2
	NO. OF ANIMALS WITH SINGLE TUMORS		1	2	1	2
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	0
	NO. OF BENIGN TUMORS		1	0	0	0
	NO. OF MALIGNANT TUMORS		0	2	1	2
	NO. OF TOTAL TUMORS		1	2	1	2
79 - 104	NO. OF EXAMINED ANIMALS		19	11	13	8
	NO. OF ANIMALS WITH TUMORS		15	10	8	8
	NO. OF ANIMALS WITH SINGLE TUMORS		9	8	3	4
	NO. OF ANIMALS WITH MULTIPLE TUMORS		6	2	5	4
	NO. OF BENIGN TUMORS		7	6	8	3
	NO. OF MALIGNANT TUMORS		16	7	9	10
	NO. OF TOTAL TUMORS		23	13	17	13
105 - 105	NO. OF EXAMINED ANIMALS		30	31	34	39
	NO. OF ANIMALS WITH TUMORS		18	24	20	28
	NO. OF ANIMALS WITH SINGLE TUMORS		13	17	10	20
	NO. OF ANIMALS WITH MULTIPLE TUMORS		5	7	10	8
	NO. OF BENIGN TUMORS		12	14	23	21
	NO. OF MALIGNANT TUMORS		11	17	11	17
	NO. OF TOTAL TUMORS		23	31	34	38

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

Time-related Weeks	Items	Group Name	Control	100 ppm	200 ppm	400 ppm
0 - 105	NO. OF EXAMINED ANIMALS		50	50	49	50
	NO. OF ANIMALS WITH TUMORS		34	36	30	38
	NO. OF ANIMALS WITH SINGLE TUMORS		23	27	15	26
	NO. OF ANIMALS WITH MULTIPLE TUMORS		11	9	15	12
	NO. OF BENIGN TUMORS		20	20	32	24
	NO. OF MALIGNANT TUMORS		27	26	21	29
	NO. OF TOTAL TUMORS		47	46	53	53

TABLE M2

NUMBER OF ANIMALS WITH TUMORS

AND NUMBER OF TUMORS-TIME RELATED : FEMALE

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

Time-related Weeks	Items	Group Name	Control	100 ppm	200 ppm	400 ppm
0 - 52	NO. OF EXAMINED ANIMALS		2	2	1	2
	NO. OF ANIMALS WITH TUMORS		1	1	0	1
	NO. OF ANIMALS WITH SINGLE TUMORS		1	1	0	1
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	0
	NO. OF BENIGN TUMORS		0	0	0	0
	NO. OF MALIGNANT TUMORS		1	1	0	1
	NO. OF TOTAL TUMORS		1	1	0	1
53 - 78	NO. OF EXAMINED ANIMALS		3	3	3	2
	NO. OF ANIMALS WITH TUMORS		3	3	3	2
	NO. OF ANIMALS WITH SINGLE TUMORS		3	3	3	2
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	0
	NO. OF BENIGN TUMORS		0	0	0	0
	NO. OF MALIGNANT TUMORS		3	3	3	2
	NO. OF TOTAL TUMORS		3	3	3	2
79 - 104	NO. OF EXAMINED ANIMALS		14	17	20	12
	NO. OF ANIMALS WITH TUMORS		14	15	20	12
	NO. OF ANIMALS WITH SINGLE TUMORS		12	12	15	3
	NO. OF ANIMALS WITH MULTIPLE TUMORS		2	3	5	9
	NO. OF BENIGN TUMORS		2	2	7	8
	NO. OF MALIGNANT TUMORS		14	16	20	13
	NO. OF TOTAL TUMORS		16	18	27	21
105 - 105	NO. OF EXAMINED ANIMALS		31	27	26	34
	NO. OF ANIMALS WITH TUMORS		21	19	17	23
	NO. OF ANIMALS WITH SINGLE TUMORS		15	10	6	13
	NO. OF ANIMALS WITH MULTIPLE TUMORS		6	9	11	10
	NO. OF BENIGN TUMORS		16	17	17	18
	NO. OF MALIGNANT TUMORS		12	13	14	17
	NO. OF TOTAL TUMORS		28	30	31	35

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : FEMALE

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

Time-related Weeks	Items	Group Name	Control	100 ppm	200 ppm	400 ppm
0 - 105	NO. OF EXAMINED ANIMALS		50	49	50	50
	NO. OF ANIMALS WITH TUMORS		39	38	40	38
	NO. OF ANIMALS WITH SINGLE TUMORS		31	26	24	19
	NO. OF ANIMALS WITH MULTIPLE TUMORS		8	12	16	19
	NO. OF BENIGN TUMORS		18	19	24	26
	NO. OF MALIGNANT TUMORS		30	33	37	33
	NO. OF TOTAL TUMORS		48	52	61	59

TABLE N1

HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : MALE

Organ	Findings	Group Name / No. of animals on Study	Control 50	100 ppm 50	200 ppm 49	400 ppm 50
{Integumentary system/appandage}						
skin/app			<50>	<50>	<49>	<50>
	squamous cell papilloma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
	keratoacanthoma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
subcutis			<50>	<50>	<49>	<50>
	lipoma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
	fibrosarcoma		0 (0%)	1 (2%)	0 (0%)	1 (2%)
	hemangiosarcoma		0 (0%)	0 (0%)	2 (4%)	0 (0%)
{Respiratory system}						
nasal cavit			<50>	<50>	<49>	<50>
	malignant lymphoma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
lung			<50>	<50>	<49>	<50>
	bronchiolar-alveolar adenoma		4 (8%)	4 (8%)	3 (6%)	5 (10%)
	bronchiolar-alveolar carcinoma		2 (4%)	3 (6%)	2 (4%)	3 (6%)
{Hematopoietic system}						
bone marrow			<50>	<50>	<49>	<50>
	hemangioma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
	hemangiosarcoma		0 (0%)	0 (0%)	1 (2%)	1 (2%)
lymph node			<50>	<50>	<49>	<50>
	histiocytic sarcoma		1 (2%)	0 (0%)	0 (0%)	1 (2%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 50	100 ppm 50	200 ppm 49	400 ppm 50
{Hematopoietic system}						
lymph node			<50>	<50>	<49>	<50>
	malignant lymphoma		9 (18%)	6 (12%)	6 (12%)	13 (26%)
spleen			<50>	<50>	<49>	<50>
	hemangioma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
	mastcytoma:malignant		1 (2%)	0 (0%)	0 (0%)	0 (0%)
	hemangiosarcoma		0 (0%)	0 (0%)	0 (0%)	2 (4%)
{Digestive system}						
tongue			<50>	<50>	<49>	<50>
	squamous cell papilloma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
stomach			<50>	<50>	<49>	<50>
	squamous cell papilloma		1 (2%)	1 (2%)	1 (2%)	1 (2%)
	carcinoid tumor		0 (0%)	0 (0%)	1 (2%)	0 (0%)
small intes			<50>	<50>	<49>	<50>
	leiomyosarcoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
liver			<50>	<50>	<49>	<50>
	hemangioma		2 (4%)	0 (0%)	1 (2%)	1 (2%)
	hepatocellular adenoma		6 (12%)	8 (16%)	18 (37%)	10 (20%)
	histiocytic sarcoma		2 (4%)	1 (2%)	1 (2%)	1 (2%)
	hemangiosarcoma		6 (12%)	3 (6%)	3 (6%)	3 (6%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 50	100 ppm 50	200 ppm 49	400 ppm 50
{Digestive system}						
liver			<50>	<50>	<49>	<50>
	hepatocellular carcinoma		5 (10%)	8 (16%)	4 (8%)	2 (4%)
gall bladd			<50>	<50>	<49>	<50>
	papillary adenoma		2 (4%)	1 (2%)	1 (2%)	2 (4%)
pancreas			<50>	<50>	<49>	<50>
	islet cell adenoma		1 (2%)	0 (0%)	1 (2%)	0 (0%)
{Urinary system}						
urin bladd			<50>	<50>	<49>	<50>
	histiocytic sarcoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
{Endocrine system}						
pituitary			<50>	<49>	<49>	<50>
	histiocytic sarcoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
{Reproductive system}						
mammary gl			<50>	<50>	<49>	<50>
	adenocarcinoma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
{Special sense organs/appendage}						
Harder gl			<50>	<50>	<49>	<50>
	adenoma		2 (4%)	4 (8%)	4 (8%)	4 (8%)
{Musculoskeletal system}						
bone			<50>	<50>	<49>	<50>
	osteosarcoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 50	100 ppm 50	200 ppm 49	400 ppm 50
{Body cavities}						
pleura			<50>	<50>	<49>	<50>
	histiocytic sarcoma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
mediastinum			<50>	<50>	<49>	<50>
	histiocytic sarcoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
peritoneum			<50>	<50>	<49>	<50>
	leiomyosarcoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
retroperit			<50>	<50>	<49>	<50>
	hemangioma		0 (0%)	0 (0%)	1 (2%)	0 (0%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

TABLE N2

HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : FEMALE

Organ	Findings	Group Name / No. of animals on Study	Control 50	100 ppm 49	200 ppm 50	400 ppm 50
{Integumentary system/appandage}						
skin/app			<50>	<49>	<50>	<50>
	squamous cell papilloma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
subcutis			<50>	<49>	<50>	<50>
	fibrosarcoma		0 (0%)	1 (2%)	1 (2%)	0 (0%)
	leiomyosarcoma		0 (0%)	2 (4%)	0 (0%)	0 (0%)
{Respiratory system}						
lung			<50>	<49>	<50>	<50>
	bronchiolar-alveolar adenoma		0 (0%)	1 (2%)	1 (2%)	0 (0%)
	bronchiolar-alveolar carcinoma		2 (4%)	1 (2%)	1 (2%)	1 (2%)
{Hematopoietic system}						
lymph node			<50>	<49>	<50>	<50>
	histiocytic sarcoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
	malignant lymphoma		15 (30%)	14 (29%)	15 (30%)	13 (26%)
spleen			<50>	<49>	<49>	<50>
	histiocytic sarcoma		1 (2%)	0 (0%)	1 (2%)	0 (0%)
{Digestive system}						
tongue			<50>	<49>	<50>	<50>
	squamous cell papilloma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
stomach			<50>	<49>	<50>	<50>
	squamous cell papilloma		2 (4%)	0 (0%)	1 (2%)	1 (2%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 50	100 ppm 49	200 ppm 50	400 ppm 50
{Digestive system}						
liver			<50>	<49>	<50>	<50>
	hemangioma		0 (0%)	1 (2%)	2 (4%)	1 (2%)
	hepatocellular adenoma		1 (2%)	5 (10%)	3 (6%)	3 (6%)
	histiocytic sarcoma		2 (4%)	0 (0%)	0 (0%)	2 (4%)
	hemangiosarcoma		0 (0%)	1 (2%)	2 (4%)	2 (4%)
gall bladd			<50>	<49>	<50>	<50>
	papillary adenoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
pancreas			<50>	<49>	<50>	<50>
	islet cell adenoma		1 (2%)	1 (2%)	0 (0%)	0 (0%)
	hemangiosarcoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
{Endocrine system}						
pituitary			<50>	<48>	<50>	<50>
	adenoma		10 (20%)	11 (23%)	13 (26%)	12 (24%)
	adenocarcinoma		0 (0%)	0 (0%)	0 (0%)	2 (4%)
adrenal			<50>	<49>	<50>	<50>
	pheochromocytoma		1 (2%)	0 (0%)	0 (0%)	1 (2%)
{Reproductive system}						
ovary			<50>	<49>	<50>	<50>
	adenoma		1 (2%)	0 (0%)	0 (0%)	3 (6%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 50	100 ppm 49	200 ppm 50	400 ppm 50
{Reproductive system}						
ovary			<50>	<49>	<50>	<50>
	hemangioma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
	hemangiosarcoma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
uterus			<50>	<49>	<50>	<50>
	histiocytic sarcoma		9 (18%)	7 (14%)	14 (28%)	8 (16%)
	hemangiosarcoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
vagina			<50>	<49>	<50>	<50>
	histiocytic sarcoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
mammary gl			<50>	<49>	<50>	<50>
	adenocarcinoma		0 (0%)	2 (4%)	1 (2%)	2 (4%)
{Nervous system}						
spinal cord			<50>	<49>	<50>	<50>
	histiocytic sarcoma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
periph nerv			<50>	<49>	<50>	<50>
	histiocytic sarcoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
{Special sense organs/appendage}						
Harder gl			<50>	<49>	<50>	<50>
	adenoma		1 (2%)	0 (0%)	3 (6%)	2 (4%)
{Musculoskeletal system}						
bone			<50>	<49>	<50>	<50>
	osteosarcoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 50	100 ppm 49	200 ppm 50	400 ppm 50
(Body cavities)						
mediastinum			<50>	<49>	<50>	<50>
	malignant lymphoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
peritoneum			<50>	<49>	<50>	<50>
	hemangioma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
	fibrosarcoma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
	liposarcoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

TABLE O1

NEOPLASTIC LESIONS-INCIDENCE

AND STATISTICAL ANALYSIS : MALE

Group Name	Control	100 ppm	200 ppm	400 ppm
	SITE : lung			
	TUMOR : bronchiolar-alveolar adenoma			
Tumor rate				
Overall rates(a)	4/50(8.0)	4/50(8.0)	3/49(6.1)	5/50(10.0)
Adjusted rates(b)	10.00	12.90	6.82	11.11
Terminal rates(c)	3/30(10.0)	4/31(12.9)	2/34(5.9)	4/39(10.3)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.4064			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.7224			
Fisher Exact test(e)		P = 0.6425	P = 0.5114	P = 0.5000
	SITE : lung			
	TUMOR : bronchiolar-alveolar carcinoma			
Tumor rate				
Overall rates(a)	2/50(4.0)	3/50(6.0)	2/49(4.1)	3/50(6.0)
Adjusted rates(b)	6.67	6.45	4.88	4.44
Terminal rates(c)	2/30(6.7)	2/31(6.5)	1/34(2.9)	1/39(2.6)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.2873			
Prevalence method(d)	P = 0.5093			
Combined analysis(d)	P = 0.4034			
Cochran-Armitage test(e)	P = 0.7406			
Fisher Exact test(e)		P = 0.5000	P = 0.6837	P = 0.5000
	SITE : lung			
	TUMOR : bronchiolar-alveolar adenoma,bronchiolar-alveolar carcinoma			
Tumor rate				
Overall rates(a)	6/50(12.0)	7/50(14.0)	5/49(10.2)	8/50(16.0)
Adjusted rates(b)	16.67	19.35	11.36	15.56
Terminal rates(c)	5/30(16.7)	6/31(19.4)	3/34(8.8)	5/39(12.8)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.2873			
Prevalence method(d)	P = 0.4278			
Combined analysis(d)	P = 0.3628			
Cochran-Armitage test(e)	P = 0.6162			
Fisher Exact test(e)		P = 0.5000	P = 0.5144	P = 0.3871

Group Name	Control	100 ppm	200 ppm	400 ppm
	SITE : lymph node			
	TUMOR : malignant lymphoma			
Tumor rate				
Overall rates(a)	9/50(18.0)	6/50(12.0)	6/49(12.2)	13/50(26.0)
Adjusted rates(b)	13.33	12.90	8.82	20.51
Terminal rates(c)	4/30(13.3)	4/31(12.9)	3/34(8.8)	8/39(20.5)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.4453			
Prevalence method(d)	P = 0.1713			
Combined analysis(d)	P = 0.2188			
Cochran-Armitage test(e)	P = 0.1805			
Fisher Exact test(e)		P = 0.2883	P = 0.3030	P = 0.2348
	SITE : liver			
	TUMOR : hepatocellular adenoma			
Tumor rate				
Overall rates(a)	6/50(12.0)	8/50(16.0)	18/49(36.7)	10/50(20.0)
Adjusted rates(b)	13.16	23.53	40.00	25.00
Terminal rates(c)	3/30(10.0)	6/31(19.4)	13/34(38.2)	9/39(23.1)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.7256			
Prevalence method(d)	P = 0.1235			
Combined analysis(d)	P = 0.1708			
Cochran-Armitage test(e)	P = 0.2163			
Fisher Exact test(e)		P = 0.3871	P = 0.0038**	P = 0.2070
	SITE : liver			
	TUMOR : hemangiosarcoma			
Tumor rate				
Overall rates(a)	6/50(12.0)	3/50(6.0)	3/49(6.1)	3/50(6.0)
Adjusted rates(b)	10.00	6.45	2.94	4.65
Terminal rates(c)	3/30(10.0)	2/31(6.5)	1/34(2.9)	1/39(2.6)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.6802			
Prevalence method(d)	P = 0.8329			
Combined analysis(d)	P = 0.8576			
Cochran-Armitage test(e)	P = 0.3434			
Fisher Exact test(e)		P = 0.2435	P = 0.2536	P = 0.2435

Group Name	Control	100 ppm	200 ppm	400 ppm
	SITE : liver			
	TUMOR : hepatocellular carcinoma			
Tumor rate				
Overall rates(a)	5/50(10.0)	8/50(16.0)	4/49(8.2)	2/50(4.0)
Adjusted rates(b)	6.06	22.58	11.76	2.56
Terminal rates(c)	1/30(3.3)	7/31(22.6)	4/34(11.8)	1/39(2.6)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.8877			
Prevalence method(d)	P = 0.9115			
Combined analysis(d)	P = 0.9654			
Cochran-Armitage test(e)	P = 0.1333			
Fisher Exact test(e)		P = 0.2768	P = 0.5130	P = 0.2180
	SITE : liver			
	TUMOR : hemangioma, hemangiosarcoma			
Tumor rate				
Overall rates(a)	8/50(16.0)	3/50(6.0)	4/49(8.2)	4/50(8.0)
Adjusted rates(b)	16.67	6.45	5.88	6.98
Terminal rates(c)	5/30(16.7)	2/31(6.5)	2/34(5.9)	2/39(5.1)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.6802			
Prevalence method(d)	P = 0.8621			
Combined analysis(d)	P = 0.8820			
Cochran-Armitage test(e)	P = 0.3111			
Fisher Exact test(e)		P = 0.0999	P = 0.1882	P = 0.1783
	SITE : liver			
	TUMOR : hepatocellular adenoma, hepatocellular carcinoma			
Tumor rate				
Overall rates(a)	10/50(20.0)	16/50(32.0)	19/49(38.8)	11/50(22.0)
Adjusted rates(b)	17.65	44.12	42.86	25.00
Terminal rates(c)	4/30(13.3)	13/31(41.9)	14/34(41.2)	9/39(23.1)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.9233			
Prevalence method(d)	P = 0.4353			
Combined analysis(d)	P = 0.6669			
Cochran-Armitage test(e)	P = 0.9940			
Fisher Exact test(e)		P = 0.1271	P = 0.0331*	P = 0.5000

Group Name	Control	100 ppm	200 ppm	400 ppm
	SITE : Harderian gland			
	TUMOR : adenoma			
Tumor rate				
Overall rates(a)	2/50(4.0)	4/50(8.0)	4/49(8.2)	4/50(8.0)
Adjusted rates(b)	5.26	10.26	11.76	10.26
Terminal rates(c)	0/30(0.0)	0/31(0.0)	4/34(11.8)	4/39(10.3)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.2771			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.5108			
Fisher Exact test(e)		P = 0.3389	P = 0.3292	P = 0.3389

(HPT360A) BAIS4

(a): Number of tumor-bearing animals/number of animals examined at the site.
(b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
(c): Observed tumor incidence at terminal kill.
(d): Beneath the control incidence are the P-values associated with the trend test.
Standard method : Death analysis
Prevalence method : Incidental tumor test
Combined analysis : Death analysis + Incidental tumor test
(e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
? : The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.
------ : There is no data which should be statistical analysis.
Significant difference ; * : $P \leqq 0.05$ ** : $P \leqq 0.01$
N.C. :Statistical value cannot be calculated and was not significant.

Group Name	Control	100 ppm	200 ppm	400 ppm
	SITE : ALL SITE TUMOR : histiocytic sarcoma			
Tumor rate				
Overall rates(a)	3/50(6.0)	2/50(4.0)	2/49(4.1)	4/50(8.0)
Adjusted rates(b)	0.0	0.0	0.0	7.69
Terminal rates(c)	0/30(0.0)	0/31(0.0)	0/34(0.0)	3/39(7.7)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.8481			
Prevalence method(d)	P = 0.0067**			
Combined analysis(d)	P = 0.3525			
Cochran-Armitage test(e)	P = 0.5631			
Fisher Exact test(e)		P = 0.5000	P = 0.5097	P = 0.5000
	SITE : ALL SITE TUMOR : malignant lymphoma			
Tumor rate				
Overall rates(a)	9/50(18.0)	6/50(12.0)	7/49(14.3)	13/50(26.0)
Adjusted rates(b)	13.33	12.90	11.76	20.51
Terminal rates(c)	4/30(13.3)	4/31(12.9)	4/34(11.8)	8/39(20.5)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.4453			
Prevalence method(d)	P = 0.1723			
Combined analysis(d)	P = 0.2180			
Cochran-Armitage test(e)	P = 0.1752			
Fisher Exact test(e)		P = 0.2883	P = 0.4101	P = 0.2348

(a): Number of tumor-bearing animals/number of animals examined at the site.
(b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
(c): Observed tumor incidence at terminal kill.
(d): Beneath the control incidence are the P-values associated with the trend test.
Standard method : Death analysis
Prevalence method : Incidental tumor test
Combined analysis : Death analysis + Incidental tumor test
(e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
? : The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.
------- : There is no data which should be statistical analysis.
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01
N.C. :Statistical value cannot be calculated and was not significant.

TABLE O2

NEOPLASTIC LESIONS-INCIDENCE

AND STATISTICAL ANALYSIS : FEMALE

Group Name	Control	100 ppm	200 ppm	400 ppm
	SITE : lymph node			
	TUMOR : malignant lymphoma			
Tumor rate				
Overall rates(a)	15/50(30.0)	14/49(28.6)	15/50(30.0)	13/50(26.0)
Adjusted rates(b)	25.81	18.52	34.62	20.59
Terminal rates(c)	8/31(25.8)	5/27(18.5)	9/26(34.6)	7/34(20.6)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.6912			
Prevalence method(d)	P = 0.5969			
Combined analysis(d)	P = 0.7065			
Cochran-Armitage test(e)	P = 0.6748			
Fisher Exact test(e)		P = 0.5259	P = 0.5862	P = 0.4120
	SITE : liver			
	TUMOR : hepatocellular adenoma			
Tumor rate				
Overall rates(a)	1/50(2.0)	5/49(10.2)	3/50(6.0)	3/50(6.0)
Adjusted rates(b)	3.23	18.52	10.00	8.82
Terminal rates(c)	1/31(3.2)	5/27(18.5)	2/26(7.7)	3/34(8.8)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.3705			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.6944			
Fisher Exact test(e)		P = 0.0976	P = 0.3087	P = 0.3087
	SITE : liver			
	TUMOR : hemangioma, hemangiosarcoma			
Tumor rate				
Overall rates(a)	0/50(0.0)	2/49(4.1)	4/50(8.0)	3/50(6.0)
Adjusted rates(b)	0.0	7.41	15.38	8.82
Terminal rates(c)	0/31(0.0)	2/27(7.4)	4/26(15.4)	3/34(8.8)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.1100			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.1524			
Fisher Exact test(e)		P = 0.2424	P = 0.0587	P = 0.1212

Group Name	Control	100 ppm	200 ppm	400 ppm
	SITE : liver			
	TUMOR : hepatocellular adenoma, hepatocellular carcinoma			
Tumor rate				
Overall rates(a)	1/50(2.0)	5/49(10.2)	3/50(6.0)	3/50(6.0)
Adjusted rates(b)	3.23	18.52	10.00	8.82
Terminal rates(c)	1/31(3.2)	5/27(18.5)	2/26(7.7)	3/34(8.8)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.3705			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.6944			
Fisher Exact test(e)		P = 0.0976	P = 0.3087	P = 0.3087
	SITE : pituitary gland			
	TUMOR : adenoma			
Tumor rate				
Overall rates(a)	10/50(20.0)	11/48(22.9)	13/50(26.0)	12/50(24.0)
Adjusted rates(b)	29.03	39.29	33.33	27.91
Terminal rates(c)	9/31(29.0)	10/27(37.0)	8/26(30.8)	7/34(20.6)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.4099			
Prevalence method(d)	P = 0.3709			
Combined analysis(d)	P = 0.3632			
Cochran-Armitage test(e)	P = 0.6379			
Fisher Exact test(e)		P = 0.4577	P = 0.3176	P = 0.4048
	SITE : pituitary gland			
	TUMOR : adenoma, adenocarcinoma			
Tumor rate				
Overall rates(a)	10/50(20.0)	11/48(22.9)	13/50(26.0)	14/50(28.0)
Adjusted rates(b)	29.03	39.29	33.33	30.23
Terminal rates(c)	9/31(29.0)	10/27(37.0)	8/26(30.8)	8/34(23.5)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1406			
Prevalence method(d)	P = 0.2827			
Combined analysis(d)	P = 0.2030			
Cochran-Armitage test(e)	P = 0.3347			
Fisher Exact test(e)		P = 0.4577	P = 0.3176	P = 0.2415

Group Name	Control	100 ppm	200 ppm	400 ppm
	SITE : ovary			
	TUMOR : adenoma			
Tumor rate				
Overall rates(a)	1/50(2.0)	0/49(0.0)	0/50(0.0)	3/50(6.0)
Adjusted rates(b)	3.23	0.0	0.0	7.50
Terminal rates(c)	1/31(3.2)	0/27(0.0)	0/26(0.0)	1/34(2.9)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.0564			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.0893			
Fisher Exact test(e)		P = 0.5051	P = 0.5000	P = 0.3087
	SITE : uterus			
	TUMOR : histiocytic sarcoma			
Tumor rate				
Overall rates(a)	9/50(18.0)	7/49(14.3)	14/50(28.0)	8/50(16.0)
Adjusted rates(b)	3.23	14.81	3.85	5.88
Terminal rates(c)	1/31(3.2)	4/27(14.8)	1/26(3.8)	2/34(5.9)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.4707			
Prevalence method(d)	P = 0.5451			
Combined analysis(d)	P = 0.4987			
Cochran-Armitage test(e)	P = 0.9654			
Fisher Exact test(e)		P = 0.4101	P = 0.1710	P = 0.5000

Group Name	Control	100 ppm	200 ppm	400 ppm
SITE : Harderian gland				
TUMOR : adenoma				
Tumor rate				
Overall rates(a)	1/50(2.0)	0/49(0.0)	3/50(6.0)	2/50(4.0)
Adjusted rates(b)	2.44	0.0	8.57	4.44
Terminal rates(c)	0/31(0.0)	0/27(0.0)	2/26(7.7)	1/34(2.9)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.1767			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.3306			
Fisher Exact test(e)		P = 0.5051	P = 0.3087	P = 0.5000

(HPT360A) BAIS4

(a): Number of tumor-bearing animals/number of animals examined at the site.
(b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
(c): Observed tumor incidence at terminal kill.
(d): Beneath the control incidence are the P-values associated with the trend test.
Standard method : Death analysis
Prevalence method : Incidental tumor test
Combined analysis : Death analysis + Incidental tumor test
(e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
? : The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.
------ : There is no data which should be statistical analysis.
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01
N.C. :Statistical value cannot be calculated and was not significant.

Group Name	Control	100 ppm	200 ppm	400 ppm
	SITE : ALL SITE			
	TUMOR : histiocytic sarcoma			
Tumor rate				
Overall rates(a)	12/50(24.0)	10/49(20.4)	16/50(32.0)	10/50(20.0)
Adjusted rates(b)	9.68	14.81	3.85	8.82
Terminal rates(c)	3/31(9.7)	4/27(14.8)	1/26(3.8)	3/34(8.8)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.5317			
Prevalence method(d)	P = 0.6540			
Combined analysis(d)	P = 0.6053			
Cochran-Armitage test(e)	P = 0.8073			
Fisher Exact test(e)		P = 0.4258	P = 0.2522	P = 0.4048
	SITE : ALL SITE			
	TUMOR : malignant lymphoma			
Tumor rate				
Overall rates(a)	15/50(30.0)	14/49(28.6)	15/50(30.0)	13/50(26.0)
Adjusted rates(b)	25.81	18.52	34.62	20.59
Terminal rates(c)	8/31(25.8)	5/27(18.5)	9/26(34.6)	7/34(20.6)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.6912			
Prevalence method(d)	P = 0.5969			
Combined analysis(d)	P = 0.7065			
Cochran-Armitage test(e)	P = 0.6748			
Fisher Exact test(e)		P = 0.5259	P = 0.5862	P = 0.4120

(a): Number of tumor-bearing animals/number of animals examined at the site.
(b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
(c): Observed tumor incidence at terminal kill.
(d): Beneath the control incidence are the P-values associated with the trend test.
Standard method : Death analysis
Prevalence method : Incidental tumor test
Combined analysis : Death analysis + Incidental tumor test
(e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
? : The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.
------ : There is no data which should be statistical analysis.
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01
N.C. :Statistical value cannot be calculated and was not significant.

TABLE P1

HISTOPATHOLOGICAL FINDINGS :

METASTASIS OF TUMOR :

MALE

Organ	Findings	Group Name / No. of Animals on Study	Control 50	100 ppm 50	200 ppm 49	400 ppm 50
{Integumentary system/appandage}						
subcutis			<50>	<50>	<49>	<50>
	metastasis:peritoneum tumor		0	1	0	0
{Respiratory system}						
nasal cavit			<50>	<50>	<49>	<50>
	leukemic cell infiltration		0	1	0	0
	metastasis:spleen tumor		1	0	0	0
larynx			<50>	<50>	<49>	<50>
	leukemic cell infiltration		1	0	0	0
lung			<50>	<50>	<49>	<50>
	leukemic cell infiltration		3	5	3	3
	metastasis:liver tumor		1	3	3	1
	metastasis:subcutis tumor		0	1	0	1
	metastasis:bone tumor		0	1	0	0
	metastasis:pleura tumor		0	0	1	0
	metastasis:mediastinum tumor		0	0	0	1
	metastasis:lymph node tumor		1	0	0	0
{Hematopoietic system}						
bone marrow			<50>	<50>	<49>	<50>
	leukemic cell infiltration		2	2	1	2
	metastasis:liver tumor		0	1	0	0

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control 50	100 ppm 50	200 ppm 49	400 ppm 50
{Hematopoietic system}						
bone marrow			<50>	<50>	<49>	<50>
	metastasis:spleen tumor		1	0	0	0
lymph node			<50>	<50>	<49>	<50>
	metastasis:spleen tumor		1	0	0	0
spleen			<50>	<50>	<49>	<50>
	leukemic cell infiltration		5	4	3	9
	metastasis:liver tumor		1	1	0	0
	metastasis:lymph node tumor		0	0	0	1
{Circulatory system}						
heart			<50>	<50>	<49>	<50>
	leukemic cell infiltration		1	0	0	0
	metastasis:pleura tumor		0	0	1	0
{Digestive system}						
tongue			<50>	<50>	<49>	<50>
	leukemic cell infiltration		1	0	0	0
salivary gl			<50>	<50>	<49>	<50>
	leukemic cell infiltration		1	1	0	2
stomach			<50>	<50>	<49>	<50>
	leukemic cell infiltration		0	0	1	0
	metastasis:spleen tumor		1	0	0	0
small intes			<50>	<50>	<49>	<50>
	leukemic cell infiltration		2	0	0	1

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control 50	100 ppm 50	200 ppm 49	400 ppm 50
{Digestive system}						
small intes			<50>	<50>	<49>	<50>
	metastasis:liver tumor		1	0	0	0
	metastasis:subcutis tumor		0	1	0	0
	metastasis:lymph node tumor		0	0	0	1
large intes			<50>	<50>	<49>	<50>
	leukemic cell infiltration		0	0	1	0
liver			<50>	<50>	<49>	<50>
	leukemic cell infiltration		2	2	3	3
	metastasis:subcutis tumor		0	1	0	0
	metastasis:mammary gland tumor		1	0	0	0
	metastasis:spleen tumor		1	0	0	0
	metastasis:lymph node tumor		1	0	0	0
pancreas			<50>	<50>	<49>	<50>
	leukemic cell infiltration		0	1	1	2
	metastasis:subcutis tumor		0	1	0	0
{Urinary system}						
kidney			<50>	<50>	<49>	<50>
	leukemic cell infiltration		1	2	1	2
	metastasis:liver tumor		0	0	1	0
	metastasis:mammary gland tumor		1	0	0	0

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control 50	100 ppm 50	200 ppm 49	400 ppm 50
{Urinary system}						
kidney			<50>	<50>	<49>	<50>
	metastasis:spleen tumor		1	0	0	0
urin bladd			<50>	<50>	<49>	<50>
	leukemic cell infiltration		1	1	1	0
{Endocrine system}						
adrenal			<50>	<50>	<49>	<50>
	leukemic cell infiltration		0	0	1	0
	metastasis:liver tumor		0	0	0	1
	metastasis:subcutis tumor		0	1	0	0
	metastasis:pleura tumor		0	0	1	0
{Reproductive system}						
epididymis			<50>	<50>	<49>	<50>
	metastasis:liver tumor		0	0	0	1
	metastasis:urinary bladder tumor		0	0	0	1
semin ves			<50>	<50>	<49>	<50>
	leukemic cell infiltration		0	0	0	1
	metastasis:subcutis tumor		0	1	0	0
prostate			<50>	<50>	<49>	<50>
	leukemic cell infiltration		0	1	2	1
{Nervous system}						
brain			<50>	<50>	<49>	<50>
	leukemic cell infiltration		0	0	0	1

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control 50	100 ppm 50	200 ppm 49	400 ppm 50
{Nervous system}						
spinal cord			<50>	<50>	<49>	<50>
	leukemic cell infiltration		0	0	0	1
{Special sense organs/appendage}						
Harder gl			<50>	<50>	<49>	<50>
	leukemic cell infiltration		1	1	0	0
{Musculoskeletal system}						
bone			<50>	<50>	<49>	<50>
	metastasis:spleen tumor		1	0	0	0
{Body cavities}						
peritoneum			<50>	<50>	<49>	<50>
	metastasis:liver tumor		0	0	0	1
	metastasis:subcutis tumor		0	1	0	0
	metastasis:pleura tumor		0	0	1	0

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

TABLE P2

HISTOPATHOLOGICAL FINDINGS :

METASTASIS OF TUMOR :

FEMALE

Organ	Findings	Group Name / No. of Animals on Study	Control 50	100 ppm 49	200 ppm 50	400 ppm 50
{Integumentary system/appandage}						
skin/app			<50>	<49>	<50>	<50>
	leukemic cell infiltration		2	1	0	0
subcutis			<50>	<49>	<50>	<50>
	leukemic cell infiltration		1	0	0	0
	metastasis:lung tumor		1	0	0	0
{Respiratory system}						
nasal cavit			<50>	<49>	<50>	<50>
	leukemic cell infiltration		2	1	0	1
	metastasis:uterus tumor		0	1	2	0
	metastasis:peripheral nerve tumor		0	1	0	0
larynx			<50>	<49>	<50>	<50>
	leukemic cell infiltration		4	0	2	0
trachea			<50>	<49>	<50>	<50>
	leukemic cell infiltration		1	0	0	1
lung			<50>	<49>	<50>	<50>
	leukemic cell infiltration		12	9	10	8
	metastasis:liver tumor		0	0	0	1
	metastasis:uterus tumor		7	3	9	6
	metastasis:peripheral nerve tumor		0	1	0	0
{Hematopoietic system}						
bone marrow			<50>	<49>	<50>	<50>
	leukemic cell infiltration		6	4	2	6

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control 50	100 ppm 49	200 ppm 50	400 ppm 50
{Hematopoietic system}						
bone marrow			<50>	<49>	<50>	<50>
	metastasis:liver tumor		0	0	0	1
	metastasis:uterus tumor		3	3	4	2
lymph node			<50>	<49>	<50>	<50>
	metastasis:uterus tumor		1	1	4	0
	metastasis:peritoneum tumor		0	0	1	0
	metastasis:subcutis tumor		0	1	0	0
spleen			<50>	<49>	<50>	<50>
	leukemic cell infiltration		9	7	10	7
	metastasis:liver tumor		0	0	0	1
	metastasis:uterus tumor		2	4	7	4
	metastasis:ovary tumor		1	0	0	0
	metastasis:lymph node tumor		0	1	0	0
{Circulatory system}						
heart			<50>	<49>	<50>	<50>
	leukemic cell infiltration		2	0	0	1
	metastasis:uterus tumor		0	1	1	0
{Digestive system}						
tongue			<50>	<49>	<50>	<50>
	leukemic cell infiltration		4	1	2	1

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control	100 ppm	200 ppm	400 ppm
			50	49	50	50
{Digestive system}						
salivary gl			<50>	<49>	<50>	<50>
	leukemic cell infiltration		3	4	0	2
stomach			<50>	<49>	<50>	<50>
	leukemic cell infiltration		5	0	0	1
	metastasis:liver tumor		1	0	0	0
small intes			<50>	<49>	<50>	<50>
	leukemic cell infiltration		0	2	3	2
large intes			<50>	<49>	<50>	<50>
	leukemic cell infiltration		1	0	0	1
liver			<50>	<49>	<50>	<50>
	leukemic cell infiltration		8	9	8	6
	metastasis:uterus tumor		9	5	13	6
	metastasis:spleen tumor		1	0	1	0
	metastasis:spinal cord tumor		0	0	1	0
	metastasis:lymph node tumor		0	1	0	0
gall bladd			<50>	<49>	<50>	<50>
	leukemic cell infiltration		1	0	0	0
pancreas			<50>	<49>	<50>	<50>
	leukemic cell infiltration		5	4	1	4
	metastasis:uterus tumor		1	0	1	0
	metastasis:subcutis tumor		0	1	0	0
{Urinary system}						
kidney			<50>	<49>	<50>	<50>
	leukemic cell infiltration		4	4	2	3

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control 50	100 ppm 49	200 ppm 50	400 ppm 50
{Urinary system}						
kidney			<50>	<49>	<50>	<50>
	metastasis:uterus tumor		1	1	3	0
	metastasis:subcutis tumor		0	1	0	0
urin bladd			<50>	<49>	<50>	<50>
	leukemic cell infiltration		4	2	2	3
{Endocrine system}						
pituitary			<50>	<49>	<50>	<50>
	metastasis:uterus tumor		0	0	1	0
	metastasis:peripheral nerve tumor		0	1	0	0
thyroid			<50>	<49>	<50>	<50>
	leukemic cell infiltration		4	0	0	0
adrenal			<50>	<49>	<50>	<50>
	leukemic cell infiltration		3	2	0	2
	metastasis:uterus tumor		0	0	2	1
{Reproductive system}						
ovary			<50>	<49>	<50>	<50>
	leukemic cell infiltration		8	6	7	3
	metastasis:liver tumor		1	0	0	0
	metastasis:uterus tumor		9	4	9	3
	metastasis:peritoneum tumor		0	0	1	0

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control 50	100 ppm 49	200 ppm 50	400 ppm 50
{Reproductive system}						
uterus			<50>	<49>	<50>	<50>
	leukemic cell infiltration		3	1	2	2
	metastasis:peritoneum tumor		0	0	1	0
vagina			<50>	<49>	<50>	<50>
	leukemic cell infiltration		2	0	1	0
	metastasis:peritoneum tumor		0	0	1	0
{Nervous system}						
brain			<50>	<49>	<50>	<50>
	leukemic cell infiltration		2	1	0	1
	metastasis:pituitary tumor		0	0	0	2
	metastasis:peripheral nerve tumor		0	1	0	0
spinal cord			<50>	<49>	<50>	<50>
	leukemic cell infiltration		1	0	0	1
{Special sense organs/appendage}						
Harder gl			<50>	<49>	<50>	<50>
	leukemic cell infiltration		2	1	1	0
{Musculoskeletal system}						
muscle			<50>	<49>	<50>	<50>
	leukemic cell infiltration		1	2	0	0
{Body cavities}						
peritoneum			<50>	<49>	<50>	<50>
	leukemic cell infiltration		0	0	1	2

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control 50	100 ppm 49	200 ppm 50	400 ppm 50
{Body cavities}						
peritoneum			<50>	<49>	<50>	<50>
	metastasis:liver tumor		1	0	0	0
	metastasis:uterus tumor		1	0	0	0

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

TABLE Q1

CAUSE OF DEATH : MALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
SEX : MALE

COUSE OF DEATH (SUMMARY)
(0-105W)

Group Name	Control	100 ppm	200 ppm	400 ppm
Number of Dead and Moribund Animal	20	19	15	11
no microscop confirm	1	0	1	1
renal lesion	0	1	1	0
urinary retention	3	4	2	0
hydronephrosis	1	5	2	0
tumor d:leukemia	5	2	3	5
tumor d:subcutis	0	1	1	1
tumor d:lung	0	1	0	1
tumor d:lymph node	1	0	0	0
tumor d:spleen	1	0	0	0
tumor d:liver	8	3	4	3
tumor d:pituitary	0	1	0	0
tumor d:bone	0	1	0	0
tumor d:pleura	0	0	1	0

TABLE Q2

CAUSE OF DEATH : FEMALE

STUDY NO. : 0676
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
SEX : FEMALE

COUSE OF DEATH (SUMMARY)
(0-105W)

Group Name	Control	100 ppm	200 ppm	400 ppm
Number of Dead and Moribund Animal	19	22	24	16
no microscop confirm	1	2	0	0
renal lesion	0	1	0	0
urinary retention	0	0	1	0
hydronephrosis	0	1	0	0
tumor d:leukemia	7	9	6	7
tumor d:subcutis	0	2	0	0
tumor d:lung	1	0	0	0
tumor d:lymph node	0	1	0	0
tumor d:spleen	0	0	1	0
tumor d:liver	1	0	0	1
tumor d:pituitary	0	0	1	1
tumor d:ovary	1	0	0	0
tumor d:uterus	8	3	13	6
tumor d:vagina	0	1	0	0
tumor d:spinal cord	0	0	1	0
tumor d:periph nerv	0	1	0	0
tumor d:bone	0	0	0	1
tumor d:peritoneum	0	1	1	0